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I. CHAPTER: General introduction 
1. Abstract 
Today, ultrasound (US) applications in medicine are so extensive that one cannot imagine 
routine clinical practice without them. US applications provide non-invasive, cost-efficient 
and well-developed modalities for imaging and diagnostics. In addition, several therapeutic 
approaches involving US have gained public acceptance and compliance. For example, high-
intensity focused US (HIFU) is used to ablate solid tumors and tissue regions, and lithotripter 
shockwaves are used to destroy kidney stones.  
The introducing of the first microbubble US contrast agents (MBs) has brought a great 
improvement in US diagnostics. Until the 1990’s, they were mainly used for right heart 
opacification and cardiac shunt diagnostics. This approach was limited due to MBs’ low 
stability and large size, making them unable to pass pulmonary capillaries after intravenous 
injection. Developing stable and sufficiently small gas filled MBs allowed systemic 
circulation of an effective US contrast agent after intravenous injection, thus opening a wide 
range of new diagnostic applications. More recently, such MBs have evolved into a promising 
carrier for therapeutic substances. This work will focus on the aspects of pharmaceutical 
developing of MB carriers for site specific tumor and gene therapy. 
 
Keywords: Ultrasound, microbubble contrast agents, sonoporation, capillary fenestration, 
rational formulation design; 
 
Abbreviations: AAL – acoustically active lipospheres, US – ultrasound, MB – microbubble, 
UTMD – ultrasound-targeted microbubble destruction, HSA – human serum albumin, 
pDNA – plasmid DNA, siRNA – small interfering RNA; 
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2. Microbubble agents – a general overview 
MBs are gas-filled colloidal particles, with a size range of 1-8 µm. Their structure comprises a 
gas core which is wrapped in a more or less flexible shell of protein, surfactant, or polymer. 
Currently, MBs are marketed as contrast agents for ultrasound (US) diagnostics and imaging. 
Their introduction into clinical practice led to the development of more sensitive imaging 
techniques both in cardiology and radiology, including subharmonic and multi-pulse imaging, 
pulse inversion and harmonic power Doppler [1]. Recently, MBs are anticipated to find 
further uses in therapy as efficient and safe targeted deliverers of drugs and genes.  
Forty years ago, Gramiak and Shah (1968) [2] reported that agitated saline enhanced the US 
echo signal in the human ascending aorta and cardiac chambers. Since this first breakthrough, 
three generations of acoustically-active US contrast agents have been developed (Table 1).  
First generation MB products were simple air bubbles. Since they lacked a stabilizing shell, 
they were stable for only a few seconds in circulation and would not pass capillaries due to 
their large size. Therefore, first generation MBs could not reach the left heart if injected 
intravenously, and left ventricular opacification could only be achieved by direct injection 
into the left ventricular cavity. A stabilized form of such airbubbles was approved and 
marketed by Schering AG as Echovist®, still being used for cardiac shunt diagnostics.  
The second generation MBs was stabilized by a shell of protein, polymer or surfactant, and 
had a smaller size distribution (transpulmonary MBs). Thus, they were able to pass through 
the lungs and reach the left heart and other organs after intravenous application. However, the 
second generation MBs had instable gas cores consisting of air and dissolved in blood within 
less than five minutes.  
In third generation MBs, the air core was replaced by gases that were only sparingly soluble 
in blood and physiologically inert. This improvement prolonged the half-life of MBs to more 
than fifteen minutes. 
The development of more stable MB agents made possible them to reach any US accessible 
and blood perfused organ. This and some specific physical characteristics of MBs broadened 
the scope of their applications beyond US imaging and encouraged the development of US-
targeted drug delivery. Today, studying the potential use of MBs in gene and drug delivery is 
the focus of many research groups worldwide [3].  
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Table 1: Classification and constitution of MB products. 1) Licensed for clinical use by FDA; 2) Licensed for 
clinical use by EMEA; 3) No longer commercially available or development suspended, 4) Under development. 
PLGA – polylactide-co-glycolide; PCA – polycyanoacrylate; HSA – human serum albumin; DPPC – dipalmitoyl 
phosphatidylcholine; DPPA – dipalmitoyl phosphoric acid; DPPG – dipalmitoyl phosphatidylglycerol; 
MPEG 5000-DPPE – polyethyleneglycol 5000-dipalmitoyl phosphatidylethanolamine; DMPC – dimyristoyl 
phosphatidylcholine; DSPC – distearoyl phosphatidylcholine; PA – palmitic acid [6-8]; n.a. – not available. 
MB agent Marketing Authorization Holder Presentation 
Core 
material Shell material 
First Generation Vascular Agents 
Echovist® 3) Schering AG, Germany 
D-galactose microparticles 
for reconstitution Air None 
Second Generation Vascular Agents (transpulmonary MBs) 
Levovist® 2) Schering AG, Germany 
D-galactose microparticles 
for reconstitution Air PA 
Albunex® 3) Molecular Biosystems, USA Aqueous MB suspension Air HSA 
Quantison® 3) Quadrant Ltd, UK Spray-dried powder Air HSA 
Third Generation Vascular Agents 
Optison® 1),2) GE Healthcare, USA Aqueous MB suspension C3F8 HSA 
EchoGen® 3) Sonus Pharmaceuticals Ltd., USA 
Phase shift colloid 
emulsion C5F12 
Surfactant: PEG-
telomer B 
SonoVue® 1),2) Bracco International B.V., The Netherlands Lyophilized powder SF6 
Phospholipid 
composition: DSPC /  
DPPG / PA 
Definity® 1),2) 
(in the EU: 
Luminity®) 
Bristol-Myers Squibb 
Medical Imaging, 
USA 
Aqueous phospholipid 
solution for agitation C3F8 
Phospholipid 
composition 
DPPC / DPPA /  
MPEG 5000-DPPE 
Imagent® 1),2) Alliance Pharm. Corp., USA Spray-dried powder 
C6F14 / 
Nitrogen Phospholipid: DMPC 
CardioSphere® 4) Point Biomed. Corp., USA Lyophilized powder Nitrogen 
Polymer-based bilayer 
(biSphereTM): 
PLGA / HSA  
Third Generation Liver Specific Agents 
BR-14 4) Bracco Research SA, Switzerland n.a. C4F10 
Phospholipid 
composition 
SonazoidTM 4) GE Healthcare, USA Dry powder C4F10 
Hydrogenated egg 
phosphatidylserine 
SonoVist® 4) Schering AG, Germany n.a. SF6 PCA 
Third Generation Agents for Research Purposes 
PESDA Porter et al. (1997) [4] n.a. C4F10 HSA 
Quanfuxian Chi et al. (2003) [5] n.a. C3F8 HSA 
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3. Microbubble behavior in ultrasonic field 
There is a very intensive interaction between MBs and diagnostic US (Figure 1). When 
exposed to US with lower intensity MBs perform a symmetric volume contractions and 
expansions (linear oscillations). At increasing US intensity, the oscillations are accompanied 
by bubble shape deformations (non-linear oscillations), and at reaching of a certain intensity 
limit – cavitation threshold, the oscillating MB is fragmented or “burst” by US to smaller gas 
artifacts and shell fragments. 
 
 
Figure 1: MB oscillation and fragmentation (“bursting”) in dependence of the US intensity.  
 
The higher acoustic response of MBs compared to blood and most body tissues can be 
explained by their differing acoustic impedances. At moderate acoustic pressures the acoustic 
impedance (Z) is linearly dependent from the specific density of the propagation 
medium (ρ, [g/cm3]) and the respective sound velocity (c, [m/s]) according to Equation 1 [9]. 
 
cZ .ρ=  
Equation 1 
 
While the acoustic impedance of most tissues lies in the range 1.5-8.0 x 106 kg/m2s, it is about 
five orders of magnitude lower for gases (4.0 x 101 kg/m2s) [10, 11]. The greatly higher 
acoustic responsiveness of MBs, compared to blood and tissues, allows specifically 
addressing them by diagnostic US with a minimal burden to the organism [12, 13]. 
The cavitation threshold and the MB half-life in an US field depend mainly on the US 
frequency and MB diameter, but also on the physico-chemical properties of the MB shell, 
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drug-loading, etc. On their turn, these factors are decisive for the magnitude of non-thermal 
mechanic in-situ effects of cavitation and accordingly for the permeabilization of biological 
structures. For example, MBs with soft shells such as phospholipid monolayers follow a 
specific pattern of destruction, during which the flexible membrane expands and reseals 
again, accompanied by gradually shedding out of submicron lipid associates in the order of 
liposomes to micelles [14]. The mechanic effects of soft-shelled MBs on capillaries and cells 
is therefore mostly considered rather moderate and safe [15].  
On the other hand, MBs with robust shells made of protein or polymeric material are rather 
weak oscillators and are mostly fragmented by “sonic cracking”, where the gas explosively 
escapes the shell. Therefore, the mechanic effects of sonic cracking to cells and tissues are 
more intensive compared to soft-shelled MBs [16]. 
Another class of MBs – acoustically active lipospheres (AALs), comprises an additional oil 
layer between the gas core and the outermost surfactant monolayer. The acoustic 
fragmentation of AALs has been explained by May et al. (2001) [17]. Depending on their 
diameter and US parameters, AALs may undergo one-step collapse fragmentation producing 
a set of smaller fragments, or continuously pinch off small shell fragments and eventually 
shed out a large fragment, containing the main fraction of shell material. 
The fragmentation behavior of US contrast agents is an important factor for their contrasting 
activity, therapeutic efficacy, and biological safety with regard to the US intensity, necessary 
to achieve MB bursting and drug release. 
 
4. Microbubbles as targeted drug carriers 
It is known that exposure to US may improve cellular uptake of polynucleotides [18-21], 
proteins [18], and small-molecule drugs [19]. Cavitation has been found to be responsible for 
this effect. However, the high US energy levels required to induce gas cavitation in organisms 
bears a high risk of acoustic damage and are clinically impractical.  
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Figure 2: MB structure classes and drug-load localizations (in red). A: Attachment to the outer shell surface; 
B: Intercalation between monolayer phospholipids; C: Incorporation in an oil layer (acoustically active 
lipospheres, AALs); D: Complexes with smaller particles (secondary carriers, in blue); E: Physical 
encapsulation in a polymer layer (grey) and coating with biocompatible material (yellow); F: Surface loading of 
protein-shelled MBs; G: Entire shell volume loading of protein MBs; H: Layer-by-layer loaded protein-shelled 
MBs. The negatively charged DNA is represented in blue, and the polycationic polymer – in red. 
 
MBs offer a different approach to facilitate the US triggered drug uptake. They respond to the 
US field of their resonance frequency by oscillation. At higher US energies, high amplitude 
oscillations cause MB destruction. If such MBs have been loaded with a drug or gene vector, 
ultrasound targeted microbubble destruction (UTMD) can be used to locally deliver and 
release the transported substance. Because MBs act as cavitation nuclei, they lower the 
required US energy to safe intensity levels, mandated by the FDA [20, 21]. 
On the cellular- and tissue-level several additional effects, associated with high amplitude 
oscillations, have been described that mediate the drug transport into cells. In the near vicinity 
of oscillating MBs cell membranes may show sonopores [22-24] which could be due to 
several MB phenomena including microstream swirling [25, 26], micro-jetting [27], and the 
formation of hydrodynamic shock waves [28, 29]. Some authors also suggest a significant 
role of free radical stress on cells [30-32], others however doubt their contribution [30, 31]. 
The auxiliary impact of enhanced ion-channel conductance has also been proposed as a 
possible mechanism [32]. 
Sonopores may range in size from 30-100 nm up to a few micrometers [33] (Figure 3A to D). 
They have a transient character and actively reseal by an endogenous vesicle-based healing 
response [33] with the aid of Ca2+ [34] and ATP [35] after several seconds [36] or 
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minutes [37]. It is strongly suggested that bioactive substances, such as proteins, plasmids and 
siRNA can permeate the cytosol through these membrane pores (Table 2).  
 
 
Figure 3: Scanning electron microscopic images of HL-60 cells exposed to US in the presence of MBs (A to D), 
irradiated with US alone (F) or untreated (E). From Liu et al. (2006)1 [38]. 
 
The development of pores is limited to the cell membrane and most reports indicate that it 
does not affect the nucleus [33] apparently because the highly viscous cytoplasm prevents 
direct perturbations of it. However, Duvshani-Eshet et al. (2006a,b) [39, 40] recently reported 
that nuclear uptake of rhodamine-labeled pDNA by UTMD in cell cultures is possible.  
In addition to the effects on a cellular level, UTMD has also effects on the microvasculature. 
It has been shown that UTMD transiently increases capillary permeability by putting micron-
range pores in the endothelium. These endothelial gaps allow the transportation of colloidal 
particles towards the tissue interstitium. 
The UMTD mediated transport through blood vessels is limited through the thickness of the 
vessel wall. In small vessels such as arteriole and venule small molecules and 
macromolecules but no colloidal particles can be transferred out of the vessel bed [41]. 
Permeabilization of the blood-brain barrier and transportation of small polar molecules, 
macromolecules, and colloidal particles is also possible using MBs [48-50].  
                                                 
1 Reprinted, with permission, from the Journal of Controlled Release, Volume 114 ©2006 by Elsevier Ltd. 
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Biological barrier 
Size/molecular weight 
of molecules/particles 
transported by UTMD 
Examples 
Cell membrane 2-3 MDa [33] Polar macromolecules, micelles, polyplexes, or viruses [42] 
Capillary endothelium 
(vessel diameter < 7 µm [43]) 6-8 μm 
Small- and macromolecules [44], colloidal 
nanoparticles sized approx. 100 [45], 200 
and 500 nm, and cells [46, 47] 
Vessel wall 
(vessel diameter approx. 55 µm) approx. 9 nm Polar macromolecules [41] 
Blood-brain barrier (BBB) approx. 100 nm 
Small polar molecules [48], polar 
macromolecules (pDNA) [49], colloidal 
particles (liposomes) [50] 
Table 2: Transfer of molecules and particles across biological barriers using UTMD. Approx. – approximately. 
 
The experience in using MBs as contrast agents helped pave the way for their use in the 
therapeutic research. Extensive studies have established the MB safety profile [51], and 
guidelines for the use of contrast enhanced US have been recommended [13, 52]. 
Furthermore, several recent diagnostic devices e.g. Sonos 5500, Philips Medical Systems, 
USA are appropriately equipped and can be directly applied for UTMD-assisted drug 
delivery. Additionally, there are established methods for the small and large scale production 
of MBs.  
In the past years, the trends in the MB-mediated drug and gene delivery have diverged from 
the development of US contrast agents in many aspects. Diverse MB structure types have 
been specifically developed to accommodate molecules with various molecular weights and 
physico-chemical properties (Figure 2).  
According to the particular MB structure classes, the thickness and shell volumes of MBs can 
vary broadly (Table 3).  
 
MB structure class Shell thickness 
Phospholipid-MBs 2 – 3 nm [53] 
Microcapsules 
(emulsification method) 50 – 200 nm [15] 
HSA-shelled MBs 
(probe-type sonication method) 200 – 300 nm [54] 
AALs 500 – 1000 nm (triacetin layer), 300 – 700 nm (soy-bean oil layer) [17] 
Table 3: Shell thickness of the main MB structure classes. AALs – acoustically active lipospheres; HSA – 
human serum albumin. 
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Compared to phospholipid-MBs, microcapsules, AALs, and protein-shelled MBs possess 
larger shell volumes and can potentially embed higher drug loads. On the other side, a greater 
shell thickness can impair the acoustic properties of such MBs. 
Drug molecules can be associated with the MB shell by means of electrostatic or hydrophobic 
interactions, van-der-Waals forces or merely by physical encapsulation (Table 4). For 
instance, charged hydrophilic macromolecules like DNA and RNA can be directly charge-
coupled to the outer MB surface (Figure 2 A), whereas amphiphilic molecules can penetrate 
into the monolayer (Figure 2 B). Highly hydrophobic molecules like paclitaxel can be 
included in a layer of thick oil to form acoustically-active lipospheres (AALs, Figure 2 C). 
Alternatively, the payload can be associated with smaller particles which are in turn attached 
to the MB (Figure 2 D). Drug molecules can also be encapsulated into shells of biodegradable 
polymer (Figure 2 E, in grey), and the obtained hollow microcapsules can be coated with a 
biocompatible material, such as gelatin (in yellow) to inhibit systemic elimination. In Figure 
2 F and G, the drug is complexed to adhesive serum albumin molecules, forming the shell. 
According to the formulation processes, the drug can be either surface attached or included in 
the albumin shell.  
Albumin-shelled as well as phospholipid-shelled MBs can be efficiently loaded using the 
layer-by-layer approach (Figure 2 H). According to it layers of negatively charged DNA and 
polycationic polymer such as poly-L-lysine are consecutively laid over the pre-formed MBs. 
 
MB structure class Attaching forces Drug molecule properties Examples 
Phospholipid-MBs (Figure 2 A and B)  
Electrostatic and/or 
hydrophobic 
interactions 
Electrostatically 
charged small- and 
macromolecules,  
small amphiphilic and 
lipophilic molecules 
Dexamethasone 
dipalmitoyl 
ester [55], 
pDNA [56, 57] 
protein [58, 59] 
Acoustically-active lipospheres 
(AALs, Figure 2 C) 
Hydrophobic 
interactions 
Small lipophilic 
molecules 
Paclitaxel [60-62], 
resveratrol [60] 
Double-emulsified microcapsules 
(Figure 2 E) Physical encapsulation 
Hydrophilic small- 
and macromolecules 
pDNA [61], 
doxorubicin [62] 
Secondary-carrier MB (Figure 2 D), 
coupled with liposomes [63], 
nanoparticles [64], viruses [65], 
polyplexes [66, 67], lipoplexes [71-73] 
Mostly electrostatic 
interactions 
Electrostatically 
charged 
macromolecules 
pDNA [69-72] 
Protein-shelled MB  
(Figure 2 F) 
Diverse non-covalent 
interactions  
Hydrophilic small- 
and macromolecules pDNA [68-70] 
Table 4: Drug and gene carrier potentials of various MB structure classes. 
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One further approach – the MB formulation concept of phase shift colloid emulsions, was 
originally implemented in the diagnostic product EchoGen® (Table 1) and advanced by 
Rapoport et al. (2007) [68]. The authors designed a sophisticated microemulsion system of 
perfluoropentane, stabilized by biodegradable block copolymer surfactants and loaded with 
doxorubicin. Under heating to physiological temperatures or mild sonication a droplet-to-
bubble phase shift proceeded, resulting in the in-situ formation of stable drug-loaded MBs.  
 
5. Advanced formulation design of phospholipid microbubbles 
MBs are complex structures, where numerous physico-chemical parameters and interactions 
play a crucial role in order to provide an adequate MB stability along with a sufficient 
acoustic backscatter activity and destructibility. Together with the complexation interactions 
between drug molecules and MB shell, there are interactions between gas core and 
surrounding medium, as well as processes within the MB shell taking place. From this reason, 
an in-depth formulation design is needed towards an advanced MB product. 
In a phospholipid-shelled MB the gas core is surrounded by a flexible, but stable layer of 
amphiphilic molecules which may also embed an effective drug payload. The crucial role of 
shell and core gas for an optimal MB stability can be illustrated by the following example. A 
shell-free air MB with initial diameter of 2 μm in water at 37 °C is theoretically predicted to 
fully dissolve within 25 ms. A bubble of the same size, but consisting of octafluoropropane is 
predicted to dissolve within 400 ms [69]. In contrast, third generation MBs such as Definity®, 
possessing a stabilizing phospholipid-shell, have a circulation half-life of over 15 minutes. 
Shell-free air bubbles dissolve nearly instantaneously due to the effect of surface tension and 
hydrostatic blood pressure. The pressure difference across the bubble surface ΔP is given by 
the Laplace equation [70]:  
 
r
PPP ab
σ2
=−=∆
 
Equation 2 
 
where Pb is the pressure inside the bubble, Pa is the hydrostatic pressure outside the bubble, σ 
is the surface tension, and r is the bubble radius. The high surface curvature in the MB size 
range of 1 μm to 5 μm renders a significant pressure drop of e.g. 1 bar for a bubble with a 
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diameter of 2 μm. This pressure difference drives gas into the surrounding medium and causes 
the bubbles’ rapid dissolving. 
MB shell contributes two major stabilizing components – a resistance to gas escape from the 
core and a reduction of the surface tension, as modeled in the modified Epstein-
Plesset equation [71, 72] (Equation 3). 
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Equation 3 
 
where dr/dt is the time-resolved reduction of MB radius after gas loss; L is the Ostwald’s 
coefficient; Dw – gas diffusion coefficient in water; Rshell – shell resistance to gas permeation; 
σshell is the shell surface tension, and ƒ is the ratio of core gas concentration in the medium vs. 
the gas concentration at saturation. The Epstein-Plesset model assumes a perfectly spherical 
form of the MB and neglects shell deformation effects like folding and buckling throughout 
the gas escape. 
Following from above, one possible way to increase the bubble lifespan is by implementing 
poorly soluble core gases such as SF6 or perfluorinated hydrocarbons rather than nitrogen or 
air. By using poorly water soluble gases the gas permeation resistance into water (L-1Dw-1) can 
be increased in several orders of magnitude compared to air [73, 74]. This concept has been 
employed in the development of third generation US contrast agents such as 
SonoVue® (Bracco International, B.V., The Netherlands) and Definity® (Bristol-Myers 
Squibb Medical Imaging, USA). 
 
 25 
 
Figure 4: Osmotically stabilized MB. There is an osmotic equilibrium between the water-soluble gases inside 
the MB and in the blood, whereas the water-insoluble perfluorocarbon (PFC) remains inside the shell. 
 
The blood plasma contains physiological amounts of dissolved gases of low molecular weight 
such as nitrogen, oxygen, and carbon dioxide. Considering a gas core composed of 
perfluoropropane and surrounded by physiological gases, dissolved in the blood plasma 
(mainly nitrogen and oxygen), there is an osmotic gradient directed into the bubble where the 
blood-gases concentration is zero. While the phospholipid shell and the surrounding aqueous 
medium widely prevent inside-out perfluorocarbon permeation, the shell still can be passed in 
the opposite direction by the small blood gas molecules. Consequently, when MBs containing 
only perfluorocarbon are introduced into the blood, they increase in size by taking up blood 
gases. The bubbles swell until the partial pressures of blood gases inside them equal the 
ambient concentrations, and the partial pressure of perfluorocarbon counterbalances the 
combined Laplace and blood pressure [74]. These equilibrium observations support the 
development of osmotically stabilized MBs (Figure 4). Schutt et al. (2003) [75] have 
previously published a detailed review on the principles of gas-exchange and osmotic 
stabilization of MBs. The ingenious designing concept of osmotically stabilized MBs has 
found application in Imagent® (Alliance Pharm. Corp., USA). 
One further MB stabilizing factor – the shell resistance to gas permeation, is considered 
negligible for gases with low molecular weight [73, 74, 76], though it is greatly enhanced for 
high molecular weight gases like the perfluorocarbons. For example, the shell resistance for 
perfluorobutane compared to air is estimated to be approximately 1,400 times higher [77]. 
The shell resistance to gas permeation depends on the rate of monolayer condensation on an 
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exponential manner [78]. Since the phospholipid condensation state also depends on the 
temperature, the shell phospholipids should have a phase-transition temperature (Tm) above 
the physiological body temperature of 37 °C [14] and persist in condensed phase state at 
physiological conditions. For the same reason – maintaining the condensed phospholipid 
packaging, a MB formulation cannot include unsaturated phospholipids with extensive 
conformational freedom, since they would destroy the dense monolayer order [79].  
According to the Epstein-Plesset theory, the second major component of MB stability 
contributed by the phospholipid shell is the reduction of surface tension. In homological 
orders of saturated symmetric diacyl phosphatidylcholines the equilibrium surface tension on 
the air / water surface was extremely sensitive to phospholipid chain length, decreasing by 
more than an order of magnitude for each methylene group added [80]. Their values varied 
from 9.8 mN/m (for n = 6) through 4.0 mN/m (for n = 12) [80] down to 1.3 mN/m (for 
n = 16) [81].  
Beneath surface tension hydrophobic chain length plays a role for the MB shell permeation 
resistance to gases either [80, 84, 86, 90, 91]. The exponential relationship between shell 
resistance and phospholipid acyl chain length has been first predicted by the energy barrier 
model [82, 83] (Equation 4)  
 

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where R0 is a frequency constant, E(n) is the activation energy that depends on the number of 
carbon atoms per phospholipid acyl chain, B is the Boltzmann universal gas constant, and T is 
the temperature. 
Later on, it has been experimentally proven that the cohesive energy between n-alkyl chains 
increases linearly with the addition of each methylene group [84] which renders reasonable an 
exponential increase of the shell resistance to monolayer gas permeation. On the other hand, 
the increase of acyl chain length raises the shell viscosity which results in more robust and 
less echogeneous MBs [85]. 
Recently, semi-synthetic phospholipids are generally preferred in the designing of MBs 
because of their non-animal origin and the favorable acoustic properties of phospholipid 
monolayers. Presently there is also a broad range of phospholipids with a variety of 
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hydrophobic chain lengths and electrostatic charges that are commercially available. In 
aqueous surroundings the phospholipids MB shell presents a flexible, thin monolayer film 
with the hydrophobic tails facing the gas core and the headgroups coming into contact with 
the medium. The stability of the shell monolayer is provided by its highly condensed structure 
of saturated fatty acid tails.  
Including certain shell excipients, such as PEGylated phospholipids, can sterically stabilize 
MBs and delay their blood elimination. This advantageous effect has been implemented in the 
design of Definity® (Bristol-Myers Squibb Medical Imaging, USA). However, the bulky 
PEGylated headgroups possess a large positive intrinsic curvature which may be 
unadvantageous for the MB geometry and can disturb shell integrity as will be demonstrated 
below. 
Recent research by Kim et al. (2003) [85] and Borden et al. (2006a) [86] disproved the 
prevailing opinion of phospholipid MB shell as a homogeneous structure. Now the 
phospholipid monolayer is realized to be a complex, multiphase structure of ordered 
(condensed) and disordered (liquid) domains. This lateral phase separation within the 
monolayer sheet results from the imperfect miscibility of certain shell components, for 
example, single-chain PEGylated emulsifiers and double-chain phospholipids.  
On the one hand, the coexistence of liquid and condensed phospholipid phase states confers 
the MB shell physical flexibility and stability. On the other, it has been demonstrated that 
phase heterogeneity dictates MB properties including the localization of targeting ligands, 
protective brush moieties, and drug loading. Phase heterogeneity may thus have negative 
consequences on the formulation quality. According to several studies, it is possible to 
confine the effects of lateral phase separation by adjusting the shell composition and 
manufacturing parameters [86].  
Two factors are decisive for the miscibility in phospholipid systems – the intrinsic miscibility 
of phospholipid components and the possible influence of the drug on it. The prevailing effect 
results from the phospholipid acyl tails, but the structure and physico-chemical properties of 
the headgroup may also have an influence on the miscibility.  
In binary mixtures saturated phospholipids with the same headgroup and various acyl chains 
possess different miscibilities. Nearly ideal mixing was observed between phospholipids with 
a chain length difference of up to two carbon atoms [87]. Imperfect lateral miscibility or a 
complete immiscibility in condensed state was demonstrated for chain length differences of 
four and more carbon atoms [87-89]. 
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Lateral phase immiscibility can occur even in chain-uniform mixed phospholipid monolayers 
if the headgroups of phospholipid components possess distinct differences in terms of their 
physical size, state of hydration, and possible conformational flexibility. Phase separation has 
been observed e.g. in chain-uniform binary monolayers of DPPC and DPPI [90].To minimize 
lateral phase separation and optimize the MB shell stability, the shell should preferably 
consist of phospholipid species with equal fatty-acid residues and close phase-transition 
temperatures.  
Abundant surface electrostatic charges can also disturb the formation and stability of the MB 
monolayer shell by causing lateral electrostatic repulsions within the monolayer [67]. The 
repulsing between charged headgroups can overcome the associative hydrophobic forces 
between acyl chains on a concentration dependent manner and disrupt the shell monolayer. 
The lyotropic phase behavior of phospholipids is their important characteristic, determined 
mainly by their molecular geometry i.e. the ratio between the areas of head group and acyl 
chains. Phospholipid geometry determines the average intrinsic curvature (C0,ave) of its 
lyotropic phase. At C0,ave ~ 0 phospholipid molecules have a roughly “cylindrical” geometry 
and tend to form lamellar phase structures as in the case of DPPC and DPPG. Intrinsic 
curvatures smaller than zero indicate that head-group area is smaller than the acyl-chain area. 
The stable lyotropic phase for such phospholipids e.g. DPPE is bended towards the aqueous 
phase. Phospholipids with sterically “bulky” hydrophobic headgroups such as PEGylated 
phospholipids, possess a positive C0,ave and tend to curve towards the acyl-chain region, thus 
forming micellar structures. 
 
Phospholipid Electrostatic charge Hydrogen bonding Lyotropic phase at room temperature 
DPPE Zwitterionic Donor: 2 Acceptor: 1 
Inverse hexagonal  
phase (HII) [91] 
 
DPPC Zwitterionic Non-bonding Lamellar gel  phase (Lα) [91, 92] 
 
DPPG One negative charge (pH > 4) 
Donor: 2 
Acceptor: 2 
Lamellar gel  
phase (Lα) [91] 
 
DPPE-PEG2000 One negative charge 
Donor: 1 
Acceptor: multiple Micellar phase 
 
Table 5: Some important characteristics of phospholipids, used in following pre-formulation studies. 
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Following in this thesis, several phospholipids have been focused on in order to reveal their 
complexation potential for doxorubicin, their ability to produce sufficiently stable liposomal 
formulations, and to form MBs with an appropriate stability, size, and loading capacity. 
The selected range of phospholipid candidates includes DPPC, DPPG, and DPPE, and DPPE-
PEG2000 (Table 5). Rather strong lateral cohesion forces exist between DPPC molecules. 
Hence, this phospholipid is able to form mechanically stable mono- and bilayers [93]. 
Concerning its head-group hydration, DPPC interacts weakly with the external aqueous 
phase [93]. 
DPPE is another zwitterionic phospholipid, thus its properties differ much from DPPC. Its 
headgroup possesses a primary amine residue, allowing hydrogen-bond formation. Therefore, 
the hydration of DPPE is much more pronounced compared to DPPC [93, 94]. On the other 
hand, the molecular geometry of DPPE is governed by its small headgroup. Therefore DPPE 
forms in water an inverted hexagonal HII phase which causes lacking colloidal stability and 
sedimentation of aqueous DPPE dispersions.  
DPPG is an acidic phospholipid, existing above a pH of 4 in its anionic form [95]. At 
physiological pH and in the presence of sodium DPPC obtains the lamellar phase like 
DPPC [96]. 
At last in this chapter, focus will be put on the mid-term stability of MBs in aqueous media. In 
contrast to albumin- and polymer-shelled MBs, phospholipid MBs does not provide over long 
shelf-life in the range of months or years. For this reason, all of the approved phospholipid 
MB products are formulated as vials for activation by either reconstitution (SonoVue®, 
Imagent®, Sonazoid®) or by mechanical agitation (Definity®). 
When stored at rest, MBs form in aqueous media highly hydrated microfoam colloidal 
systems, denoted in the literature as wet foam, microfoam, or “kugelschaum”. One surprising 
quality of near-sized MBs is that in microfoams they order almost perfectly in 3D and form 
quasi-crystalline structures. In the crystalline microfoam the MBs mainly have a three-
dimensional organization in body centered cubic, face centered cubic, or hexagonal close-
packed crystalline structures [97, 98]. 
The colloidal state of microfoams is metastable and mainly depends on their hydration since 
the microfoam remains wet up to a height h, reversely depending on the MB diameter d and 
straightly depending on the square of the capillary length l0 according to Equation 5: 
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On its side the capillary length l0 can be expressed by the following equation: 
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Equation 6 
 
where ρ is the density of the medium, γ is the surface tension, and g is the gravitational 
acceleration. Due to the action of gravitational forces microfoam dehydration affects on the 
first place the top layers which are mostly occupied by bubbles of the upper size range. For 
this reason, MBs of size above 10 µm should be considered as an unstable fraction of the 
“native” MB suspension.  
In summary, the MB stability after the activation of the precursor vial depends on several 
pharmaceutical factors in a complex interplay. The medium density plays together with the 
gravitation a negative role for the stability of the microfoam. In contrast, the capillary length 
is rendered greater and the microfoam wet layer is thicker provided the surface tension is 
lower and the MB diameter is smaller.  
The complicated physico-chemical interactions between gas core, phospholipid monolayer, 
drug, and surrounding medium dictate the formulation design of soft-shelled MBs. An 
advanced MB structure design is supposed to assure MB pharmaceutical quality, sustainable 
in-vivo behavior, echogenicity, and an adequate therapeutic effect. 
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II. CHAPTER: Formulation and characterization of model 
microbubbles 
1. Abstract 
Originally developed as contrast agents for ultrasound diagnostics, in the past years, 
microbubbles (MBs) have made an unusual way from the patient’s bedside back to the 
researcher’s laboratory, since their potential as carriers for drugs, nucleotides, and proteins 
has been discovered. Today, numerous MB structures have been designed for the purposes of 
targeted drug delivery.  
The present thesis work is focused on the formulation of drug and gene-loaded MBs with soft 
phospholipid shells. Thereby, drug and gene-loaded liposome formulations are used as 
precursors for the production of MBs by high-speed mechanical agitation together with the 
MB core gas.  
The following chapter provides some insights on the validation of mechanical agitation for 
production of MBs with optimal pharmaceutical properties. The influence of several process 
factors such as the agitation time, tube fill volume, and tube shape, will be studied and 
discussed. 
Furthermore, validation and selection of appropriate methods will be put on MB particle size 
distribution, Zeta potential, and concentration.  
 
Keywords: Phospholipid microbubbles, production, quality control, process control, particle 
sizing; 
 
Abbreviations: LCMP – liposomal-controlled microbubble production, MB – microbubble; 
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2. Introduction 
In the past decades microbubbles (MBs) have gained wide clinical applications as well 
tolerated contrast agents for the ultrasound diagnostics. Recently, they have made an unusual 
way from the clinical practice back to the research laboratory, since their potential as specific 
drug and gene-carriers for targeted therapy has been discovered. Drug-loaded MBs provide 
the unique ability to outline the site of disease and to achieve drug targeting in a single needle 
prick. 
The present dissertation work focuses on the formulation of phospholipid-shelled MBs by 
mechanical high speed agitation. Thereby, a pre-filled sterile vial containing liquid phase and 
MB core gas is agitated on its length-axis for a definite time and with an exact frequency 
using a mechanical device. For the first time mechanical agitation has been implemented on a 
commercial scale by Bristol-Myers Squibb Medical Imaging, Inc. with the diagnostic US 
contrast product Definity®. In this case, the precursor vial comprises an aqueous phospholipid 
dispersion and octafluoropropane gas. Immediately prior to the drug administration the vial is 
activated by agitation for 45 s at 4,500 oscillations/min using VialMix® (Bristol-Myers 
Squibb Medical Imaging, Inc., North Billerica, USA). The produced concentrated MB 
dispersion is than diluted with physiological medium and administered mostly by intravenous 
infusion or bolus injection.  
Mechanical agitation is a comfortable one-step method for MB production which is 
appropriate for the in-situ production of drug-loaded MBs [56] and acoustically active 
lipospheres [99]. It requires a two-step formulation process, whereby initially a precursor 
liposomal formulation is created using a conventional method such as thin-film hydration, 
phase inversion, or ethanol injection. Next, the liposomal dispersion is placed into vials, and 
the remaining head-space of the vial is filled with a suitable gas which will form the MB cores 
upon agitation. Liposome precursors may be additionally stabilized by spray-drying or freeze-
drying. Shortly prior to the administration the vial is activated by high-speed agitation. 
After the vial activation the resulting MB dispersion is mainly stable for a couple of hours, 
therefore MBs have to be produced at the patient’s bedside. 
MBs can be drug-loaded by means of two approaches – loading of pre-formed MBs by 
incubation with the active drug, or by loading of the liposome precursors which are then 
transformed into drug-loaded MBs. Many authors prefer the first approach of drug-loading 
pre-formed MBs [64, 66, 102] which is yet complicated and barely practicable on a large 
scale and in the clinical practice.  
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On the contrary, drug-loading of precursor liposomes offers a better applicable and elegant 
approach, having the advantage to provide a ready precursor formulation for one-step 
production of drug-loaded MBs in a single vial [55, 56, 58].  
The present work proposes a method to control the formulation properties of drug-loaded 
MBs such as size, particle yield, and encapsulation efficiency by manipulating the 
formulation properties of the precursor liposomes which will be referred to as liposomal-
controlled microbubble production (LCMP) approach. In the following chapter an optimal 
setup for MB production by mechanical agitation will be established, without yet considering 
the aspect of drug loading which will be addressed in later chapters. Furthermore, appropriate 
methods for characterization of MBs e.g. in their concentration and particle size distribution 
will be selected. The effects of various formulation factors such as the volume ratio of gas to 
liposomal dispersion, the agitation time, etc. on the formulation properties will be observed 
and discussed. Following, an attempt will be made to establish a theory about the mechanism 
of MB formation under high mechanical shear. 
One further aspect in this chapter will be the characterization of MBs in their particle size, 
Zeta potential, and concentration. These pharmaceutical properties play an important role for 
the in-vivo applicability of drug-loaded MB formulations and must therefore be accurately 
determined. For example, the particle size distribution in MB formulations is decisive for their 
therapeutic effectiveness and clinical safety, since large gas bubbles are not only very rapidly 
cleared from the circulation [100], but may also cause embolism and ischemic stroke. On its 
turn, Zeta potential of MBs can influence their microcirculation behavior and capillary 
retention [101].  
Various approaches for particle sizing and Zeta potential measuring will be following 
compared and the most suitable method will be selected as well as the optimal setup 
parameters for its application.  
Unfortunately, recent research literature still lacks studies on method applicability, validation, 
and application comparisons for the characterization of such complex systems as the MBs. 
Most difficulties of MB characterization are related to their intricate light scattering features, 
the phenomenon of buoyancy i.e. the size dependent flotation in upright direction, and their 
sensitivity to pressure fluctuations and shear stress.  
Many particle sizing approaches such as the dynamic light scattering and the laser diffraction 
are based on the correlation between light scattering pattern and particle size. Depending on 
the ratio between particle diameter and light wavelength the light scattering has been 
described by the theories of Rayleigh, Mie, and Fraunhofer. Roughly, the light scattering 
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theories of Rayleigh and Fraunhofer describe the scattering from particles which are either 
much smaller (about a factor of 10) or much larger (about a factor of 50) than the light 
wavelength. MBs are typically sized between 1 µm and 3-5 µm and are considered under the 
scattering theory of Mie [102], since their size is comparable to the wavelength range used by 
the most particle sizing instruments – 400-600 nm. The equations of Mie are complex and 
require an imaginary number, comprising of two material specific parameters: the refractive 
index and the absorption index which must be known in order to derive the particle size from 
the intensity of scattered light.  
Several literature works have dealt with light scattering by MBs with regard to accurately 
determining of their particle size. The refractive index of pure water is 1.333 and lies above 
the values for MB core gases such as nitrogen and air which are about 1.000. Commonly, the 
refractive index of dispersed media lies above the refractive index of the dispersant as in the 
case of liposomes (1.440) or proteins (1.450). Compared to droplet dispersions, MBs scatter at 
the angle region from 40° to 110°, rather than at 120° to 180° with regard to the axis of light 
beam. Therefore, light scattering characteristics for MBs strongly differ from other known 
dispersion systems such as suspensions or emulsions, even if they have exactly the same 
size [103].  
The light scattering by MBs is even more complicated by the existing multiple order light 
refractions within a single particle. In the simplified model of a shell-free gas bubble the light 
scattering is distorted by reflections and internal refractions of first, second, or higher 
orders [104]. Another factor, playing role in the theoretical modeling, is the presence of MB 
shell which possesses an intrinsic refractive index of roughly 1.20 for proteins and 1.10 for 
lipids [105], and contributes to the overall refraction and absorption.  
Optical sizing methods typically consider the particle shape as spherical which in many cases 
evolves significant deviations form the real particle size. Bubbles sized under 100 µm are 
considered spherical [106] and thus no stereological conversions are necessary due to their 
shape [107].  
All this exemplifies the need of properly established optical models for MBs and even for MB 
formulations with different shell constitutions which are based on empirical relations rather 
than on complex mathematical models. For the first time, laser diffraction for MBs has been 
established in approximation for coated spheres based on modifications of the Mie 
theory [108] and applied later for coated gas bubbles [109]. It has been shown that there is a 
monotonic relationship between the bubble size and the scattered light intensity [110]. Further 
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in this chapter, an optical model will be proposed for laser diffraction particle sizing of 
phospholipid-shelled perfluorocarbon MBs.  
One further problematic issue on the particle sizing and Zeta potential measuring of MBs is 
their buoyancy. The effective net force F, [N] exerted on a MB surrounded by liquid, can be 
expressed as the sum of the buoyant force and the gravitational force: 
 
VgmgF ρ−=  
Equation 7 
 
where m is the mass of the MB, [g], g is the gravitational acceleration, [m/s2], ρ is the density 
of the liquid, [g/l], and V is the volume of the liquid, displaced by the object [cm3]. However, 
it has to be taken into account that soft-shelled MBs are compressible objects and their 
volume V as well as the resulting buoyant force decrease when the hydrostatic pressure 
increases in accordance with the particle position on the z-axis. 
The rising velocity of MBs in a diluted dispersion is further determined by the viscosity of the 
surrounding medium which can be roughly described on the theoretical basis of the Stokes’ 
law (Equation 8) [111]. 
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Equation 8 
 
where V is the rising velocity of the MB, [m/s], g is the gravitational acceleration, [m/s2], d is 
the MB diameter, [m], and v is the kinematic viscosity the dispersant medium, [m2/s]. On 
Figure 5 the graphic plot according to this equation is represented.  
The effect of buoyancy may significantly influence particle sizing and determination of Zeta 
potential depending on the particular measurement method. For this reason, one of the criteria 
for selection of methods for MB characterization will be the independence from buoyancy.  
In order to thoroughly characterize one MB dispersion, especially with regard to newly 
developed formulations, particles of all size classes must be compassed in the sampling. The 
effect of buoyancy turns MB sampling intricate since shortly after dilution of the freshly 
prepared concentrated MB dispersion large MBs float on the liquid surface and disrupt.  
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Figure 5: Mathematical calculation of the MB rising velocity according to the particle diameter based on the 
Stokes’ law. The buoying speed exponentially increases with the MB size. 
 
According to Figure 5, a MB with a diameter of 100 µm in diluted aqueous medium rises with 
a velocity of 5.5 mm/s and is exposed on the liquid surface quickly after the dilution of the 
MB dispersion. As seen from Equation 5, p.30 the stability of wet MB foams decreases with 
increasing MB size, thus on the air / water interface larger MBs are quickly dehydrated and 
degraded. Therefore, although larger MB fractions are mostly present in the undiluted MB 
dispersion they are undetectable with the most particle sizing methods which require 
exhaustive. On the other hand, since dilution precedes every clinical application of MBs, 
large-sized bubbles will be degraded in the vial, too. Nevertheless, since large bubbles may be 
clinically harmful their analysis requires special attention. One further criterion for selection 
of particle sizing methods will be therefore the detection of large bubble fractions in MB 
dispersions. 
Particle size and concentration measurements using electrical zone sensing were performed in 
cooperation with Mr. Raffi Bekeredjian, MD from the Internal Medicine III, Ruprecht-Karls-
University – Heidelberg, Germany and with Mr. Stefan Zahler, Ph.D. from Department of 
Pharmacy, Pharmaceutical Biology at the Ludwig-Maximilians-University – Munich, 
Germany. The author expresses his acknowledgements to Mr. Michael Pohl, Ph.D., Vice 
President Scientific Marketing at Horiba Instruments, Inc., Irvine, USA for the peer-reviewing 
of this chapter. 
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3. Materials and Methods 
3.1. Reagents 
 
Substance Abbreviation Purchased from 
Dipalmitoyl phosphatidylcholine DPPC Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl phosphatidylglycerol 
sodium DPPG Lipoid AG, Ludwigshafen, Germany 
Chloroform, HPLC-grade --- Sigma-Aldrich GmbH, Munich, Germany 
Octafluoropropane --- Sauerstoffwerk Friedrich Guttroff GmbH, Wertheim, Germany 
1,2,3-Propanetriol, water free Glycerol Sigma-Aldrich GmbH, Munich, Germany 
 
3.2. Production of liposome precursors and model microbubbles 
3.2.1. Production of liposome precursors 
Liposomes were formulated as intermediate product, and were following used to produce 
MBs by mechanical agitation. The thin-film hydration method was applied as described 
below. Briefly, dipalmitoyl phosphatidylcholine (DPPC) and dipalmitoyl 
phosphatidylglycerol sodium (DPPG) were dissolved under heating in HPLC-grade 
chloroform. After removing the organic solvent for 60 min at 65 °C under vacuum using a 
Büchi Rotavapor R-114 (Büchi Labortechnik GmbH, Essen, Germany), the phospholipid 
blend was hydrated with highly purified electrolyte-free water (Purelab Plus®, USF Elga 
Ionpure GmbH, Germany) to produce large multilamellar liposomes. Accordingly, the 
liposomes were shortly processed with low-frequency horn-type US homogenizer (Branson 
Sonifier®, Branson Ultrasonics Corp., USA) to produce small unilamellar vessels. The final 
total phospholipid concentration was 5 mM (3.68 mg/ml). The concentration of DPPC was 
80 mol% of the total phospholipid, corresponding to 4 mM or 2.94 mg/ml, and that of 
DPPG – 20 mol%, corresponding to 1 mM or 0.75 mg/ml. 
3.2.2. Production of model MBs 
The prepared small unilamellar anionic liposomes were placed in 2 ml safe-lock 
tubes (Eppendorf AG, Hamburg, Germany), cap space was filled with octafluoropropane gas 
and agitated at 4,500 oscillations / minute using a mechanical agitator 
 39 
CapMixTM (3M Deutschland GmbH, Neuss, Germany). With exception to experiments where 
the agitation time was varied, tubes were agitated for 20 s at room temperature. 
 
3.3. Pre-formulation studies on model microbubbles 
3.3.1. Effects of agitation time 
Microbubbles were produced by mechanical agitation, as the length of agitation (agitation 
time) was varied from 0 s to 60 s with an increment of 20 s. Immediately after agitation the 
tube temperature was measured by immersing a sensor (Ama-digit ad 15th, Amarell GmbH, 
Kreuzwertheim, Germany) into the liquid phase. Simultaneously, the air temperature under 
the CapMixTM protective hood was measured in order to eliminate the influence of device 
heating on the tube temperature. Air temperature increase was then subtracted from the tube 
temperature. 
Accordingly, the MB size distribution was determined by laser diffraction using Partica LA-
950 (Horiba Ltd., Kyoto, Japan). MB concentration was determined by PAMAS SVSS-
C (PAMAS GmbH, Rutesheim, Germany). All measurements were carried out in triplicate.  
3.3.2. Effect of liposome viscosity 
Liposomal precursor formulations were prepared as described above, whereby the aqueous 
phase was adjusted with glycerol from 0 mass% to 30 mass% with an increment of 5 mass%. 
The viscosity of liposomal formulations was determined by rheometry using 
Physica MCR (Anton Paar GmbH, Graz, Austria) at a constant shear of 2 Pa and a torsional 
moment of 61.4 µNm. Tubes were agitated for 20 s. Temperature in the tube was measured 
with an immersed sensor (Ama-digit ad 15th, Amarell GmbH, Kreuzwertheim, Germany). 
MB concentration was determined in freshly prepared samples by light blockage using 
PAMAS SVSS-C (PAMAS GmbH, Rutesheim, Germany). MB size distribution was 
determined by laser diffraction using Partica LA-950 (Horiba Ltd., Kyoto, Japan).  
3.3.3. Effect of tube fill volume 
Tube fill volume will be defined here as the per cent ratio between the volume of liquid phase 
and the total volume of the tube container. Tube fill volume was varied from 10% to 50% of 
the total tube volume of 2 ml. Polypropylene tubes with U-shaped bottom (Eppendorf AG, 
Hamburg, Germany) were used in this study. Filled tube containers were agitated for 20 s and 
the MB concentration was measured in the freshly prepared samples by light blockage using 
PAMAS SVSS-C (PAMAS GmbH, Rutesheim, Germany). MB size distribution was 
 40 
determined by laser diffraction using Partica LA-950 (Horiba Ltd., Kyoto, Japan). Samples 
were prepared and measurements were carried out in triplicate (m = 3, n = 3). 
3.3.4. Effect of tube shape 
Containers with constant volumes of 2 ml and different bottom geometry were tested in order 
to evaluate the influence of agitation dynamics, determined by the container geometry, on the 
MB size distribution and concentration at constant agitation speed and time. Polypropylene 
tubes having V-shaped and U-shaped bottoms (Eppendorf AG, Hamburg, Germany), as well 
as glass vials with F-shaped bottom (VWR International GmbH, Darmstadt, Germany) were 
tested.  
Particle concentration was determined by light blockage using PAMAS SVSS-C (PAMAS 
GmbH, Rutesheim, Germany). Particle size distribution was determined by laser diffraction 
using Partica LA-950 (Horiba Ltd., Kyoto, Japan). 
 
3.4. Characterization of microbubbles 
3.4.1. Size distribution measurements 
Five instrumental methods for particle sizing were compared in their applicability for 
characterization of MB samples. The methods included laser diffraction, dynamic light 
scattering, light blockage, and electrical zone sensing.  
Laser diffraction measurements were performed using Partica LA-950 (Horiba Ltd., Kyoto, 
Japan), equipped with a blue LED laser source, operating at a wavelength of 405 nm, and a 
red laser source, operating at 650 nm. The measurement range of the device was from 40 nm 
up to 3 mm. The laser diffractometer was equipped with quartz cuvettes with volumes of 
15 ml and 10 ml and a magnetic stirring facility. Optical model was produced and data 
processing was carried out using the software Horiba LA950 v.5.00. The iteration value was 
set to 15 for all measurements. MB formulations were sampled immediately prior to 
measurements by addition of 20-100 µl undiluted freshly prepared MB dispersion into the 
dilution medium – highly purified water, under continuous stirring.  
Optical method parameters – refractive index and absorption index, were established based on 
the approach of Kinoshita et al. (2001) [112]. Briefly, the detected intensity of scattered light 
(s) was mathematically transformed into particle size distribution and back again into 
estimated light intensity distribution (s*). The conformity of s and s* was automatically 
calculated by the application software as the cosine of the value of the angle between 
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them (cosθ). When the optimal refractive index has been selected, the most accurate particle 
size distribution has been obtained and then it was expected that s* would be completely the 
same or very close to s and cosθ would trend to zero.  
In order to determine an appropriate refractive index range for MB sizing, three identical MB 
samples were measured by laser diffraction. Rough measurement data for each sample was re-
calculated using various refractive index values ranging from 0.300 to 3.000 with an 
increment of 0.300 for both blue and red laser sources, while keeping the absorption index at 
zero. Values of cosθ, as well as number-weighted median particle sizes, were calculated by 
the application software for each value of the refractive index. Accordingly, cosθ and median 
particle size were graphically plotted against the refractive index. Refractive index values, 
corresponding to the minimum values of cosθ, were selected as appropriate for MB particle 
sizing and implemented in the optical model. In the application software Horiba LA950 
v.5.00, cosθ  is referred to as chi-square (χ2). 
The same procedure was followed in order to determine appropriate values for the MB 
absorption index which was varied in the range from 0.0100 to 0.1000 with an increment of 
0.0100, while keeping the refractive index at the previously selected optimum value.  
For verification MB particle size data, obtained with the established optical model, was 
compared with data, obtained from electrical zone sensing and light blockage measurements. 
Alternatively, particle size in MB formulations was determined by dynamic light scattering in 
the range from 0.001 nm to 5,000 nm using right-angle and backscatter approaches. 
Zetamaster S (Malvern Instruments Ltd., Worchestershire, UK) was utilized for the right-
angle approach, while Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., 
Worchestershire, UK) was used for backscatter measurements. MB concentration was 
adjusted to about 1 x 104 MB/ml for right angle measurements and to about 1 x 107 MB/ml 
for backscatter measurements. The refractive index for MBs was set to 0.90, and the 
absorption index – to 0.01, according to the established optical model. The refractive index 
for the dispersant was set to 1.333, corresponding to water. The Zetasizer device was 
equipped with a laser source operating at 405 nm wavelength. 
MB size distribution was determined by light blockage in the size range between 800 nm and 
200 µm in diluted samples using PAMAS SVSS-C (PAMAS GmbH, Rutesheim, Germany) 
equipped with a syringe sampling pump and a stirring facility. Samples for measurements 
were prepared by dilution of 20 µl of the freshly prepared MB sample in highly-purified 
degassed water until the particle count decreased to less than 2 x 105 MB/ml. Portions of 1 ml 
were drawn in triplicate from the diluted sample for analysis. The bubble size distribution in 
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the range from 800 nm to 200 µm as well as the MB concentration were determined 
simultaneously. 
The syringe pump speed was varied from 2 ml/min to 20 ml/min in order to assess the 
influence of pressure stress on the measured MB size.  
As an alternative to the optical methods, measurements with electrical zone sensing were 
performed using MultisizerTM 3 Coulter counter (Beckman Coulter, Inc., Fullerton, USA) 
equipped with a stirring facility. Aperture current was set to 800 µA and volumes of 100 µl 
were metered. Samples were measured at concentrations of about 106 MB/ml after dilution 
with Isoton II. 
3.4.2. Determination of MB Zeta potential 
Zeta potential of MB formulations was determined by electrophoretic light scattering using 
Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., Worchestershire, UK). During the 
measurements the dielectric constant (τ) was set to 78.48 (pure water at 25 ºC). The optical 
parameters – refractive index and absorption index, for MBs were set to correspondingly 0.90 
and 0.01. The applied voltage value was set to 50 V and the monomodal analysis model was 
used. MB concentration was adjusted to about 1 x 105 MB/ml. Prior to measurements MB 
size was determined by laser diffraction using Partica LA-950 (Horiba Ltd., Kyoto, Japan). 
Measurements were carried out in triplicate for each sample. Data was processed using 
Dispersing Technology Software v.5.10 (Malvern Instruments Ltd., Worchestershire, UK). 
3.4.3. Determination of MB concentration  
MB concentration measurements in the size range from 800 nm to 200 µm were performed by 
light blockage using PAMAS SVSS-C (PAMAS GmbH, Rutesheim, Germany). The particle 
concentration in samples was kept below the maximum measurable particle concentration of 
2 x 105 MB/ml. Portions of 1 ml were automatically drawn by a syringe pump from the 
diluted MB dispersion with a pace of 5 ml/min. 
Alternatively, the MB concentration was determined by electrical zone sensing using 
MultisizerTM 3 Coulter counter (Beckman Coulter, Inc., Fullerton, USA) after dilution with 
Isoton II. 
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4. Results and Discussion 
4.1. Pre-formulation studies on model microbubbles 
4.1.1. Effect of agitation time 
According to the results of this study, the net energetic effect of mechanical agitation is 
exothermic and depends rather linearly from the agitation time (Figure 6, dashed line). The 
temperature of the liquid phase increased from 24.31 °C ± 1.75 °C to 46.57 °C ± 3.04 °C 
within 60 s of agitation. The tube temperature was not significantly influenced by the device 
heating since the air temperature under the protective hood only raised by 2.08 °C ± 0.87 °C. 
Interestingly, the MB concentration increased during the first 20 s of agitation, followed by a 
steep 3-fold decline after 40 s to 60 s. The influence of tube temperature on the MB yield can 
be attributed to the transition state of the shell phospholipids. MB shell is much more stable 
when the phospholipid exists in condensed gel state. The phase-transition temperature of the 
used DPPC / DPPG mixture is 41.55 °C ± 0.11 °C (refer to Table 10, p.98) which was 
approached after 40 s of agitation. The resulting phase shift from condensed gel to liquid-
crystalline phase state apparently destabilized the monolayer shell and led to degradation of 
MBs.  
 
 
Figure 6: Effect of agitation time on the tube temperature and MB yield (n = 3). Tube temperature increased 
proportionally to the agitation time, while MB concentration reached a maximum at 20 s and steeply decreased, 
when the melting temperature of the shell phospholipid was reached. 
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However, the effect of MB degradation cannot be explained only by the temperature increase, 
since in follow-up studies MB dispersions, incubated for over 90 min at 60 °C under static 
conditions, showed only a moderate concentration decrease of about 17.5%. Apparently, the 
observed phenomenon can only be explained under consideration of the combined effect of 
temperature and shear stress.  
A significant effect of the agitation time on the MB particle size distribution was also 
demonstrated, as shown on Figure 7. Initially, a single broad peak between 260 nm and about 
10.1 µm was present in MB samples 20 s after agitation start. Longer agitation of 40 s 
resulted in a peak sharpening and narrowing to size values between about 800 nm and 5.8 µm. 
Furthermore, a second small peak was formed between 34 µm and 77 µm. At 60 s agitation, 
the large-sized peak gained intensity and broadened between about 23 µm and 153 µm.  
 
 
Figure 7: Surface-weighted MB particle size distribution as a function of the agitation time.  
 
Microscopic observations revealed that during the first five to ten seconds of agitation the MB 
dispersion is rather “immature” and inhomogeneous, comprising micrometer- to millimeter-
sized agglomerates of small and large bubbles and phospholipid (data not shown). Later on, 
after 20-30 s the phospholipid aggregates and large “primary” bubbles were sheared and a 
homogeneous MB dispersion was formed. 
Obviously, the optimal MB size distribution was obtained 40 s after agitation start. However, 
this was accompanied by an about 1.5-fold decrease of MB concentration after 40 s agitation 
compared to 20 s. These results suggest that with regard to each particular drug-loaded 
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formulation, the optimal agitation time should be sought between 20 s and 40 s under 
consideration of the two factors – MB size distribution and yield. 
4.1.2. Effect of liposome viscosity 
Liposome viscosity increased almost linearly from 1.5 Pa.s to about 3 Pa.s upon increasing 
glycerol concentration. The influence of liposome viscosity on the production of MBs by 
mechanical agitation revealed complex trends both in the devolution of the tube temperature 
curve, as in the MB concentration.  
By increasing the viscosity in the above range two maxima were observed in the tube 
temperature curve after 20 s of agitation (Figure 8, solid line). Initially, addition of 5 mass% 
to 10 mass% glycerol led to a small but reproducible tube temperature increase of about 2 °C 
compared to glycerol-free samples. Interestingly, the moderate temperature increase was 
accompanied by an over 2-fold increase of MB concentration (Figure 8, dashed line).  
 
 
Figure 8: Effect of liposome viscosity (at τ = 2 Pa) on the tube temperature and the MB yield at agitation time 
20 s (n = 3). Dashed line represents the tube temperature after agitation for 20 s. Solid line represents the MB 
concentration in freshly prepared samples. 
 
Further increase of viscosity resulted in an unexpected drop of tube heating of over 5 °C 
together with an insignificant decrease of MB concentration. Tube heating rate rose back to 
about 37 °C upon reaching a viscosity of 2.73 Pa.s. In general, a viscosity increase of 
1.405 ± 0.054 Pa.s raised the MB yield about 10-fold. This was despite the enhanced tube 
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heating during agitation, since the gel-to-liquid phase transition of shell phospholipids – 
41.55 °C ± 0.11 °C, had not yet been reached. 
Apparently, glycerol had some more specific effects on the system rather than simply 
increasing the viscosity, since the non-linear character of both the temperature curve and the 
MB concentration curve did not correspond to the linearity of the viscosity increase at 
growing glycerol concentration. 
 
 
Figure 9: Effect of viscosity (at τ = 2 Pa and 25 °C) on the MB mean size according to number-weighted 
particle size data. 
 
Furthermore, viscosity had significant influence on the MB size distribution, yet this effect 
was only pronounced between 0 mol% and 5 mol% (Figure 9), in which range the viscosity 
increase was only 0.07 Pa.s. Thus, apparently this is also due to interactions between the 
phospholipids and glycerol, rather than an effect, caused by the viscosity.  
Generally, addition of 5 mass% to 10 mass% of glycerol resulted in a sharpening and 
narrowing of the main MB peak between 500 nm and 7 µm. On surface area-weighted 
diagrams, the emerging of a second peak between 50 µm and 100 µm was observed at 
glycerol concentrations above 10 mass%. 
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4.1.3. Effect of tube fill volume 
The proportion between the volume of liposomal dispersion and the total volume of of the 
tube container was denoted here as tube fill volume. It had a moderate, but significant 
influence on the MB yield (Figure 10), and a more pronounced effect on the MB size 
distribution. Generally, with increasing the tube fill volume from 10% to 50% of the total tube 
volume the MB concentration decreased approximately two times, as maximum yield was 
achieved at 20% tube fill volume.  
Along with this, the fraction of large MBs in the size range of several hundred micrometers 
steeply increased. In surface area-weighted size diagrams only the MB peak between about 
500 nm and about 6 µm was present at fill volumes of 10% and 20%. At 30% tube fill volume 
the size peak between about 60 µm and about 100 µm appeared, while further increase to 40% 
and 50% of the tube volume resulted in the emerging of smearing peaks from about 200 µm 
to about 600 µm.  
 
 
Figure 10: Effect of tube fill volume on the MB yield (m = 3, n = 3) after agitation for 20 s. Maximal MB yield 
was achieved, when 400 µl liquid phase – liposome precursor dispersion, were filled in the tubes, having a total 
volume of 2,000 µl (20% tube fill volume). 
 
The observed effects can be explained with the downgraded mixing kinetics of gas and liquid, 
if the cap space is too small to allow adequate bouncing of the liquid phase during agitation. 
At higher tube fill volumes of e.g. 50% a large part of the gas phase is absorbed into the liquid 
phase. Because of the MB formation, the dynamic viscosity of the liquid phase grows about 
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300-fold (data not shown). Therefore, the fluid dynamics in the tube are hindered and no 
sufficient shear forces can result.  
This is an appropriate explanation for the reduced fraction of small MBs since at higher tube 
fill volumes more shell material is employed in larger bubbles.  
4.1.4. Effect of tube shape  
Tube geometry had a moderate effect on the MB formulation. No difference could be found 
between size distribution and concentration of MBs, produced in F-bottom and U-bottom 
tubes. When V-bottom tubes were used, there was a significant increase of MB size and a 
large-sized bubble peak between 60 µm and 120 µm emerged. Once again this effect could be 
attributed to the unadvantageous fluid dynamics during agitation, caused by the narrow V-
shaped tube bottom. 
 
4.2. Characterization of microbubbles 
4.2.1. Size distribution measurements 
MB optical parameters – absorption index and refractive index, are additive values, resulting 
from the interplay of gas core and MB shell. The light scattering pattern by MBs is rather 
complex and influenced by high-order refraction, reflection, and light absorption events.  
Optimal refraction- and absorption indices for phospholipid-shelled MBs were established by 
plotting the cosθ function at various refractive index values (Figure 11). On the refractive 
index scale from 0.3 to 3.0 the value of cosθ varied from 0.2100 ± 0.0500 to 8.7960 ± 0.8000. 
The number-weighted median particle size varied correspondingly from 
0.2070 µm ± 0.0200 µm to 0.8330 µm ± 0.0500 µm (Figure 12). The plot of cosθ revealed 
two minima at refractive index values from 0.600 to 0.900 and from 2.700 to 3.000, 
corresponding to median particle sizes of about 0.80 µm ± 0.08 µm. 
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Figure 11: Graphical plot of the value cosθ at refractive index-values, ranging from 0.300 to 3.000. The 
minimum cosθ value of 0.21 corresponded to the correct refractive index of 0.90. 
 
 
Figure 12: Graphical plot of the value median particle size in number-weighted size distributions at refractive 
index-values, ranging from 0.300 to 3.000. The selected refractive index value of 0.90 corresponded to a median 
MB size of about 0.800 µm which was consistent with referent measurements by light blockage. 
 
Since the refractive index of MB gas cores is about 1.000 values between 0.900-0.950 were 
rendered suitable for MB size measurements. MB particle size, corresponding to this value 
was further confirmed by electrical zone sensing and light blockage measurements. 
The effect of absorption index on cosθ and median particle size is shown on Figure 13. 
Interestingly, varying of absorption index in the range between 0.01 and 0.10 resulted in no 
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change of cosθ. Nevertheless, a deviation of about 200 nm was observed in the median 
particle size in this range.  
 
Figure 13: Graphical plot of the value cosθ at absorption index-values, ranging from 0.01 to 0.10 (dashed line) 
and a refractive index of 0.95. Next to that, the change of median particle size in number-weighted size 
distributions is represented (solid line). 
 
Taking a look on the surface-weighted MB size distribution at refractive indices in the above 
range, peak form and size range variations were even more pronounced. At refractive index 
values below 1.000 they mainly affected the MB peak between 0.8 µm and 6.0 µm, whereby 
the larger-sized peak between 60.0 µm and 100.0µm remained mostly unchanged. Higher 
values of the refractive index completely distorted the size distribution.  
Based on these findings, the values of refractive index and absorption index for MBs were 
correspondingly set to 0.90 and 0.01. 
Comparisons between number-weighted data provided by laser diffraction with light blockage 
and by electrical zone sensing proved that the established optical model successfully 
represents the MB particle size in the size region between about 0.8 µm and 10 µm. This 
finding rendered as a proof of concept for the applicability of the own optical model. 
Another important issue regarding particle sizing of MBs is the data weighting approach and 
how to interpretate the size distribution data.  
The original particle size data, produced by laser diffraction, is the volume-weighted 
distribution, represented as a dashed-line plot on Figure 14. When weighing size distribution 
according to the particle volume, large particles are overstated in their intensity. However, the 
payload-carrying MB compartment is not their entire volume, but the MB shell, since over 
90% of MB volume comprises of gas. In the case of phospholipid MBs, the MB shell is only a 
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few nanometers thick and therefore its volume can be approximated to the MB surface. 
Therefore, in several recent publications [113] the MB loading is represented as a ratio of the 
loaded mass per surface area in [pg/µm2].  
Therefore, the surface area-weighted particle size distribution (Figure 14, dotted line) is 
apparently the most purposeful mode to display the size distribution of drug-loaded MBs, 
while the volume-weighted size distribution can be considered as a quality method, when 
large MBs need to be observed. The surface-area weighted distribution can provide an 
approximate estimation about the percent amount of MBs smaller than 10 µm and the percent 
payload amount, carried by them. As it is known, MBs greater than 10 µm are liable to be 
more rapidly eliminated by the narrow capillary vasculature of the lungs and the spleen.  
 
 
Figure 14: Particle size distribution in a whole freshly-prepared MB formulation, represented in number-
weighted (solid line), surface area-weighted (dotted line), and volume-weighted (dashed line) modes. The value 
q, [%] on the y-axis represents the percentage of particles with a certain size in the measured sample. 
 
The number-weighted size distribution can be either mathematically derived from the volume-
weighted distribution. In this mode, smaller sized particles are displayed with the greatest 
peak intensity, while larger particles are ignored. Therefore, the number-weighted size 
distribution os less purposeful in the characterization of MB size distribution.  
The sampling of undiluted MB dispersion directly into the measurement cuvette under 
continuous stirring allowed to measure larger bubbles in the range over 50 µm which are not 
detectable after dilution.  
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Another light scattering method – dynamic light scattering which is less frequently used in 
accordance to MBs [68, 114, 115] has been either assessed for particle sizing of MBs. The 
dynamic light scattering derives particle size information from the time-dependent 
fluctuations in the intensity of scattered light due to the random Brownian motion of the 
particles. Thereby, the mathematical conversion is based on the Stokes’ law. Its measuring 
range embraces the entire nanometer range and the lower micrometer range up to about 3-
6 µm. Similarly to the laser diffraction, particles’ refractive and absorption indices are needed 
for measurements in certain particle sizes. 
Two different setups of dynamic light scattering were tested: the right angle scattering, where 
the laser beam and the detector are positioned at a 90° angle, and the backscattering approach, 
where laser source and detector embrace an angle of 173°. While the right angle scattering 
setup was limited concerning concentrated and turbid samples, the backscattering setup was 
applicable with highly concentrated MB dispersions. However, both approaches suffered 
serious reproducibility problems as well by measuring of different samples as during 
consecutive measurements of a single sample over a certain time span. Apparently, the 
measurements were disturbed by upright particle movement due to buoyancy which 
overlapped the random Brownian movement. Furthermore, the typical MB size distribution 
lies on the upper end of the size scale of dynamic light scattering. For these reasons, dynamic 
light scattering was considered inappropriate as a method to determine MB particle size. 
Light blockage is a particle counting method which operates independently from the particles’ 
optical parameters refractive and absorption index. According to it, particles flow one at a 
time through a narrow region of uniform light illumination and their light shades are detected. 
The method is applicable for simultaneously particle counting and sizing in the range from 
0.8 µm to 200 µm.  
 
 53 
 
Figure 15: Number-weighted particle size distribution of MB dispersions, obtained by light blockage (dashed 
line), electrical zone sensing (solid line), and laser diffraction (dotted line). MB formulation comprised 80 mol% 
DPPC and 20 mol% DPPG. 
 
The particle size data, originating from light blockage measurements, is number-weighted and 
is therefore less useful to determine the drug-load mass distribution than the surface-weighted 
data (Figure 15, dashed line). Furthermore, since the size region below 800 nm is out of the 
method range, the MB size peak cannot be represented completely. Recent particle counting 
devices, implementing both the concepts of light blockage and single particle light scattering, 
such as Accusizer 780A (NICOMP Particle Sizing Systems, Santa Barbara, USA) can 
overcome these limitations in the nanometer region [116]. 
One further limitation of light blockage as particle sizing method for MBs is the exhaustive 
sample dilution necessary for measurements. As stated above, due to their rapid buoyancy and 
low stability at the water-air interface larger MBs were undetectable by this method.  
Another setup complication was revealed by varying the speed of the sampling syringe pump 
from 2 ml/min to 20 ml/min. Since MBs are sensitive to pressure changes a shift in the 
measured upper MB size from 5 µm to about 3 µm was detected during measurements of the 
same sample. With increasing syringing pace the MB size decreased continuously 
corresponding to the increased hydrostatic pressure within the measuring cell.  
An effect of decreasing of MB concentration was observed under continuous stirring of 
diluted MB dispersions. The particle concentration decreased by 32.1% ± 1.51% during 
stirring at 100 rpm for 20 min.  
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For these reasons conditions for MB size measurements should be selected very consciously, 
avoiding excessive shear forces and pressure stress, and the measurements ought to be carried 
out immediately after sampling.  
Electrical zone sensing is a non-optical method for particle sizing and counting which has 
been most widely applied in the literature for characterization of MB formulations [59, 117, 
118]. It allows particles to be counted and sized on the basis of the impedance change in an 
electromagnetic field when a particle passes through an aperture, positioned between two 
electrodes. The size capacity of the method ranges between 0.4 µm and 1.0 µm when using an 
aperture of 1 µm and from 1.0 to about 30 µm when using an aperture of 50 µm. In the case 
of MBs, only the larger aperture of 50 µm is applicable which limits the sizing range to the 
micrometer range (Figure 15, solid line). Occurring aperture clogging through larger bubbles 
makes measurements in the nanometer range impossible. Important advantages of electrical 
zone sensing are the independency from buoyancy effects and the stirring option. However, 
little is yet known about the electric resistance of shelled MBs. This renders the precise 
calibration of Coulter counters complicated. 
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In comparison, from the tested particle sizing 
methods laser diffraction appears to be the 
most suitable approach, since it covers both the 
nanometer and micrometer size ranges, and is 
not affected by MB buoyancy (Table 1). 
However, because of the complex light 
scattering characteristics of MBs, an arbitrary 
method such as electrical zone sensing or light 
blockage should be used to prove the reliability 
of measurement data. Particle size data, 
obtained using these three methods for 
characterization of model MBs comprising 
80 mol% DPPC and 20 mol% DPPG, is 
represented in Figure 15. Measured MB peak 
from 0.8 µm to 4.10 µm appeared on the 
bottom limit of the measurement range of light 
blockage. The peak, obtained using electrical 
zone sensing, slightly deviated and emerged 
between 1.18 µm and 2.97 µm. Compared to 
the above standard methods, laser diffraction 
delivered a MB size peak, ranging from 
1.005 µm to 2.976 µm. The above comparison 
was a proof of the concept that laser diffraction 
in combination with the properly established 
optical model provides reliable particle size 
data for phospholipid-shelled MBs. Based on 
the comparison between advantages and 
drawbacks of the evaluated particle sizing 
methods (Table 6), laser diffraction was 
established as standard method further on in 
this thesis. 
Table 6 
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4.2.2. Determination of MB Zeta potential 
Zeta potential is an important characteristic of a MB formulation and provides information on 
its colloidal stability, biological characteristics, and drug-loading capacity. For example, 
anionic MBs are longer retained in the myocardium and in the lungs compared to neutral 
MBs [101]. The charge-coupling of e.g. pDNA to cationic MBs is dependent on the Zeta 
potential, too [57, 117, 118].  
Electrophoretic light scattering is the most commonly used method to determine the Zeta 
potential of MBs [119]. Charged particles are brought to oscillation by means of alternating 
electric field. Laser scattering, caused by the moving particles, is than measured and the 
particle mobility is determined. The electrophoretic mobility is then mathematically converted 
to Zeta potential. 
Because Zeta potential measurements are based on directed particle movements, they can be 
influenced by MB buoyancy. According to the present study, the influence of buoyancy on 
Zeta potential measurements was size dependent. Repeated measurements in MB samples 
with narrow size distribution of between 0.8 µm and about 4.0 µm revealed no shift of the 
measured Zeta potential within a time span of 40 min, but a gradual decrease of the count rate 
from about 500 kcps to about 200 kcps. On the contrary, Zeta potential in samples comprising 
larger MBs, sized between 30 µm and 60 µm could not be determined with a satisfactory 
reproducibility. This was attributed to their more rapid buoyancy which caused a gradual shift 
of measured Zeta potential from -43.2 mV ± 3.75 mV to -29.8 mV ± 4.12 mV. Therefore, in 
further studies the Zeta potential of liposomes will be determined instead of that of MBs 
under the assumption that these two values are similar or identical. 
4.2.3. Determination of MB concentration  
MB concentration was reliably determined both by electrical zone sensing and by light 
blockage. In the case of light blockage, the upper measurement concentration limit for MBs 
was about 2 x 105 MB/ml, corresponding with manufacturer’s specifications. Above this 
concentration, measured particle counts were significantly lower than expected values, based 
on the dilution coefficients. This effect can be explained with the overlapping of particle 
shades within the illuminated region of counting, whereby two or more particles are detected 
as a single larger particle. A similar effect of detection co-incidence could also be observed in 
measurements with electrical zone sensing in the concentration range of about 1-2 x 105 
MB/ml. 
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5. Summary 
Although mechanical agitation as a method to produce MBs is well-known for a long time, its 
basics have not yet been discussed in the literature. Therefore, one purpose of the studies in 
this chapter was to arrange the basic process parameters for MB production, using model 
phospholipid MBs without considering the impact of drug load. Several intriguing effects of 
such process parameters as agitation time, tube fill volume, and tube geometry on the MB size 
distribution and MB yield have been demonstrated. Based on this, an attempt was made to 
describe the mechanism of MB formation under high mechanical shear.  
There seems to be an analogy between the dispersing processes during high-shear mechanical 
agitation and horn-type ultrasound emulsification, yet by aid of some approximation. 
Similarly to the shear forces during high-speed agitation, intensive shear – acoustic streaming 
emerges around the sonication horn-type, too. Nonetheless, in the case of mechanical 
agitation there is no evidence of occurring cavitation, as during horn-type homogenization.  
A model of the mechanic processes, occurring during US horn-type emulsification has been 
described by Li et al. (1978) [120, 121]. According to it, the dispersing of the oil phase in the 
water phase takes place in two stages. Instability of the oil / water interface results in the 
entrapment of large “primary” droplets into the aqueous phase. Following, the “primary” 
droplets are broken down to smaller “final” droplets of various sizes which is the origin of the 
emulsion polydispersity. 
During mechanical agitation the contact interface between liquid phase and gas phase is 
rapidly enhanced by the dispersing of gas into the aqueous phase. The enhanced gas-liquid 
interface is stabilized by phospholipid monolayers, emerging from the “unzipping” of 
liposome bilayers. By analogy, large “primary” bubbles are formed during the first 5-10 s of 
agitation as described in 4.1.1 Effect of agitation time, p.43. 
In the context of 4.1.3 Effect of tube fill volume, p.47 the second step of the MB formation – 
breaking down of large “primary” bubbles was apparently inhibited by the insufficient free 
tube volume at tube fill volumes of 40-50%. Therefore, the “primary” bubbles could be still 
observed in these samples. 
During the mechanical agitation, equilibrium appears to exist between liposomes and MBs, 
since liposomes are degraded to form MBs and MBs can be degraded back to liposomes. 
Within the vial, mechanical shear forces and temperature increase are apparently the two main 
physical factors, governing the equilibrium.  
For the first time the temperature increase in the tube due to the exothermic character of 
mechanical agitation has been disclosed as the correlation link between agitation time and MB 
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yield. Furthermore, it was possible to steer the equilibrium between MBs and liposomes as 
well as the MB size by manipulating several properties of the precursor liposome 
formulations, agitation process parameters, etc. This approach rendered a novel effective 
strategy for formulation development of drug-loaded MBs which has been named liposomal-
controlled microbubble production (LCMP). 
The effect of liposome viscosity on MB size and yield has been revealed in this chapter, too. 
However, it was difficult to discuss on the observed effects since there seemed to be an 
additional effect of glycerol, used as thickening agent, on the phospholipids.  
One further aim of the studies in this chapter was to select appropriate methods for particle 
sizing, determination of Zeta potential, and MB concentration. Candidate particle sizing 
methods embraced laser diffraction, dynamic light scattering, light blockage, and electrical 
zone sensing. Laser diffraction in combination with a properly established optical model for 
MBs was chosen as standard MB sizing approach, based on its broad size range, sampling 
manner, allowing the detection of large bubbles, and independency of buoyancy effects. The 
applicability of the own optical model was scrutinized by comparison with data, established 
by electrical zone sensing and light blockage measurements. 
Zeta potential measurements with MBs did not always deliver a satisfactory reproducibility 
depending on the MB size and intensity of buoyancy effects. Therefore, only precursor 
liposome formulations were characterized in their charge under the assumption that Zeta 
potential of the resulting MBs is close to its value. 
Measurements of MB concentration were possible by both approaches tested – electrical zone 
sensing and light blockage.  
The studies under this chapter revealed the most important process parameters for MB 
production by mechanical agitation and for MB characterization. These will be applied by 
analogy in formulation studies on drug and gene-loaded MBs further in this work. 
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III. CHAPTER: In-vitro studies on the acoustic destructibility 
of microbubbles 
1. Abstract 
Microbubble contrast agents (MBs) in combination with diagnostic ultrasound (US) have 
recently become a very promising approach for specific drug and gene targeting. Numerous 
MB structure designs have been adapted to carry and deliver genes and drug molecules with 
different physico-chemical properties. Drug-loaded MBs can be administered by intravenous 
infusion or injection and reach even distant tissues and organs. On the target site they can be 
visualized by well tolerated diagnostic US and aid the localizations of tissue lesions, tumors, 
etc. Accordingly, the drug can be released from the MB carriers by increasing the US 
intensity and “bursting” the MBs. 
The acoustic destructibility is one of the most important MB features, especially for those, 
having polymeric, albumin, or oil shells. Nevertheless, loading of MBs with drugs and genes 
may also have an influence on the acoustic properties and destructibility of MBs. In the 
present work, an improved, near physiological conditions acoustic transmission line (PCATL) 
in-vitro model will be described for fast pre-clinical screening of MB formulations. 
The PCATL model will be used to demonstrate the differences in the destructibility of MBs 
with various sizes and give an empirical proof of the theory of Apfel and Holland (1989). 
Following, the destructibility of MBs will be examined at various US frequencies and 
intensities.  
In the next IV. CHAPTER: Ultrasound targeted tumor therapy the PCATL model will be 
applied to evaluate the acoustic destructibility of doxorubicin-loaded phospholipid MBs and 
doxorubicin-loaded acoustically-active lipospheres in order to select the better candidate for 
in-vivo clinical studies. 
 
Keywords: microbubbles, ultrasound, acoustic destructibility, in-vitro modeling; 
 
Abbreviations: PCATL – (near) physiological conditions acoustic transmission line, MB – 
microbubble; US – ultrasound; 
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2. Introduction 
Ultrasound mediated destruction of microbubbles (MBs) has become a promising tool for site 
specific drug and gene delivery. One of the most important properties of drug-loaded MBs is 
their destructibility by ultrasound (US). Therefore, the aim of this study was to establish an 
improved in-vitro model that allows evaluation of the kinetics of US-mediated MB 
destruction at near physiological conditions. 
With respect to the development of new drug-loaded MB formulations, the acoustic 
destructibility is an issue of great importance as it is influenced not only by the type of 
phospholipid, but even more by the physico-chemical properties and amount of the drug, 
loaded to MBs. 
Numerous in-vitro approaches for characterization of the backscatter efficacy, oscillation 
behavior, and fragmentation onset have been described in the literature (Table 7). Most in-
vitro models are based on the detection of acoustic backscatter signals or high-speed 
microscopy in order to monitor the oscillation of single bubble or a population of MBs. 
Furthermore, many authors implement facilities for near physiological conditioning of their 
in-vitro setups e.g. pressurizing, temperature adjusting, embedding MBs in physiological 
media and/or blood vessel mimicking capillaries, tissue-mimicking, etc.  
The aim of this study was to develop an in-vitro model to assess the US destructibility of 
various MB formulations at near physiological conditions. In addition, the potential influence 
of drug-loading was investigated using the newly developed in-vitro model.  
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Author Medium Detection Near physiological conditioning 
Experimental 
MB type 
Commercial 
standard 
Degassed water Echo-backscatter 
Pressurizing at 0, 
80, or 150 mmHg Unger 
et al. (1998) [122] Saline Echo-backscatter 
Blood-vessel 
simulation 
soy-bean oil 
AALs 
Aerosomes 
MRX-113, 
(ImaRx, Tucson, 
USA) 
Moran 
et al. (2000) [123] 
Sterile water 
(Definity ® and 
Optison ®), or 5% 
dextrose solution 
(Sonazoid ®) 
Echo-
backscatter 
Tissue-mimicking 
material 
Definity ® 
(Bristol-Myers 
Squibb, USA), 
Sonazoid ®  
(GE Healthcare, 
USA), 
Optison ®  
(GE Healthcare, 
USA) 
none 
Lazewatsky 
et al. (1999) [124] Blood or saline 
Backscatter 
visual signal 
Circulation, 
pressurizing at 
110 mmHg, 
conditioning at 
37 °C 
Definity ® 
(Bristol-Myers 
Squibb, USA) 
none 
Marsh 
et al. (2002) [125] Phosphate buffer 
Acoustic 
microscopy Circulation 
Liquid 
perfluorocarbon 
nanoparticles 
none 
Hoff 
et al. (1998) [126] Isoton II 
Echo-
backscatter 
Pressurizing at 
120 mmHg 
Sonazoid ®  
(GE Healthcare, 
USA) 
none 
Caskey 
et al. (2007) [127] 
0.75% agarose gel 
phantom 
High-speed 
microscopy none 
Phospholipid-
monolayer 
shelled MBs 
none 
Caskey 
et al. (2006) [128] n.a. 
High-speed 
microscopy 
Artificial capillary 
tubes 
Phospholipid-
monolayer 
shelled MBs 
none 
Lum 
et al. (2005) [64] n.a. 
Fluorescence 
microscopy 
Cellulose capillary 
tubes 
Fluorescent 
nanobeads-
associated 
phospholipid 
MBs 
none 
Table 7: Previously described in-vitro models for characterizing of MB acoustic properties. AALs – acoustically 
active lipospheres; n.a. – not available;  
 
The in-vitro model was designed in cooperation with Mr. Ralf Hiermaier from the University 
workshop for fine mechanics at the Ludwig-Maximilians-University – Munich, Germany and 
build by himself. 
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3. Materials and methods 
3.1. Reagents 
 
Substance Abbreviation Purchased from 
Bovine serum albumin --- Sigma-Aldrich GmbH, Munich, Germany 
Dipalmitoyl phosphatidylcholine DPPC Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl phosphatidylglycerol 
sodium DPPG Lipoid AG, Ludwigshafen, Germany 
Dulbecco’s phosphate-buffered saline --- Sigma-Aldrich GmbH, Munich, Germany 
Chloroform, HPLC-grade --- Sigma-Aldrich GmbH, Munich, Germany 
Octafluoropropane --- Sauerstoffwerk Friedrich Guttroff GmbH, Wertheim, Germany 
1,2,3-Propanetriol, water free Glycerol Sigma-Aldrich GmbH, Munich, Germany 
 
3.2. In-vitro experimental setup 
The experimental setup represents an improved, near physiological conditions acoustic 
transmission line (PCATL) model, based on the work of Lazewatsky et al. (1999) [124].  
The in-vitro model comprised a closed circulating system of silicone Tygon® tubings (Figure 
16) driven by a programmable peristaltic pump (Ismatec® IPC 8, Ismatec SA, Switzerland).  
 
 
Figure 16: Main experimental setup scheme: 1. Sample input / output syringe; 2. Acoustic absorbing plate; 3. 
Sonotrode (sonication probe); 4. Sonication membrane window; 5. Water bath; 6. Immersion heater; 7. Pressure 
input (110 mm Hg); 8. Gastric pump; 9. Tygon® tubing; The arrows represent the flow direction of the medium. 
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The interaction between MBs and US took place in a membrane flow-cell where the MBs 
were pumped through in an upright direction (Figure 17, C and D). The flow-cell was 
provided with a self-sealing septum that allows collecting samples for measurements (Figure 
17, A). Another port served to adjust the pressure in the system (Figure 17, B).  
 
 
Figure 17: Membrane flow-cell of the in-vitro model. A: Input / output septum gap; B: Pressure input port; C: and 
D: Circulation inlet- and outlet-ports. Black arrows represent the proposed MB flow-through pattern in the cell. 
 
The membrane flow-cell encompassed an egg-shaped inner compartment with a volume of 
4.5-4.8 ml and an oval membrane window where the US beam was applicated. The distance 
between the front and rear membrane of the flow-cell window was 8-10 mm at working 
conditions.  
The setup allowed certain physiological conditions such as blood pressure and body 
temperature to be mimicked. The pressure in the system was adjusted to 110 mmHg by the aid 
of a gauge-controlled syringe and a manometer. In all experiments the temperature was 
conditioned at 37 °C using a circulating water bath.  
The flow-cell was mounted in the water bath with a slide mechanism, allowing the distance 
between the sonotrode and the membrane window to be precisely adjusted.  
The US beam was produced by a technical US source Sonitron-2000 (RichMar Corp., 
Chattanooga, USA) equipped with 3 mm and 5 mm sonication probes. The sonication probe 
was installed on a membrane window in the wall of the water bath.  
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3.3. Establishing the in-vitro model  
The PCATL model was validated in order to determine the optimal operation conditions and 
to assure reproducibility of results.  
A series of blank measurements was performed with circulating MBs without applying US in 
order to assess the pace of MB decay through shear stress, pressure, and tube squeezing by the 
peristaltic pump. Additionally, the sampling syringe was calibrated by repeatedly drawing 
100 µl portions of water and determining their weight (n = 30). 
Generally in this manuscript, the US intensity is expressed through the overall energy output 
at the tip of the sonication probe, called output intensity, [W/cm2]. However, due to the 
specific conditions in the flow-cell, distribution of the US field and its attenuation, the peak-
negative acoustic pressure, [MPa] was measured directly in the flow cell under working 
conditions. A 250 µm fiber-optic probe hydrophone (FOPH 2000, RP Acoustics, Germany), 
equipped with an 810 nm infra-red laser source was used. In this manner the optimal focal 
distance of the sonication probe and the peak-negative acoustic pressure in the flow-cell under 
working conditions were determined.  
The flow conditions and the potential occurrence of dead volume compartments within the 
membrane cell were observed by injecting aqueous solutions of methylene blue into the 
circulation and pursuing their admixing with the medium. 
Finally, the flow rate through the membrane cell was optimized by determining the MB decay 
upon exposure to US with a frequency of 1 MHz and an intensity of 4 W/cm2 during varying 
the flow rate from 1 ml/min to 10 ml/min. 
Compared to previous similar in-vitro models the PCATL model was optimized in the 
following aspects: 
a) For the first time a particle-counting method is involved to simultaneously monitor MB 
concentration and size distribution during sonication; 
b) The optimized flow-cell shape minimizes the appearance of dead volume compartments; 
c) The model fulfills a number of physiological conditioning parameters such as 
temperature, hydrostatic pressure, ionic strength, and medium viscosity. 
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3.4. Acoustic destructibility studies  
The studies were directed towards investigation of the acoustic destructibility of MBs 
depending on the US frequency and intensity. Unloaded model phospholipid-shelled MBs 
were prepared according to the thin-film hydration method. Briefly, 80 mol% DPPC and 
20 mol% DPPG at a total concentration of 5 mM were blended in HPLC-grade chloroform. 
The organic solvent was eliminated under vacuum at 65 °C vor 60 min using a Büchi 
Rotavapor R-114 (Büchi Labortechnik GmbH, Essen, Germany). The phospholipid film was 
hydratized with highly-purified water (Purelab Plus®, USF Elga Ionpure GmbH, Germany). 
The resulting liposome formulation was aliquoted in amounts of 400 µl into 2 ml round 
bottom safe-lock tubes (Eppendorf AG, Hamburg, Germany) and covered with 
octafluoropropane gas. The liposomal dispersion was mechanically agitated for 20 s using a 
CapMixTM (3M Deutschland GmbH, Neuss, Germany).  
MBs were mounted into 1.2 µm filtered 5% w/w bovine serum albumin solution in 
Dulbecco’s phosphate-buffered saline, imitating blood plasma in viscosity, ionic strength, and 
pH. 
Prior to each experiment the flow-cell of the PCATL model was filled with medium and 
conditioned to 37 °C. The background particle concentration in the medium was measured. 
The freshly prepared MB suspensions were introduced into the running PCATL model by a 
calibrated 1 ml syringe through the septum gap. After the distribution of MBs in the entire 
setup volume, the pressure was adjusted to 110 mmHg and a sample of 100 μl was drawn 
through the septum, indicating the starting MB concentration. The drawn volume was 
replaced with medium in order to prevent pressure loss. US was applied and the above 
procedure was repeated. The collected sample was diluted in 40 ml particle free deionized 
water (Purelab Plus®, USF Elga Ionpure GmbH, Germany) and MBs size distribution and 
concentration were measured with light blockage using PAMAS SVSS-C (PAMAS GmbH, 
Rutesheim, Germany). The procedures of sampling and measuring were repeated after each 
sonication frame.  
MBs were exposed to US with a lower frequency of 1 MHz, and a higher frequency of 3 MHz 
at a constant US intensity of 4 W/cm2. This was in order to ascertain whether there is a 
dependency of MB destructibility from the MB size as known from the theory of 
Apfel et al. (1991) [129] and Holland et al. (1989) [130].  
In the second study, MBs were exposed to US with a frequency of 3 MHz and output 
intensity, increasing from 1 W/cm2 to 4 W/cm2 in order to characterize the correlation of MB 
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destructibility and US intensity. In both experiments, MBs were exposed to six sonication 
frames of 10 s at a duty cycle of 50% using a 5 mm sonication probe. 
In contrast to the in-vitro setup of Lazewatsky et al. (1999) [124] (Table 7), the 
implementation of whole blood into the PCATL model was impracticable due to the presence 
of formed blood elements which cannot be distinguished by the particle counting method 
used.  
For both studies, collected data from five repeated measurements was averaged. The standard 
deviation was determined and the significance of the results was assessed by single factor 
variance analysis (ANOVA). Mathematical curve data fitting was performed using 
SigmaPlot®, software version 9.0 (Systat Software, GmbH, Erkrath, Germany). The 
coefficient of determination R2 for each sonication decay curve was calculated. The 
experimental data was fitted using a single exponent decay two parameter function (Equation 
9), where a represents the initial population coefficient, b – the decay coefficient, and t – the 
sonication time. The MB half-life t1/2 during US exposure was calculated using Equation 10. 
 
tbeay .. −=  
Equation 9 
 
( )
b
t 2ln2/1 =  
Equation 10 
 
4. Results and Discussion 
4.1. Establishing the in-vitro model 
The optimal flow rate through the membrane cell of the PCATL model was determined to be 
4-5 ml/min (data not shown). Higher flow rates led to insufficient interaction of MBs with the 
US beam and therefore too slow destruction paces. A slower circulation caused MBs to buoy 
up and form a foam layer in the tubing, causing reduced reproducibility.  
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At optimum flow rate the minimum residence time for a MB in the membrane cell was 
calculated to be 1.5 s at a flow rate of 5 ml/min. Hence, a MB flowing through the membrane 
cell will be exposed to at least two US pulses when using a duty-cycle of 50%.  
The standard deviation of the sampling syringe was considered acceptable (σ = 1.7%) in a 
series of twenty repeats. The standard deviation of the PCATL model was derived from the 
measurement data. It was found to be 10.3% ± 3.2%. 
The focal distance between the flow-cell and the sonication probe was measured to be 
approximately 15 mm. At this distance the measured peak-negative acoustic pressure in the 
flow-cell both for 1 MHz and 3 MHz and 100% duty cycle was 0.037 ± 0.008 MPa at 
1 W/cm2 and 0.131 ± 0.027 MPa at 4 W/cm2 output intensity.  
Compared to related circulation in-vitro setups [124, 131], the PCATL model possessed a 
membrane flow-cell with a specific egg-shape which provided optimized flow 
conditions (Figure 17, black arrows) and minimized compartments with low flow 
velocity (dead volume compartments). Dead volume compartments could accumulate MBs 
and substantially distort experimental results. Within the flow-cell MBs were pumped in an 
upright direction, approached into the broader bottom part of the cell and were slowed down. 
During their habitation in the bottom cell part MBs could interact with the US beam.  
The upper flow-cell part was the most likely place for dead volume locations due to the 
affinity of MBs to float (buoyancy). Therefore, the outflow part was shaped so as to allow 
MBs to accelerate before leaving the cell.  
4.2. Acoustic destructibility studies 
According to the in-vitro studies, there was an apparent dependence of MB destructibility on 
the US frequency and intensity as well as on the MB diameter.  
When US with a lower frequency of 1 MHz was applied, acoustic destructibility of MBs did 
not correlate with their diameter, resulting to half-lives of less than 50 s for MBs of any 
size (Figure 18, dashed line).  
In contrast to that at a higher US frequency of 3 MHz MBs of sizes from 1.0 µm to 1.4 µm 
were burst 5.04 ± 3.42-fold faster than MBs of sizes from 4.0 µm to 6.0 µm (Figure 18, 
solid line).  
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Figure 18: Half-life (t1/2) of unloaded phospholipid-monolayer shelled MBs during exposure to US with an 
intensity of 4 W/cm2 and frequencies of 1 MHz (dashed line) and 3 MHz (solid line). 
 
Specific size-dependent destruction patterns for MBs at different US frequencies have been 
explained by different thresholds of transient cavitation which is required for MB destruction. 
This suggestion links the observed phenomenon to the analytical model established by 
Apfel et al. (1991) [129] and Holland et al. (1989) [130] (Figure 19) and recently related to 
SonoVue® by Greis et al. (2004) [132]. The authors proposed an approximate mathematical 
model, allowing for the calculation of acoustic pressure thresholds for transient cavitation 
over a variety of frequencies and MB diameters.  
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Figure 19: Computed plot of the cavitation threshold in water as a function of initial bubble radius for three 
frequencies of sonication: 1, 5, and 10 MHz. From: Apfel et al. (1991) [129]. 
 
In the context of the current study, MBs with larger diameters, exposed to ultrasound with a 
higher frequency (in this case 3 MHz), reach their bursting threshold at much higher peak-
negative acoustic pressures than smaller MBs.  
However, when exposed to US with a lower frequency (in this case 1 MHz) and the same 
output intensity, the influence of the MB size on the bursting threshold minimum decreases. 
As a consequence, at a frequency of 1 MHz both smaller and larger MBs are fragmented with 
a similar decay pace. 
 
 
Figure 20: MB half-life during US exposure at a frequency of 3 MHz and an increasing intensity. 
 
The dependence of the acoustic destructibility of unloaded MBs during US exposure at a 
frequency of 3 MHz and an intensity increasing from 1 W/cm2 to 4 W/cm2 is represented on 
Figure 20. Thereby, the MB life-time during US exposure decreases with 49.45% ± 2.73%, 
following a polynomial inverse second order equation (R2 = 0.9934). 
 
5. Summary 
In recent years the knowledge about microbubbles (MBs) as targeted drug and gene-carreers 
grew rapidly. Since the relevance of this promising approach steadily increases and new drug-
loaded formulations emerge on a pre-clinical stage, an accurate and fast screening method has 
 71 
been necessary to characterize their acoustic destructibility. Expectably, any new drug-loaded 
MB formulation possesses different physico-chemical characteristics which affect MB 
acoustic characteristics such as echogenicity and destructibility.  
In-vivo techniques are generally not suitable for high-throughput formulation screening. 
Therefore, near to physiologic conditions have to be imitated in-vitro, if clinically relevant 
data is to be obtained.  
In this chapter, an improved in-vitro model was developed and tested for pre-clinical 
assessment of the acoustic destructibility of newly developed MB formulations, based on 
previous literature work. This tool combines many physical aspects of the in-vivo setup, such 
as flow conditions, pressurizing, temperature conditioning, and mounting of MBs in artificial 
blood plasma. 
The near to physiological conditions acoustic transmission line (PCATL) in-vitro model 
proved as an useful tool for reproducible and reliable characterization of the MB acoustic 
destruction kinetics. Thus, it is possible to predict which drug-loaded MB formulations are 
appropriate candidates for further in-vivo evaluation, with regard to their sufficient acoustic 
destructibility. 
In the above studies, MB acoustic destructibility of model unloaded phospholipid MBs was 
correlated to their diameter and an empirical evidence to the theory of Apfel and 
Holland [129, 130] was provided. According to it, at higher ultrasound frequencies MBs of 
smaller size are better destructible than larger ones. At lower frequencies no size-dependent 
difference could be observed.  
Furthermore, MB destructibility was studied at various ultrasound intensities with no regard 
to the MB size. Thereby, MB destruction pace increased non-linearly with ultrasound 
intensity, following a polynomial inverse second order kinetics.  
Further in this thesis, the PCATL in-vitro model will be implemented for characterization of 
doxorubicin-loaded MBs and acoustically active lipospheres, comprising an additional oil 
layer. The in-vitro data will be correlated with in-vivo studies and a correlation model will be 
established. The formulation with better acoustic properties – echogenicity and acoustic 
destructibility, will be selected for further in-vivo studies. 
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IV. CHAPTER: Ultrasound targeted tumor therapy  
1. Abstract 
In recent years drug targeting in the tumor therapy has become a rather challenging topic for 
the pharmaceutical research. The clinical treatment with many potent anti-tumor drugs e.g. the 
anthracyclines is time- and dose-limited by occurring severe adverse effects such as 
cardiotoxicity.  
One promising recent approach for targeting solid tumors is the application of microbubble 
ultrasound contrast agents loaded with chemotherapeutic drugs. These novel drug delivery 
systems can release their active load in response to well tolerated diagnostic ultrasound. 
Microbubbles can be safely administered by intravenous injection or infusion. They are able 
to reach the even more distant tissues and organs such as the liver and the brain. Tumors can 
be precisely localized by diagnostic ultrasound since at low ultrasound intensities 
microbubbles act as contrasting agents. The site specific release of the active load can then be 
triggered by increasing the ultrasound intensity. Moreover, the energy, released from 
“bursting” microbubbles, opens small gaps in capillary walls and cell membranes and 
promotes the drug uptake and action. 
In the present work a novel phospholipid microbubble carrier for doxorubicin has been 
developed and characterized. Doxorubicin-loaded phospholipid microbubbles rendered 
outstanding ultrasound contrasting properties comparable with the commercial agent 
SonoVue® (Bracco International B.V., The Netherlands). Furthermore, they demonstrated 
good acoustic destructibility by ultrasound. In combination with ultrasound the doxorubicin-
carrying microbubbles demonstrated a 2.3-fold increase of the therapeutic activity compared 
to aqueous doxorubicin in cell cultures. In rat tumor models the doxorubicin-loaded 
microbubbles achieved an efficient tumor targeting by reaching an over 10-fold increased 
concentration of the drug in ultrasound-treated tumors compared to tumors which became 
doxorubicin-loaded microbubbles, but no ultrasound. 
 
Keywords: drug targeting, tumor therapy, microbubbles, ultrasound, contrast agents; 
 
Abbreviations: DOX – doxorubicin hydrochloride, AALs – acoustically active lipospheres, 
MBs – microbubbles; US - ultrasound; EPR – enhanced retention and permeability effect; 
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2. Introduction 
One of the most promising therapeutic applications of the MB targeting is the drug and gene 
delivery to solid tumors. Recently, numerous research articles have dealt with this application 
of US contrast agents [68, 133-135], thus all of them being pursuing an adequate tumor 
targeting and minimum effects on healthy cells.  
Anthracycline antibiotics are widely used anti-tumor agents with high treatment efficacy. 
Doxorubicin (DOX) is one of nowadays mostly used chemotherapeutics. In the form of 
aqueous solution it is indicated for the treatment of acute lymphoblastic leukemia, acute 
myeloblastic leukemia, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, 
ovarian carcinoma, etc. Liposomal DOX has been indicated for advanced ovarian 
cancer (Doxil®, Ortho Biotech, Bridgewater, USA), advanced breast cancer, AIDS-related 
Kaposi’s sarcoma, and multiple myeloma (Caelyx®, SP Labo, N.V., Heist-op-den-Berg, 
Belgium). However, the broad therapeutic spectrum of DOX is accompanied by severe 
adverse effects like myelosuppression, cardiotoxicity, alopecia, gastro-intestinal ulceration, 
and hand-foot syndrome [136]. 
DOX anti-tumor activity is most directly attributed to its intercalation between nucleotide 
pairs [137], and / or to the inhibition of DNA topoisomerase II [138]. There is also a growing 
body of evidence of alternative action mechanisms which do not afford entering the 
cytoplasm [139], complexation to DNA [140], or inhibition of DNA synthesis [141]. To 
substantiate these phenomena, several interactions on the level of the cell membrane have 
been suggested in the literature [122-125]. For example, DOX was shown to increase 
membrane fluidity [142], to cause massive perturbations in phospholipid domains [143], and 
to inhibit several cardiolipin-dependent processes of energy conservation in 
mitochondria [144, 145]. These unspecific membrane interactions are currently considered the 
main cause for the adverse effects of DOX.  
In addition to this, the pharmacokinetic behavior of DOX is rather complex, too. If used in 
stand-alone therapy, a typical injection dose of DOX is generally 60 mg/m2 to 75 mg/m2 of 
body surface area. About 62% of the applied dose binds to plasma proteins [146], while the 
free drug fraction rather freely distributes in blood and tissues (steady-state volume of 
distribution – 1.049 l) and is eliminated fast from the blood plasma (mean clearance – 
73.7 l/h) [147]. A large portion of the administrated drug is retained mainly in the liver, the 
kidneys, and the spleen [148]. For these reasons, DOX circulates and is eliminated to a great 
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extend outside of the tumor which is approached only by a relatively small portion of the 
administered drug amount.  
The unfavorable pharmacokinetic features together with the severe adverse effects of DOX 
are the arguments to look forward to modern strategies to direct drug distribution and 
therapeutic action to the tumor site. The need for targeting approaches guided recent research 
towards the development of particulate drug carriers for DOX such as liposomes, polymeric 
nanoparticles [149, 150], or covalent complexes with biodegradable polymers [151]. 
Up to now one of the best clinically established carriers for DOX are the PEGylated 
liposomes which are also marketed as Doxil®, Caelyx®, and Myocet® (Elan Pharmaceuticals, 
Princeton, NJ, USA). The encapsulation into liposomes fulfills several important clinical 
advantages for the application of DOX. It drastically decreases the mean clearance in 
humans (at least 250-fold) and the steady-state volume of distribution (60-fold) [152]. 
Furthermore, the susceptibility of cardiac events is at least three times reduced in patients, 
treated with liposomal DOX, compared to treatment with aqueous DOX [153]. However, 
because of their particulate nature, liposomes are prone to uptake by the reticulo-endothelial 
system and their retention in the liver is about 2-fold higher and roughly 3.5-fold longer than 
for the free drug [154]. 
In recent years there is a growing research interest at developing of strategies to direct DOX 
action to the disease site by means of tumor targeting. In solid tumors with fenestrated blood 
vessels nanoparticulate colloidal carriers can feature the enhanced permeability and 
retention (EPR) effect which results in a passive drug accumulation on the target site. For 
example, an about 3-fold higher drug uptake in tumors could be achieved in mouse xenograft 
models after administration of 10 mg/kg DOX as PEGylated liposomes (48 h after 
administration) compared to free DOX (3 h after administration) [154]. However, the EPR 
effect is a form of passive targeting and is limited in its therapeutic potential. In contrast, the 
active targeting approach through immunoliposomes [155, 156], pH-sensitive micelles [157], 
etc. can provide higher target concentrations and a better therapeutic efficacy.  
Another effective approach to trigger the drug action at the target tumor site is by application 
of external energy in the form of e.g. temperature [158], magnetic fields [159], or diagnostic 
US [68, 133-135]. The targeting approach by means of diagnostic US and drug-loaded MBs 
gives several advantages, compared to other strategies. As first, it is possible to detect and 
visualize tumors and assess their replenishment with drug, since MBs act as contrasting 
agents. Furthermore, in combination with US MBs enhance the permeability of capillary 
walls and cell membranes and can improve the drug efficacy. At last, the drug release can be 
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precisely site targeted by focusing the US beam at the tumor. Rapoport et al. (2007) [68] 
designed a surfactant-stabilized perfluoropentane microemulsion, loaded with DOX. 
Burstein et al. (2006) [160] developed DOX-loaded hollow microcapsules with rigid 
polymeric shells. Finally, Treat et al. [50] co-administered Doxil® liposomes together with the 
US contrast agent Optison® (GE Healthcare, Oslo, Norway) and achieved therapeutically 
relevant administration through the blood-brain barrier in rats.  
In the present work two novel acoustically active carrier candidates for DOX were developed 
and evaluated under in-vitro conditions in order to select the more appropriate formulation. 
The selected candidate was further launched into in-vivo studies.  
The first carrier candidate comprised MBs with stable but surprisingly flexible phospholipid 
monolayer shell which was highly loaded with the active drug. Within the shell positively 
charged DOX molecules were electrostatically complexed to anionic phospholipid molecules. 
The complexation was further complemented by intercalation of DOX aglycon between the 
phospholipids (Figure 2 B, p.19) through hydrophobic forces.  
The second candidate formulation comprised acoustically active lipospheres (AALs, Figure 
2 C, p.19), possessing outermost phospholipid monolayer, covered by inner oil coat of 
glycerol triacetate (triacetin), and gas core. In this case DOX was dissolved in the triacetin 
layer. 
The complex between DOX and negatively charged phospholipids has been well described 
and has found therapeutic applications on an experimental scale in the form of liposomal 
formulations [145-147]. Clinical studies revealed that DOX-loaded anionic liposomes have a 
similar anti-tumor activity compared to free DOX together with a substantially reduced 
cardiac toxicity, and at least no greater immunotoxicity [166-168]. In multidrug-resistant mice 
the therapeutic efficacy of the DOX-phospholipid complex was even superior to free 
DOX [161]. In terms of pharmacokinetics an about 4-fold increase of DOX half-life was 
achieved through encapsulation in anionic liposomes [148]. Anthracycline cardiotoxicity has 
been mainly related to the intervention of DOX into mitochondrial activity in heart due to the 
formation of a very stable complex with cardiolipin [144, 145, 162, 163]. According to 
Herman et al. (1983) [164] the complexation of DOX to the anionic phospholipid cardiolipin 
can totally prevent the occurrence of drug-induced cardiotoxicity in big animal models. Yet, it 
was a challenging task to combine the above benefits with the high targeting potential of MBs 
with regard to the fragility of phospholipid monolayers, especially when perturbed by 
intercalating molecules. 
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DOX molecule (Figure 21) consists of an anthraquinone aglycon moiety – adriamycinone, 
and a glycoside – daunosamine. At physiological pH of 7.4, about 96% of all DOX molecules 
in a solution bear one positive charge due to the protonation of the primary amine group on 
C3´ position in daunosamine, having a pKa ranging from 7.2 to 8.6, according to different 
authors [173-176]. Another pKa value of 9.6 corresponds to the phenol function in position 
C11 of the aglycon [150]. The molecule of DOX has an amphiphilic character but its net 
polarity is rather high with an experimental octanol / water partition coefficient (at pH 7.4) 
between 0.45 and 1.85 according to different authors [180-182]. DOX molecule further 
provides over seven hydrogen-bond donor and twelve acceptor sites.  
 
 
Figure 21: The chemical structure of DOX. Dashed line represents an intramolecular hydrogen bond. 
 
DOX forms rather stable non-covalent complexes with various anionic phospholipids such as 
cardiolipin, phosphatidic acid, phosphatidylglycerol, and phosphatidylserine. The 
stoichiometric coefficients of complex binding roughly correspond to the phospholipid 
negative net charge being 1.8 mol DOX per mol cardiolipin, and 0.75 mol DOX per mol 
phosphatidylserine and phosphatidic acid [165]. Other authors have determined higher 
saturation coefficients of 2.4 mol DOX per mol phosphatidic acid, 1.5 equivalents for 
phosphatidylserine and phosphatidylglycerol, 1.3 equivalents per mol cardiolipin, and solely 
0.02 equivalents per mol phosphatidylcholine [166].  
Two complex structures have been suggested for the interactions between DOX and anionic 
phospholipids (Figure 22). In the first configuration an electrostatic interaction is involved in 
the association of the sugar moiety with the anionic phospholipid headgroup. Thereby, the 
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more lipophilic aglycon moiety intercalates into the lipophilic alkyl chain bilayer 
region (Figure 22 A) [166, 167]. According to several authors, the prevailing component of 
the interaction between DOX and anionic phospholipids appears to be the electrostatic 
attraction [178, 180-182], while according to others’ opinion it is the hydrophobicity [168].  
In the second complex configuration besides the electrostatic interaction the planar 
adriamycinone rings remain outside and may further interact with each other to form “stack” 
associates (Figure 22 B) [181, 186-188].  
Furthermore, DOX possesses hydrogen-bond donor as well as acceptor sites. Therefore 
additional complexation interactions are expectable through hydrogen-bridges with hydrogen-
bonding phospholipids such as DPPE and DPPG (Table 5, p.28). Indeed, literature data 
suggests that DPPE can enhance the binding of DOX to phospholipid bilayers better than 
other non-hydrogen bonding zwitterionic phospholipids [169].  
Because of its weak lipophilicity, no significant interaction [165] or a very weak 
absorption [170] has been observed between DOX and the non-hydrogen bonding zwitterionic 
phospholipid DPPC.  
 
 
Figure 22: Configuration states of the complex between DOX and anionic phospholipids. A: Cationic 
daunosamine moiety is closely electrostatically bound to phospholipid anionic headgroups, while the 
hydrophobic aglycon penetrates the hydrophobic acyl chain region; B: Electrostatic complexation further 
persists, but aglycon moieties are detached from the monolayer and build “stack” aggregates. The centers of 
anionic charge are represented in blue and cationic charges – in red. 
 
The present research work is focused on the formulation development of DOX-loaded 
liposomes which were used as intermediates for the production of DOX-loaded MBs through 
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mechanical high-speed agitation. The pharmaceutical properties of the liposome intermediates 
such as formulation constitution, particle size, etc. could be successfully used as steering 
levers to tune MB characteristics – a novel formulation approach called liposomal-controlled 
microbubble production (LCMP). According to this, the formulation properties of the 
precursor liposomes were varied and correlations with the properties of resulting MB 
formulations were studied.  
Later in this chapter, various ratios between the amounts of excipients and DOX will be 
screened in order to establish optimal concentration ranges for the production of MBs. 
Following, the impact of further more specific formulation parameters such as the ionic 
strength, agitation time, filling volume of the agitated tube, etc. will be studied. The chemical 
stability of DOX in liposomal and in aqueous formulations will also be assessed.  
Considering the second candidate formulation of DOX-loaded triacetin AALs, it presumably 
possesses a greater loading potential due to its extended shell volume compared to the thin 
MB monolayer shell (Table 3, p. 16). However, this US contrast agent structure class bears 
the concern of lacking acoustic echogenicity and / or destructibility.  
In the next stage of development, the acoustic destructibility of the formulation candidates –
DOX-loaded MBs and AALs will be compared using a properly build and improved in-vitro 
model which allows simulating close to physiological conditions [171]. The acoustic 
properties of the candidates will be further characterized in-vivo using rat’s myocardium 
model, and for the first time an in-vivo / in-vitro correlation will be drawn. The anti-
proliferative activity of the selected formulation will be firstly demonstrated in tumor cell 
cultures and following in-vivo in rat tumor models. 
In the following work several studies were performed in cooperation. Fluorescence confocal 
laser scanning microscopy studies were carried out in cooperation with Mr. Stefan 
Zahler, Ph.D. from the Department of Pharmacy, Pharmaceutical Biology at the Ludwig-
Maximilians-University – Munich, Germany. Studies involving measurements of peak-
negative acoustic pressure in US fields were made together with Mr. Rainer Pecha, Ph.D. 
from the University of Stuttgart, Germany. Electron microscopy experiments were performed 
together with Mr. Markus Döblinger, Ph.D. from the Department of Chemistry, Physical 
Chemistry II at the Ludwig-Maximilians-University – Munich, Germany. Cell culture studies 
were carried out in cooperation with Mr. Martin Meyer, Ph.D. and Mr. Alexander Philipp 
from the Department of Pharmacy, Pharmaceutical Biology – Biotechnology, Ludwig-
Maximilians-University – Munich. In-vivo clinical studies were performed in cooperation 
with Mr. Raffi Bekeredjian, MD, Ph.D. from the Internal Medicine III, Ruprecht-Karls-
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University – Heidelberg, Germany. The research work was funded through a research grant 
by the NanoforLife initiative of the Federal Ministry of Education and Research, Germany in 
cooperation with Mr. Raffi Bekeredjian, MD, Ph.D. 
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3. Materials and Methods 
3.1. Reagents 
Substance Abbreviation Purchased from 
Acetonitril, HPLC-grade --- VWR International GmbH, Darmstadt, Germany 
Calcium chloride, granulated, dehydrated  --- Sigma-Aldrich GmbH, Munich, Germany 
Chloroform, HPLC-grade --- Sigma-Aldrich GmbH, Munich, Germany 
Cholesterol, ≥ 99% --- 
Sigma-Aldrich GmbH, Munich, 
Germany 
Concanavalin A- 
Alexa Fluor® 488 conjugate --- 
Invitrogen Molecular ProbesTM, 
Eugene, USA 
1,4-Diazabicyclo[2.2.2]octane DABCO Sigma-Aldrich GmbH, Munich, Germany 
Dimethyl sulfoxide DMSO Sigma-Aldrich GmbH, Munich, Germany 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide MTT 
Sigma-Aldrich GmbH, Munich, 
Germany 
Dipalmitoyl phosphatidylcholine DPPC Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl-phosphatidylethanolamine DPPE Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl-phosphatidylethanolamine-
polyethylenglycol-2000 DPPE-PEG2000 
Avanti Polar Lipids, Alabaster, AL, 
USA 
Dipalmitoyl phosphatidylglycerol DPPG Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl 
phosphatidyltrimethylaminopropane DPTAP 
Avanti Polar Lipids, Alabaster, AL, 
USA 
Disodium hydrogenphosphate, p.a. --- Sigma-Aldrich GmbH, Munich, Germany 
Doxorubicin hydrochloride DOX Molekula Deutschland GmbH, Nienburg, Germany 
Dulbecco´s modified Eagle´s medium, 
activated with 10% fetal calf serum DMEM 
Invitrogen Molecular ProbesTM, 
Eugene, USA 
Ethylene diamine tetra-acetic acid EDTA Sigma-Aldrich GmbH, Munich, Germany 
Glucose monohydrate, p.a. Glucose Sigma Aldrich GmbH, Munich, Germany 
Glycerol triacetate, p.a. Triacetin Sigma-Aldrich GmbH, Munich, Germany 
Hoechst 33342 --- Invitrogen Molecular Probes
TM, 
Eugene, USA 
Hydrochloric acid, p.a., 1 M  --- Sigma-Aldrich GmbH, Munich, Germany 
Isopropanol, HPLC-grade --- Mallinckrodt-Baker B.V., Deventer, Holland 
Methanol, HPLC-grade, water-free --- VWR International GmbH, Darmstadt, Germany 
Octafluoropropane --- Sauerstoffwerk Friedrich Guttroff GmbH, Wertheim, Germany 
Phosphorous acid, 85%, p.a. --- Sigma-Aldrich GmbH, Munich, Germany 
Polyethyleneoxide-polypropyleneoxide 
block copolymer (Poloxamer 188) Lutrol F68 BASF SE, Ludwigshafen, Germany 
Potassium hydroxide, p.a. --- Sigma Aldrich GmbH, Munich, Germany 
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Continued from p. 80 
Sodium chloride, p.a. --- Sigma-Aldrich GmbH, Munich, Germany 
Sodium dodecyl sulfate, p.a.  --- Sigma-Aldrich GmbH, Munich, Germany 
Sodium dihydrogenphosphate, p.a. --- Sigma-Aldrich GmbH, Munich, Germany 
SonoVue®  --- Bracco International B.V., The Netherlands 
Trypsin, 0.05% with tetrasodium EDTA Trypsin/EDTA Invitrogen Molecular Probes
TM, 
Eugene, USA 
 
3.2. Pre-formulation studies on doxorubicin-loaded liposomes and 
microbubbles 
3.2.1. Differential scanning calorimetry studies 
Differential scanning calorimetry (DSC) using a Mettler Toledo DSC821e (Mettler-Toledo 
GmbH, Giessen, Germany) was the leading analytical method in the pre-formulation studies.  
Two groups of experiments were performed in this study. In the first group single 
phospholipids were screened for their binding affinity to DOX in order to select candidates 
which are able to mediate a complexation of DOX to the MB shell. For these experiments 
DOX concentration was set to 20 equivalent % (eq%) of the phospholipid concentration 
which was 100 mM. According to literature data, DPPC was expected to feature no relevant 
interaction with DOX.  
In the second part of the study the selected phospholipid candidates which showed an 
interaction with DOX were blended at various concentration (from 10 mol% to 30 mol%) in 
binary mixtures together with DPPC. In a crosswise variation for each of the above cases the 
DOX concentration was changed from 0 eq% to 180 eq% of the concentration of DOX-
binding phospholipid. 
In order to prepare sample formulations, stock solutions of phospholipid compounds – DPPC, 
DPPG, and DPPE in HPLC-grade chloroform were prepared. The solutions were 
appropriately distributed in vials and the organic solvent was removed over 24 hours under 
nitrogen flow at room temperature using a Flowtherm II (Barkey GmbH, Leopoldshöhe, 
Germany). Solvent traces were eliminated in exsiccator under vacuum at room temperature 
over 24 hours. The obtained dried phospholipid blends were hydrated with low ionic strength 
phosphate buffered saline (ion concentration 5 mM) having a pH of 7.4 with and without 
addition of DOX. The hydration occurred at 75 ºC under continuous shaking, light protection 
and nitrogen atmosphere. The total phospholipid concentration in all experiments was kept 
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high at 100 mM in order to detect even small changes in melting phase transitions. Prior to 
measurements samples were allowed to equilibrate for at least 12 hours at 4 °C in dark. 
Finally, liposome formulations in amounts of 30 µl were placed in 40 µl aluminum DSC pans 
and sealed. Three scanning runs in the temperature interval 20 °C to 85 °C at a heating rate of 
5 °C/min were performed against air in triplicate for each formulation (n = 3, m = 3). 
Measured data was accordingly normalized against the sample weight and the phospholipid 
molar concentration. 
Additionally, the colloidal condition of the formulations was macroscopically assessed and 
evaluated by scanning electron microscopy (SEM) using a JEOL 6500F (Jeol GmbH, Eching, 
Germany) equipped with an electron gun. The crystallinity of selected samples was examined 
with transition electron microscopy (TEM) using a JEOL 2011 electron microscope equipped 
with a tungsten cathode, operating at 200 kV. 
3.2.2. Effect of US homogenization of liposomes on the MB yield 
DOX-loaded liposomal formulations, comprising 80 mol% DPPC, 20 mol% DPPG, and 
100 eq% DOX according to the amount of DPPG, were produced at a total phospholipids 
concentration of 3 mM.  
The liposomes were subjected to US horn-type homogenization for different time intervals 
starting with 1 min up to 10 min using a Branson Sonifier® (Branson Ultrasonics Corp., USA) 
at a power output of 5 and a duty cycle of 50% using a 10 mm horn probe. The liposomes 
were placed in tubes, covered with octafluoropropane and agitated for 20 s using a CapMixTM 
shaker (3M Deutschland GmbH, Neuss, Germany). MB concentration and size distribution 
were determined by light blockage using PAMAS SVSS-C (PAMAS GmbH, Rutesheim, 
Germany) after dilution with particle free water. Samples were compared in their MB 
concentration (MB yield).  
3.2.3. Effect of third phospholipid compounds 
Efforts were made to further improve the liposomes’ colloidal stability and loading capacity 
through addition of small amounts of a third phospholipid component to the binary 
phospholipid mixture of bulk zwitterionic component (DPPC) and DOX-binding 
anionic phospholipid component, established through the DSC screening study above. Several 
phospholipids with widely varying properties were screened such as PEGylated (DPPE-
PEG2000), cationic (DPTAP), non-bilayer (DPPE) phospholipids, and steroids (cholesterol). 
Liposomal intermediates were produced at a fixed proportion of 80% DPPC, 20 mol% DPPG, 
and 100 eq% DOX according to the amount of DPPG. The total phospholipid 
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concentration was kept constant at 3 mM. The concentration of the third-component 
phospholipid was varied from 0 mol% to 5 mol%, while the concentration of DPPC was 
correspondingly reduced. 
Following, the liposomal size distribution and polydispersity were determined by dynamic 
light scattering Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., Worchestershire, 
UK). MB yield and size distribution were measured by light blockage using PAMAS SVSS-
C (PAMAS GmbH, Rutesheim, Germany). Median liposome size, storage stability over 
30 days, as well as median MB size and MB yield were compared and formulations with 
advantageous properties were selected for further development.  
3.2.4. Effect of agitation time on the DOX loading in MBs 
DOX-loaded liposomal formulations containing 3 mM total phospholipid of which 79 mol% 
DPPC, 20 mol% DPPG, and 1 mol% DPPE-PEG2000 were produced. Following, portions of 
200 µl liposomes were aliquoted in 2 ml Eppendorf tubes, covered with octafluoropropane 
gas, and agitated for different time intervals ranging from 10 s to 40 s with an increment of 
10 s. In order to determine the amount of DOX encapsulated in MBs (CMB), the procedure was 
followed, described under “3.6.4 Effectiveness of DOX loading into MBs and AALs”, p.89. 
3.2.5. Optimal formulation procedures for DOX-loaded liposome precursors 
and MBs 
According to the above pre-formulation research, the optimal process conditions for the 
production of DOX-loaded liposome precursors and MBs were identified. Liposomal 
precursors for the production of DOX-loaded MBs were produced via the thin-film hydration 
method. Briefly, per one milliliter liposomal formulation 1.74 mg DPPC, 0.45 mg DPPG, and 
0.08 mg DPPE-PEG2000 were blended under heating at 60 °C in chloroform in a round 
bottom flask. The organic solvent was eliminated from the stock solution using a Büchi 
Rotavapor R-114 (Büchi Labortechnik GmbH, Essen, Germany) for 60 min at 60 °C. Next to 
that, a solution of 0.35 mg DOX, 0.003 mg EDTA and 50 mg glucose per milliliter liposomal 
formulation was prepared in highly-purified water (Purelab Plus®, USF Elga Ionpure GmbH, 
Germany). The aqueous solution of DOX was brought in contact with the phospholipid thin-
film and stirred under nitrogen and light protection for 60 min at 60 °C.  
The liposomal precursor formulation was aliquoted at 400 µl in 2 ml round bottom safe-lock 
tubes (Eppendorf AG, Hamburg, Germany) and covered with octafluoropropane gas. The 
liposomal dispersion was mechanically agitated at about 4,500 oscillations/minute for 20 s 
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using a CapMixTM (3M Deutschland GmbH, Neuss, Germany). For in-vivo administration 
MBs were diluted with octafluoropropane-saturated 5 mass% glucose in water.  
 
3.3. Characterization of doxorubicin-loaded liposomes 
3.3.1. Size distribution and Zeta potential 
The size distribution and polydispersity of liposomes were determined by dynamic light 
scattering using a Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., Worchestershire, 
UK). Zeta potential of liposomal formulations was determined by electrophoretic light 
scattering using the same device.  
During the measurements the dielectric constant (τ) was set to 78.48 (pure water at 25 ºC). 
The optical parameters (refractive index and absorption index) for liposomes were set to 
correspondingly 1.450 and 0.01 [172]. Sample conductivity was kept below 0.01 mS/cm2 
during Zeta potential measurements.  
3.3.2. Measuring the DOX concentration 
DOX concentration and purity were determined using an ion-pair reversed-phase liquid 
chromatography method [173] using a C18 RP-HPLC column [Luna 5u C18(2) 100A, 
Phenomenex Ltd., Aschaffenburg, Germany]. The mobile phase consisted of 50 vol% 
acetonitril in highly purified electrolyte-free water, containing 1.44 g/l sodium dodecyl 
sulfate, p.a. and 1.125 g/l 85% phosphorous acid, p.a. A standard calibration curve was 
established (n = 5), where DOX concentration was represented as a function of the area under 
the DOX characteristic peak at 7.8 min retention time vs. the concentration of standard 
solutions.  
The samples for measurement were prepared by dissolving 20 µl liposomal dispersion in 1 ml 
solution of 7.5 vol% 1 M hydrochloric acid, p.a. in 92.5 vol% HPLC-grade isopropanol with a 
pH of 1.3. 
Analysis was performed using a Merck-Hitachi LaChrom (Merck-Hitachi GmbH, Darmstadt, 
Germany) unit equipped with a binary pump model L-7100, an autosampler model L-7200, an 
interface model D-7000, and an L-7450 diode array detector. 10 µl of each sample were 
injected into the column at a mobile phase flow rate of 1 ml/min. Time span of the HPLC 
measurement was 30 min. 
The detection and quantification of DOX and products of its chemical decay were performed 
by measuring the UV-absorption at a wavelength of 254 nm. 
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The robustness of the HPLC method was scrutinized by the addition of various phospholipid 
amounts (both DPPC and DPPG) in the concentration range from 0.5 mg/ml to 5.0 mg/ml to a 
0.5 mg/ml solution of DOX. The minimum signal-to-noise ratio was set to 3. 
3.3.3. Association of DOX with liposomes 
DOX-loaded anionic liposomes were prepared comprising a total phospholipid concentration 
of 3 mM of which 20 mol% were DPPG, 79 mol% DPPC, and 1 mol% DPPE-PEG2000. The 
amount of DOX corresponded to 100 eq% of the DPPG concentration. In whole liposome 
samples the total concentration of DOX (Ctot) was determined using RP-HPLC as described 
above. Following, DOX-loaded liposomes were subjected to freeze-thawing in order to 
destroy their colloidal structure and to separate the phospholipid from aqueous phase. The 
phospholipid was pelleted for 15 min at 14,000 rpm using a NeoLab 16/18 centrifuge (Hermle 
Labortechnik GmbH, Wehingen, Germany). The concentration of unassociated DOX (Cfree) in 
the supernatant was then measured and the effective amount of DOX loaded to liposomes was 
calculated as a difference between Ctot and Cfree. 
3.3.4. Electrolyte-induced liposomal leakage of DOX 
In order to assess the possibility of drug loss due to electrolyte-induced liposomal leakage, the 
influence of monovalent ions with various concentrations on the complexation of DOX to 
anionic liposomes was studied. Electrolytes have a shielding effect on the attractive 
electrostatic interactions between DOX and anionic phospholipids. Purpose of this study was 
to evaluate the robustness of DOX-binding prior to and after the complex formation with 
anionic phospholipids. 
Two groups of experiments were conducted throughout this study. In the first experiment 
series the influence of ion concentration on the binding between DOX and anionic 
phospholipids was studied prior to the formation of the complex. Solutions of DOX were 
prepared in water and the ion concentration was adjusted with sodium chloride, p.a., 
increasing from 0 mM to 100 mM ions. The solutions were used to produce DOX-loaded 
liposomes following the procedure described above (refer to “3.2.5 Optimal formulation 
procedures for DOX-loaded liposome precursors and MBs”, p.83). Accordingly, samples 
were freeze-thawed in order to precipitate the phospholipids and subjected to centrifugation at 
room temperature for 15 min at 14,000 rpm using the NeoLab 16/18 centrifuge (Hermle 
Labortechnik GmbH, Wehingen, Germany). The concentration of DOX was determined by 
HPLC in whole samples and in the supernatant as described in “3.3.2 Measuring the DOX 
concentration”, p.84. 
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In the second group of experiments the ability of increasing ion concentrations to dissociate 
the DOX-liposomal complex after its formation and cause liposome leakage was studied. 
Therefore, DOX-loaded liposomes were produced under electrolyte-free conditions and were 
subsequently brought in contact with electrolyte. The liposomes were incubated with sodium 
chloride in the same concentration range as above (from 0 mM to 100 mM ions) for 60 min at 
37 °C under continuous shaking. The sample preparation was carried out as described above. 
3.3.5. Chemical stability of DOX during the production of liposomes 
During the formulation development of DOX-loaded liposomes and MBs the chemical 
stability of DOX was regularly scrutinized. If chemical decay of DOX occurred, its 
concentration, measured by HPLC, would decrease. Therefore, the concentration of DOX was 
determined in equal time intervals of 20 min during the phospholipid thin-film hydration at 
60 ºC over 60 min. Accordingly, DOX concentration was determined after a 5 minute US 
horn-type homogenization procedure using Branson Sonifier® (Branson Ultrasonics Corp., 
USA) equipped with a 10 mm sonication probe. 
3.3.6. Photochemical stability of DOX 
In a second group of experiments accelerated photostability tests on DOX-loaded liposomal 
formulations were conducted according to 1997 ICH Guidelines for photostability 
testing [174] using a Heraeus Ultratest Xenon light exposure unit (Original Hanau GmbH, 
Hanau, Germany). Aqueous solutions or liposomal dispersions of DOX with a concentration 
of 0.6 mM (0.350 mg/ml) were aliquoted in 5 ml portions in Schott 10 ml type I glass 
vials (Schott AG, St. Gallen, Switzerland), covered with octafluoropropane and flanged. The 
samples were accordingly exposed to light with an output intensity of 500 W/cm2 for 
72 hours. The concentration of DOX was determined four times in 24 hour intervals by RP-
HPLC (refer to “3.3.2 Measuring the DOX concentration”, p. 84). The temperature was 
monitored using immersed sensors (Ama-digit ad 15th, Amarell GmbH, Kreuzwertheim, 
Germany) in both obscured and exposed vials containing liposomal and aqueous 
formulations. Accordingly, the concentration data was plotted against time and the half-life 
time of DOX in liposomal formulations and aqueous solutions was determined.  
 
 87 
3.4. Pre-formulation studies on doxorubicin-loaded microemulsions 
and acoustically active lipospheres 
The aim of the following pre-formulation studies was to develop an acoustically-active 
liposphere carrier for DOX. In order to increase the lipophilicity of DOX, the hydrochloride 
salt was chemically transformed into the DOX free base, where the primary amine group of 
daunosamine is not protonated. Therefore, DOX-base is more soluble in non-polar 
solvents [68] such as triacetin. Briefly, 50 mg DOX were dissolved in 50 ml methanol and 
dropwise titrated with a 1 mg/ml methanolic solution of potassium hydroxide until 
stoichiometric proportions of DOX and hydroxide ions were attained. The excess water 
resulting from the chemical neutralization was absorbed by granulated dehydrated calcium 
chloride.  
Following, 10 ml triacetin was added to the solution and stirred overnight under light 
protection and nitrogen atmosphere. To obtain the triacetin solution of DOX-base, methanol 
was removed under vacuum at a temperature of 60 °C for 120 min, until a dark-red viscous 
solution of DOX-base in triacetin was obtained. The solution was allowed to equilibrate for 
24 hours at 4 ºC and the excess DOX-base along with the insoluble potassium chloride were 
removed by centrifugation. The effective concentration of DOX-base, dissolved in triacetin, 
was then determined by HPLC as described in “3.3 Characterization of doxorubicin-loaded 
liposomes”, p. 84. 
3.4.1. Partition equilibrium of DOX-base between triacetin and water 
Partition equilibrium of DOX-base between the lipophilic triacetin and aqueous phase was 
estimated by measuring the solute equilibrium concentrations in the aqueous phase at various 
pH values. Correspondingly, the apparent partition coefficient (P) was determined as the ratio 
between DOX concentrations in triacetin and in aqueous phase.  
Partition equilibrium was obtained by continuous shaking of 2 ml DOX-base/triacetin solution 
and 2 ml Sørensen phosphate buffer for 24 hours at 4 °C. The concentration of DOX in the 
aqueous phase was measured by HPLC in time intervals of 3 hrs. Equilibrium was reached 
when the DOX concentration in water changed by no more than 5% over three hours. 
Phosphate buffers had a pH varying in the range from 5 to 9 with an increment of 0.5. The 
measured electric conductivity of all buffers used was 9-10 mS/cm2 at 25 °C. Experiments 
were not performed above a pH of 9 due to the lacking DOX chemical stability at pH 
exceeding this value [175]. Prior to experiments, aqueous phase was saturated with triacetin 
by stirring with an excess of it over 24 hours at 4 °C. The concentration of DOX in both 
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aqueous and triacetin phases was determined by HPLC (refer to “3.3 Characterization of 
doxorubicin-loaded liposomes”, p. 84.). 
3.4.2. Optimal formulation procedures for DOX-loaded microemulsions and 
AALs 
In order to produce a phospholipid-stabilized microemulsion, DPPC, DPPG, and DPPE-
PEG 2000 were blended in chloroform and the organic solvent was accordingly removed. 
750 mg DOX-base solution in triacetin and 50 ml 10 mg/ml solution of Lutrol F68 and 
30 µg/ml DOX in triacetin-saturated phosphate buffer with a pH of 8 were given to the 
phospholipid film. The mixture was then heated to 60 ºC, and stirred for 60 min under light 
protection and nitrogen atmosphere. 
The resulting coarse emulsion was divided in two portions which were further processed by 
homogenization using horn-type sonication (Branson Sonifier®, Branson Ultrasonics Corp., 
USA) for 15 min at a power output of 12 and 50% duty cycle, or by high-pressure 
homogenization using a Gaulin homogenizer (APV Deutschland GmbH, Unna, Germany) by 
applying 1,300 bar in 20 run cycles. 
DOX-loaded AALs were produced by mechanical agitation at 4,500 oscillations / minute for 
20 s of 400 µl microemulsion with 1.6 ml octafluoropropane using the CapMixTM mechanical 
agitator (3M Deutschland GmbH, Neuss, Germany). 
 
3.5. Characterization of doxorubicin-loaded microemulsions 
3.5.1. Particle size distribution and colloidal stability of DOX-loaded 
microemulsions 
DOX-loaded triacetin microemulsions obtained by US horn-type homogenization and by 
high-pressure homogenization were stored for 30 days at 4 °C in dark. The particle size 
distribution in both samples was determined by dynamic light scattering (refer to 
“3.3 Characterization of doxorubicin-loaded liposomes”, p. 84) in 48 hours terms during the 
first two weeks and once weekly afterwards. 
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3.6. Characterization of doxorubicin-loaded microbubbles and 
acoustically active lipospheres 
3.6.1. Structure analysis of DOX-loaded MBs and AALs 
The structure and colloidal homogeneity of DOX-loaded MBs and AALs were characterized 
by confocal laser scanning microscopy (CLSM) using an inverted Zeiss LSM 510 (Carl Zeiss 
Microimaging, Göttingen, Germany). No additional fluorescent staining was necessary due to 
the intensive intrinsic DOX fluorescence emission at 570 nm following an excitation with 
530 nm He-Neon laser light [176]. A pinhole of 118 µm was exerted with an oil-immersion 
objective producing optical stacks of about 225 µm thickness.  
For sample preparation 20 µl freshly prepared suspension of DOX-loaded MBs or AALs was 
mounted in 1 ml 25 mg/ml solution of DABCO in a mixture of 80 vol% glycerol, p.a. and 
20 vol% electrolyte-free water. The mounted sample was then introduced by a syringe into a 
thin-bottom Ibidi µ-slide IV (Ibidi GmbH, Munich, Germany) and imaged. 
3.6.2. Particle size distribution 
The particle size distribution in MB and AAL formulations was determined by laser 
diffraction using Partica LA-950 (Horiba Ltd., Kyoto, Japan) by means of the properly 
established optical model for MBs (refer to “II. Ch. / 4.2.1 Size distribution 
measurements”, p. 48). The MB refractive index was set to 0.90, and the absorption index – 
to 0.01. The value of cosθ was kept below 0.1. The measured data was surface-area weighted. 
3.6.3. Particle concentration 
The concentration of DOX-loaded MBs was determined by light blockage using PAMAS 
SVSS-C (PAMAS GmbH, Rutesheim, Germany). Briefly, 20 µl of the freshly prepared MB 
sample were diluted with highly-purified degassed water until the particle count decreased to 
less than 2 x 105 MB/ml. Volumes of 1 ml were drawn in triplicate for analysis from the 
diluted sample. The bubble size distribution in the range of 800 nm to 200 µm as well as the 
MB concentration were determined simultaneously. 
3.6.4. Effectiveness of DOX loading into MBs and AALs 
In order to determine the amount of DOX associated with MBs, formulations were mildly 
centrifuged for 5 min at 1,000 rpm using a NeoLab 16/18 centrifuge (Hermle Labortechnik 
GmbH, Wehingen, Germany). The MBs formed a foam cake and were separated from the 
underlying liquid phase. Portions of the liquid fraction were collected by piercing through the 
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tube wall with a syringe needle and the concentration of residual DOX after MB 
production Cres was determined by HPLC (refer to “3.3.2 Measuring the DOX 
concentration”, p.84). The total DOX concentration Ctot was determined in whole liposome or 
microemulsion formulations. The effective loading of MBs CMB was calculated as a difference 
between the total DOX concentration Ctot and Cres. 
3.6.5. In-vitro acoustic destructibility of DOX-loaded MBs and AALs 
The acoustic destructibility of DOX-loaded MBs and AALs was determined using the own 
improved near physiological conditions acoustic transmission line (PCATL) model, based on 
the work of Lazewatsky et al. (1999) [124] (refer to “III. Ch. / 3.2 In-vitro experimental 
setup”, p.63). MBs and AALs were exposed to US with a frequency of 1 MHz and an output 
intensity of 4 W/cm2 using a Sonitron-2000 (RichMar Corp., Chattanooga, USA). Each 
sonication cycle comprised four frames of 30 s at a duty cycle of 50% using a 5 mm 
sonication probe. The decrease of particle concentration due to acoustic decay was measured 
by light blockage using a PAMAS SVSS-C (PAMAS GmbH, Rutesheim, Germany). The 
plotted experimental data was processed and fitted using SigmaPlot® 2004 software, 
v.9.0 (Systat Software GmbH, Erkrath, Germany).  
3.6.6. In-vivo evaluation of the acoustic properties of DOX-loaded MBs 
Acoustic backscatter efficacy (echogenicity) and destructibility of DOX-loaded MBs were 
tested in rat’s myocardium in-vivo model. A comparison was done between DOX-loaded 
MBs, DOX-loaded AALs, unloaded MBs, and the commercial standard SonoVue® (Bracco 
International, B.V., The Netherlands).  
After test animals had been prepared, 1 ml of AAL and MB dispersions with concentrations 
of about 3-5 x 107 MB/ml were infused at a rate of 3 ml/hour. During the infusion, the left 
heart was visualized by diagnostic US (Sonos 5500, Philips Medical Systems, USA) having a 
frequency of 1.3 MHz and a mechanical index (MI) of 0.6. Following the visualization, the 
left heart was exposed to US bursting cycles with the same frequency and a higher MI of 1.6. 
A sequence of four bursting pulses was delivered every fourth diastolic cardiac cycle. It was 
triggered by the electrocardiographic R-wave with a delay of 80 ms after its peak.  
Immediately prior and after every bursting sequence backscatter images were taken in order to 
calculate the rate of MB destructibility. Backscattered signal intensity was recorded 
immediately prior to the high-intensity US sequence (I*bs) and after it (Ibs). The MB in-vivo 
acoustic destructibility A, [%] was calculated according to Equation 11: 
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Equation 11: Calculation of the in-vivo acoustic destructibility A, [%]. 
 
where A - In-vivo acoustic destructibility, [%]; I*bs - backscatter intensity before the bursting 
frame, [dB]; Ibs - backscatter intensity after the bursting frame, [dB]. 
3.6.7. In-vivo / in-vitro acoustic destructibility correlation 
The properly formulated DOX-loaded MBs, DOX-loaded AALs, and unloaded MBs were 
ranked according to their sonication half-life t1/2 which was determined in-vitro using the 
physiological conditions acoustic transmission line (PCATL) model. Next to that, the 
formulations were ranked with regard to their in-vivo acoustic destructibility, determined in 
the rat’s myocardium model. The marketed US contrast agent SonoVue® was used as a 
standard.  
The in-vitro data of MB and AAL formulations was ranked in the order of their decreasing 
half-life during sonication, corresponding to a better in-vitro acoustic destructibility. 
Accordingly, the data of in-vivo studies was ranked on the same manner with regard to the 
increasing MB in-vivo acoustic destructibility A, [%]. The in-vivo ranking coefficients were 
plotted vs. the in-vitro ranking coefficients and the coefficient of determination R2 was 
calculated. 
 
3.7. Therapeutic evaluation of doxorubicin-loaded microbubbles 
3.7.1. Intracellular distribution of DOX after treatment with DOX-loaded MBs 
295/KDR human kidney carcinoma cells were cultivated in Ibidi® µ-plate 96-well with thin 
bottom (Ibidi GmbH, Munich, Germany). The cells were treated with DOX aqueous solution 
and DOX-loaded MBs in combination with US. The final DOX concentration in all samples 
was 1.67 µg / 106 cells. Samples, containing DOX-loaded MBs were treated with US at a 
frequency of 1 MHz, an intensity of 2 W/cm2, and a duty cycle of 100% for 15 s using a 
Sonitron-2000 (RichMar Corp., Chattanooga, USA), equipped with a 3 mm probe. US was 
applied by directly immersing the probe into the culture medium. 
The cell cultures were incubated for 2 hours, followed by three washing steps with phosphate-
buffered saline. The cells were fixed by incubation for 15 min with 3% formaldehyde. Cell 
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nucleus staining was made with Hoechst 33342 while cell membranes were dyed with 
Concanavalin A – Alexa Fluor® 488 conjugate, both according to manufacturer’s protocols. 
Three washing steps were carried out after each staining procedure. Finally, the cells were 
mounted in a 25 mg/ml solution of DABCO in 80 vol% glycerol and 20 vol% electrolyte-free 
water. 
 
Fluorescent dye 
Excitation wavelength 
maximum, [nm] 
Emission wavelength 
maximum, [nm] 
Concanavalin A- 
Alexa Fluor® 488 conjugate 
495 519 
Hoechst 33342 350 461 
DOX 530 570 
Table 8: Excitation and emission wavelengths of fluorescent dyes and DOX used for fluorescence microscopy 
of cultured cells. 
 
The cells were observed by fluorescence confocal laser-scanning microscopy using a 
Zeiss LSM 510 (Carl Zeiss Microimaging, Göttingen, Germany). A pinhole of 204 µm was 
exerted with a 63x oil-immersion objective producing optical slices of about 700 nm. The 
excitation and emission wavelengths used are represented in Table 8. 
3.7.2. In-vitro evaluation of the anti-proliferative efficacy of DOX-loaded MBs 
In the following experiment, the anti-proliferative activity of DOX-loaded MBs in cell 
cultures was compared with unloaded MBs, DOX-loaded and unloaded liposomes, as well as 
with aqueous DOX solutions. Furthermore, all setups were tested with and without 
application of US. The amount of DOX was kept constant at 70 ng/well in all samples. Blank 
measurements were done with DOX-untreated cells with and without application of US.  
The therapeutic activity of DOX-loaded MBs was tested in-vitro on 293/KDR human kidney 
carcinoma cells. The decrease of cell viability was considered as a quantitative measure for 
the anti-tumor efficacy of DOX-loaded MBs.  
Prior to the experiment, the adherent cells were treated with trypsin/EDTA solution and 
counted under microscope using the modified Neubauer chamber. Following, cell 
concentration was adjusted with DMEM medium and suspension was placed into 96-well 
plates (Greiner Bio-one GmbH, Frickenhausen, Germany) at an amount of 6 x 104 cells/well. 
A 3.5 cm thick gelatin gel tissue phantom was placed beneath the well plate in order to absorb 
US and to prevent standing waves.  
 93 
Treatment medium in amount of 100 µl was added to 200 µl DMEM culture medium 
overlying the cell layer. The treatment medium contained either DOX-loaded or unloaded 
liposomes or MBs. In negative control samples phosphate-buffer saline was added, while 
DOX aqueous solution was added to positive control samples. In MB-treated samples the 
bubble-to-cell ratio was set to about 165.  
Technical US was applied to US-treated samples using a Sonitron-2000 (RichMar Corp., 
Chattanooga, USA) equipped with a 3 mm probe by directly immersing the probe into the 
culture medium. According to preliminary studies US parameters were set to 1 MHz 
frequency, 1 W/cm2 output intensity, 50% duty cycle, and a sonication time of 20 s. The peak-
negative acoustic pressure, [MPa] in the wells was measured using a 250 µm fiber-optic probe 
hydrophone (FOPH 2000, RP Acoustics, Germany) [29]. Following, cell cultures were 
incubated for 24 hours at 37 °C and 5 vol% CO2. 
Accordingly, the cell metabolic activity was assayed as previously described in the 
literature [177]. Briefly, 30 µl 5 mg/ml aqueous solution of MTT were given to each culture 
well and cells were incubated for 2 hours. The overlying culture medium was then aspirated 
and the cells were solubilized with 50 µl DMSO. The UV/Vis absorption of the cell produced 
purple formazan was measured using FluostarOmega plate reader (BMG Labtech GmbH, 
Offenburg, Germany) at a measurement wavelength of 590 nm and a reference 
wavelength of 630 nm. Cell viability was expressed as a percent ratio of the absorption of 
treated vs. untreated cell samples.  
3.7.3. In-vivo evaluation of the targeting efficacy of DOX-loaded MBs 
A double blinded study was performed in rat tumor model in order to evaluate the in-vivo 
targeting efficacy of DOX-loaded MBs. Each test animal was bearing two subcutaneously 
implanted pancreas xenograft tumors on each side of its back. Test animals were infused one 
dose unit of 400 µl MBs (corresponding to 140 µg DOX), diluted ad 1 ml with phosphate-
buffered saline and administered over 20 min through the carotid artery. Simultaneously, one 
of the back-side tumors was treated with diagnostic US, while the tumor on the other side of 
animal’s back became no US. The sonication mode was identical to that, used in “3.6.6 In-
vivo evaluation of the acoustic properties of DOX-loaded MBs”, p. 90. 
After the treatment test animals were sacrificed and the tumors were harvested along with the 
liver, the lungs, and the kidneys. The tumors and organs were homogenized using a defined 
volume of 92.5 vol% isopropanol acidified with 7.5 vol% 1 M hydrochloric acid. After 
2 hours of incubation at 4 °C the insoluble tissue compounds were centrifuged at 14,000 rpm 
for 15 min using a NeoLab 16/18 centrifuge (Hermle Labortechnik GmbH, Wehingen, 
 94 
Germany). The clear supernatant was collected and DOX was quantified by RP-HPLC using 
an Agilent 1100 Series unit (Agilent Technologies Deutschland GmbH, Böblingen, Germany) 
equipped with an UV-detector and a fluorescence detector model Spectra System 
FL 3000 (TSP Thermo Separation Products GmbH, Egelsbach, Germany). DOX was detected 
by its fluorescence at an excitation wavelength of 480 nm and an emission wavelength of 
550 nm and by its UV-absorbance at 254 nm. The amount of DOX was quantified by the area 
under its characteristic fluorescence peak at 8.1 min retention time. Mobile phase and 
measurement setup were identical with the described under “3.3.2 Measuring the DOX 
concentration”, p.84. 
 
4. Results and Discussion 
4.1. Pre-formulation studies on doxorubicin-loaded anionic 
liposomes and microbubbles 
4.1.1. Differential scanning calorimetry studies 
During the following study two series of experiments were conducted. In the first series single 
phospholipids – DPPC, DPPE, and DPPG, were brought in contact with DOX at constant 
concentrations in order to assess the phospholipid complexation affinity to DOX and to select 
the most capable candidates. In the second part, binary phospholipid mixtures including 
DPPC and the selected DOX-binding phospholipid candidate were screened towards finding 
concentration ranges which are suitable for further development.  
During the first experiment series, the found single phospholipid transitions in absence of 
DOX were in agreement with reported values [178, 179] and will not be further explained in 
detail.  
Briefly, DPPC phase diagram revealed a broad pre-transition peak between 33 ºC and 35 ºC 
due to its tilted acyl chain packaging in gel state [180]. Furthermore, a sharp main transition 
peak of DPPC was observed at 41.5 °C. Upon addition of DOX the pre-transition endotherm 
was abolished and the main transition was moderately broadened and flattened, revealing a 
peak height decrease from 1.181 kW/mol to 0.879 kW/mol (Table 9), accompanied by a slight 
reproducible decrease of the gel to liquid-crystalline phase transition temperature (Tm) to 
40.49 °C. Thereupon, the DPPC mean endotherm area slightly decreased from 31.451 kJ/mol 
to 30.538 kJ/mol. 
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DPPC DPPE DPPG 
DOX Peak area, 
[kJ/mol] 
Peak height, 
[kW/mol] 
Peak area, 
[kJ/mol] 
Peak height, 
[kW/mol] 
Peak area, 
[kJ/mol] 
Peak height, 
[kW/mol] 
(–) 31.451 ± 0.050 1.181 ± 0.013 30.472 ± 0.130 1.026 ± 0.006 41.001 ± 0.1162 1.174 ± 0.018 
(+) 30.538 ± 0.092 0.879 ± 0.007 29.456 ± 0.063 0.715 ± 0.004 34.464 ± 0.042 0.529 ± 0.021 
Table 9: Differential scanning calorimetry data on the phase transition behavior of various phospholipids alone 
and upon interaction with doxorubicin (n = 9). Numerical data established is closely compliant with previous 
work [179]. 
 
In the case of DPPE, the main transition peak was centered at 64.31 °C for the pure 
phospholipid and was slightly moved by less than 1 °C to 63.84 °C upon addition of DOX. 
The addition of DOX to DPPE caused similar moderate effects as in the case of DPPC – a 
slight peak area and peak height decrease and peak broadening.  
The same thermotropic phenomena but much more pronounced were observed in the case of 
DPPG, too. For the pure DPPG the Tm was found at 39.84 °C and sank by 2.16 °C after 
addition of DOX, while the Tm depletions for DPPC and DPPE were only correspondingly 
1.01 °C and 0.47 °C.  
The reduction of peak height caused by DOX was 54.94% for DPPG vs. 30.31% for DPPE 
and 25.57% for DPPC. Regarding the peak area decrease upon addition of DOX, nearly the 
same progression was demonstrated by the three phospholipid candidates, too: 15.94% for 
DPPG, 3.33% for DPPE, and 2.90% for DPPC. Phospholipid-free DOX solutions, used as 
negative controls, showed no transition in the temperature range from 20 ºC to 85 ºC at the 
given concentration. 
Based on the thermotropic modifications of the selected phospholipid candidates caused by 
their more or less intensive interaction with DOX, DPPG was selected as the phospholipid 
with the highest complexation affinity amongst them. These findings are also consistent with 
the calorimetric studies of Constantinides et al. (1986) [179], who found none or a very minor 
transition changes in the case of DPPC, but a remarkable effect of DOX over the behavior of 
DPPG. In the present study the phospholipid transition modifications in DOX-DPPC and 
DOX-DPPE systems were significant, apparently owing to the up to 17-fold higher 
DOX / phospholipid ratios and the 10-fold lower electrolyte concentrations used. 
Nevertheless, the substantial difference in the change of the thermotropic behavior of DPPG 
after complexation with DOX was still apparent compared to the slight alterations, 
demonstrated by the zwitterionic phospholipids DPPC and DPPE.  
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Numerous authors have also demonstrated the prevailing role of strong electrostatic 
interactions and the auxiliary contribution of hydrophobic forces in the formation of 
complexes between DOX and anionic phospholipids [166, 170, 181]. Since DOX is one of the 
most hydrophilic anthracyclines (octanol / water partition coefficient of 1.1 [182]) its 
complexation affinity to zwitterionic phospholipid layers e.g. DPPC is expectedly low as 
demonstrated above.  
Interestingly, the affinity of DPPE to DOX was constantly higher than DPPC in spite of the 
large similarity of their chemical structures. This can be attributed either to the different 
lyotropic equilibrium phases (Lα for DPPC and HII for DPPE) or to the ability of DPPE to 
form hydrogen bonds with DOX and therefore - a more stable complex than DPPC. 
Complementary CLSM data have shown that mixed DPPC-DPPE bilayers can indeed 
complex DOX to some extend (data not shown) which possibly occurs through the interplay 
of hydrogen bonding and hydrophobic interactions.  
In the second experiment series the phase behavior in mixed bilayers comprising DPPC and 
DPPG were studied in a deeper detail upon titration with increasing amounts of DOX (Figure 
23). In absence of DOX the thermotropic behavior of DPPC-DPPG at increasing DPPG 
concentrations in the range of 10 mol% to 30 mol% revealed an ideal mixing, as previously 
reported [183]. The pre-transition peak at 34.7 °C persisted until 20 mol% DPPG and was 
abolished at higher concentrations. At various molar ratios of DPPG the binary mixtures 
exhibited a single thermal transition in the range between the temperatures characteristic for 
the pure species. With increasing DPPG amount the peak height gradually diminished from 
1.515 kW/mol to 0.838 kW/mol, and the main transition peak area also decreased from 
37.128 kJ/mol to 29.192 kJ/mol.  
Although DOX at a concentration of 20 eq% had little influence on DPPC, the addition of 
even 10 mol% DPPG strongly increased the effect of DOX on the phase transition. Even at 
relatively low DOX concentrations – between 0 eq% and 20 eq% according to the molar 
concentration of DPPG, the pre-transitional peak vanished apparently as a consequence of 
aglycon penetration between the phospholipid tails.  
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Figure 23: DCS heat-flow diagrams of the interaction 
between DOX and anionic DPPC/DPPG phospholipid 
bilayers (n = 3, second scanning run). Liposomes 
comprised 10 mol% (A), 20 mol% (B), and 
30 mol% (C) of DPPG. In each case the DOX 
concentration was varied from 0 eq%, 20 eq%, 
60 eq%, 100 eq%, 140 eq% and 180 eq% (according 
to the DPPG amount) at a pH of 7.4. The temperature 
interval between 25 ºC and 60 ºC is represented. No 
transition peaks were found out of this temperature 
span. 
 
Under the same conditions, the main endotherm was broadened and Tm shifted down by 
0.67 °C. At DOX concentrations above 100 eq% two overlapping peaks with a Tm difference 
of about 1 °C could be observed. The higher-melting peak appeared first as a shoulder when 
60 eq% DOX were reached and became with increasing drug concentration a separate peak 
which finally became sharper and centered at about 42 °C. In summary, by raising of DOX 
concentration three major thermotropic phenomena could be observed:  
a) a small reproducible Tm shift towards lower temperatures at low DOX concentrations 
e.g. the shift from 41.52 °C (0 eq% DOX, 20 mol% DPPG) to 40.85 °C (20 eq% 
DOX, 20 mol% DPPG); 
b) a gradual decrease of mean transition peak intensity, mostly pronounced in samples 
with lower concentrations of DPPG e.g. in samples comprising 20 mol% DPPG the 
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mean peak area (peak 1 at 40.5 °C) decreased from 31.091 kW/mol (0 eq% DOX, 
20 mol% DPPG) to zero (140 eq% DOX, 20 mol% DPPG); 
c) a gradual formation of a peak shoulder and a new higher-melting peak between 
41.42 °C and 41.94 °C at higher DOX concentrations. This effect was the more 
pronounced, the higher the concentration of DPPG was. 
 
Peak 1 Peak 2 
DOX, [eq%] 
Tm, [°C] 
Peak area, 
[kJ/mol] 
Peak height, 
[kW/mol] 
Tm, [°C] 
Peak area, 
[kJ/mol] 
Peak height, 
[kJ/mol] 
0 41.55 ± 0.11 31.091 ± 0.012 1.394 ± 0.020 --- --- --- 
20 40.88 ± 0.05 33.772 ± 0.003 1.072 ± 0.002 --- --- --- 
60 41.00 ± 0.08 27.553 ± 0.010 0.811 ± 0.001 shoulder --- --- 
100 40.47 ± 0.13 14.366 ± 0.003 0.660 ± 0.005 41.50 ± 0.11 12.008 ± 0.001 0.526 ± 0.005 
140 shoulder --- --- 41.42 ± 0.07 7.183 ± 0.011 0.551 ± 0.003 
180 --- --- --- 41.94 ± 0.02 26.803 ± 0.007 6.023 ± 0.002 
Table 10: Progression of multiple endotherms during titration with DOX of anionic phospholipid bilayers 
comprising 20 mol% DPPG and 80 mol% DPPC. At low DOX concentration a small Tm shift can be observed, 
followed by a gradual depletion of peak 1 height. Parallel to that a second higher-melting peak appeared and rose 
in height at DOX concentrations above 100 eq% (n = 3, m = 3). 
 
Next to the phase transition perturbations in mixed anionic systems, DOX also altered the 
colloidal and lyotropic condition of liposomes. Small-angle X-ray scattering studies [166] 
indicated that DOX in the concentration range of 40 eq% to 80 eq% causes a bilayer 
reorganization of anionic liposomes into closely-packed multilamellar structures. In this 
concentration span DOX shows also small but definite fluidizing effects on phospholipid 
membranes [179] as observable from the peak broadening thermotropic phenomena. 
At higher drug concentrations the appearance of high-melting peaks were correlated with the 
formation of a coarse crystalline phase (Figure 24), exclusion of the aqueous phase, and 
obliteration of the colloidal system. Surprisingly, although the stoichiometric proportions 
given by Goormaghtigh et al. (1980) [165] were exceeded, DOX was still bound beyond the 
concentration mark of 100 eq% (data not shown). Above this limit the concentration-
dependent formation of crystalline phase could be related by its optical appearance with the 
differentiation of a high-melting peak in the thermogram. This finding substantiates the 
hypothesis that further binding of DOX above the electrostatic charge stoichiometry is 
possible due to hydrophobic and self-association interactions [166]. Apparently, the excessive 
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phospholipid complexation enhances phase crystallinity and is detrimental for the liposomes’ 
colloidal state. 
The macroscopic appearance of the crystalline aggregates was as micrometer to millimeter 
large dark-red particles, prone to sedimentation. A scanning electron microscopy (SEM) 
image revealed the various form and sharp-edged surface topography of the 
aggregates (Figure 24). Aggregate crystallinity was confirmed by transmission electron 
microscopy (TEM, data not shown). The formation of crystalline aggregates and colloidal 
collapse of the formulations can be explained by escalating formation of stacked aglycon 
associates [166], interdigitation of phospholipid acyl chains [184] or other unspecific 
interactions. 
Dilution of the anionic phospholipid DPPG with zwitterionic phospholipids such as DPPC 
lowers the DOX binding ability of liposomes [169], but it also effectively inhibits the 
formation of crystalline aggregates as seen by the tendency of bilayers with a higher DPPG 
content to form more intensive high-melting peaks at lower DOX concentrations (Figure 23).  
 
 
Figure 24: Scanning electron microscopy image of a condensed aggregate of DPPC/DPPG and DOX in 
formulations, containing 70 mol% DPPC, 30 mol% DPPG, and 140 eq% DOX. 
 
The fluidizing effect of DOX on anionic phospholipid membranes, suggested in the 
literature [179], has been observed in the above thermograms (Figure 23) in terms of peak 
broadening and flattening. These peak shape changes can be numerically represented as the 
ratio between the peak width at half peak height (W0.5) and the peak height (H). For example, 
in binary mixtures of 10 mol% DPPG and 90 mol% DPPC increasing DOX concentrations 
cause a continuous increase of the W0.5 / H coefficient i.e. membrane fluidizing until 100 eq% 
of DOX are reached (Figure 25, solid line). Beyond this mark the membrane fluidity steeply 
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declines and crystalline complexes are bound in the final stage. Interestingly, the MB yield 
follows the same progression as represented by the dashed line plot. This finding together 
with several further examples later on corroborates the hypothesis that the phospholipid 
cooperativity is a major factor for the stability of MB shell. This opinion has already been 
maintained by other authors and witnessed by fluorescence microscopy [14, 79, 93]. 
 
 
Figure 25: Transition peak flattening and broadening (solid line) of peak 1, appearing at about 41°C, in binary 
mixtures of 10 mol% DPPG and 90 mol% DPPC at DOX concentrations, increasing from 0 eq% to 180 eq% 
according to the concentration of DPPG. The dashed line represents the progression of MB yield produced upon 
mechanical agitation.  
 
The key result of this study was the selection of suitable concentrations for the formulation of 
DOX-loaded liposomal MB precursors. The choice criteria for the optimum formulation range 
were: a) the highest molar ratio between DOX and total phospholipid (greatest loading 
amount of DOX); and b) the highest bilayer fluidity derived from the lowest height of the 
melting peak, arising below 41 °C (peak 1). The selected interval of 20 mol% DPPG and 
between 60 eq% and 100 eq% DOX satisfied both requirements, although a better membrane 
fluidity was existing under 10 mol% DPPG and 100 eq% DOX, yet the drug loading was then 
lower. Further on in this work, the range of 20 mol% DPPG and 60 eq% to 100 eq% DOX 
will be used as a milestone for further optimizations and development of DOX-loaded MBs.  
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4.1.2. Effect of US homogenization of liposomes on the MB yield 
US homogenization of liposome intermediates for the production of DOX-loaded MBs in the 
time range from 0 min to 10 min had an unsteady effect on the MB particle yield (Figure 26). 
 
 
Figure 26: Progress of liposome size and MB yield during homogenization by US. 
 
Rather short sonication times of 2 min caused a rapid 5-fold decrease of liposomal size down 
to about 150 nm with no significant change after further sonication (solid line). On the other 
hand, MB yield demonstrated an about 4-fold increase after five minutes US homogenization, 
followed by a steep 2-fold decrease (dashed line). However, the pattern of MB yield increase 
did not correlate with the progression of particle size reduction. The initial increase of MB 
concentration could be indeed explained with liposome size and / or viscosity effects. The 
following decrease of MB yield is apparently due to the loss of surface activity in samples, 
treated with US as observed by other authors [81]. In consequence, US horn-type 
homogenization for 3-5 minutes can be applied for improving the colloidal state of DOX-
loaded anionic liposomes, yet with the concern of occurring chemical decay of the active 
drug. 
4.1.3. Effect of third phospholipid compounds 
In the following study DPPC-DPPG liposomal formulation were tuned by addition of minor 
amounts of third phospholipids in attempt to improve their pharmaceutical properties like 
liposomal size distribution, storage stability, MB yield, etc. Phospholipids with broadly 
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varying properties (Table 5, p. 28) such as PEGylated (DPPE-PEG2000), cationic (DPTAP), 
non-bilayer (DPPE) phospholipids and sterols (cholesterol) were applied. 
The purpose of including PEGylated phospholipids such as DPPE-PEG2000 was to enforce 
the existing electrostatic repulsing interactions between liposomes by additional steric 
shielding and to improve their colloidal stability upon storage. Furthermore, the “bulky” PEG 
moieties increase the bilayer mean curvature (H), thus promoting the bending towards the 
acyl chain region, and expectedly favor the spontaneous formation of smaller liposomes [185, 
186].  
In the concentration range from 1 mol% to 2 mol% DPPE-PEG2000 the liposome size, 
measured in un-homogenized preparations, decreased from 2,800 ± 330 nm to 
530 ± 83 nm (Figure 27). The polydispersity index (PdI) decreased from 1.000 to 
0.382 ± 0.051. This positive influence allowed eliminating the highly energetic step of US 
horn-type homogenization from the formulation procedure. Similar phenomenon of 
spontaneous small liposome formation upon addition of PEGylated phospholipids have been 
observed by Szleifer et al. (1998) [186]. In the denoted concentration interval of 1-2 mol% 
DPPE-PEG2000 the formation of MBs upon agitation was adequate with a yield of 2-
4 x 1010 MB/ml. As expected [187], a small increase (5-7 mV) of the negative liposomal Zeta 
potential was found in the above concentration range of DPPE-PEG2000, due to electrostatic 
shielding effects through the PEG-grafts. 
With increasing the concentration of DPPE-PEG2000 to 5 mol% of the total phospholipid 
molar amount only a small reduction of liposome size followed. On the other side, the 
formation of MBs and their structural stability steeply decreased resulting in MB yields of 
between 1 x 105 MB/ml down to 1 x 102 MB/ml.  
One possible hypothesis for the strongly diminished MB formation is given by the 
continuously increasing monolayer bending tension caused by the PEG-grafts. The same 
effect which decreases liposome size at lower surface PEG-graft densities apparently bends 
the MB shell monolayer towards increasingly smaller curvature radii which are no longer 
compatible with the MB geometry. This obviously leads to shell instability and MB 
degradation. 
Due to their large positive intrinsic curvature and steric shielding properties PEGylated 
phospholipids contribute on a concentration-dependent manner two positive impacts to DOX-
loaded liposomal formulations. These are first - the spontaneous formation of smaller 
liposomes with a narrower size distribution, and second - the prolonged colloidal storage 
stability from several hours to several weeks.  
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Figure 27: Effect of third phospholipid 
compounds – PEGylated (DPPE-PEG2000) and 
cationic (DPTAP) phospholipids, and cholesterol, on 
the liposome size and MB yield in DOX-loaded 
formulations. The liposome mean size after storage 
for 30 days at 4 °C is represented. 
 
On a similar fashion cholesterol strongly hampered the formation of DOX-loaded MBs, 
although it improved the size distribution and colloidal stability of liposomes. In the 
concentration range of 3-5 mol% cholesterol completely prevented the formation of 
crystalline aggregated phase between DOX and phospholipids. Same amounts of cholesterol 
further preserved liposomal size to 120 ± 13.12 nm over a month during storage at 4 °C. 
However, cholesterol in above concentrations strongly hindered the MB formation and 
reduced MB yield by over 100-fold. On the cholesterol concentration scale its positive 
stabilization effects on liposomes commence equally with the negative effects on MB 
formation. Therefore, cholesterol-adjusted formulations can well be practicable for liposomal 
preparation, yet not for the production of MBs.  
Including of non-bilayer hydrogen-bonding phospholipids such as DPPE [169] into anionic 
bilayers was done with the intension to enhance the combined electrostatic / hydrophobic 
complexation through hydrogen bonding between DOX and the free primary amine of DPPE 
headgroup. However, already small increments of DPPE in the order of 1-2 mol% strongly 
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increased the liposomal viscosity and raised the MB median size by over 3-fold. Higher DPPE 
concentrations led to the gelation of the formulations and made them useless for MB 
production. 
An interesting formulation aspect offers the inclusion of small amounts of cationic 
phospholipids e.g. DPTAP into mixed anionic phospholipid blends and forming of so called 
catanionic bilayers [188]. Driven by electrostatic repulsions, cationic phospholipid molecules 
should distribute between the negative charges and increase the distances between them [189]. 
The larger distance between negative charges will expectantly reduce the possibility of 
forming stacked DOX associates due to the decreased probability of contact between aglycon 
moieties. On the contrary to our expectation, DPTAP had no positive impact on liposomal and 
MB formulations. Higher concentrations of DPTAP (3-5 mol%) even impaired the storage 
colloidal stability and caused a 5-6 fold increase of liposome mean size after 30 days at 4 °C.  
In summary, considering the pharmaceutical properties of both DOX-loaded liposomal and 
MB formulations, only the addition of small amounts of PEGylated phospholipids brought an 
advantageous impact and was accepted into the further formulation development.  
4.1.4. Effect of agitation time on the DOX encapsulation in MBs 
The effect of agitation time on unloaded MB formulations was discussed above under 
“II. Ch. / 4.1.1 Effect of agitation time” on p. 43. The general outcome of this study was that a 
steep decrease of MB concentration occurs after about 20 s agitation apparently due to the 
combined action of temperature increase and shear forces. This tendency was proven again by 
examining of DOX amount, associated to the MB fraction (CMB) as function of the agitation 
time (Figure 28). 
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Figure 28: DOX amount, encapsulated in MBs in relation to various agitation times. As a result of temperature 
increase and shear forces, MB decay occured after 20 s agitation. Therefore, DOX has been released from the 
MB fraction in the form of liposomes (n = 6). 
 
After an agitation time of 20 s the amount of DOX, associated with MBs CMB declined from 
approximately 95% to about 82% (after 30 s) and further to 59% after 40 s. Compared to 
Figure 6, p. 43 the reduction of CMB (62% between the 20th and the 40th second) nearly 
quantitatively corresponds to the decrease of MB concentration (65.2% in the same time 
span). Therefore, the agitation time was set to 20 s in the standard formulation approach for 
DOX-loaded MBs.  
Further formulation parameters such as tube fill volume and tube shape were adopted from 
“II. Ch. / 4.1 Pre-formulation studies on model microbubbles”, p. 43 without additional 
modifications. 
4.1.5. Optimal formulation procedure for DOX-loaded liposome precursors and 
MBs 
Based on the pre-formulation research the following standardized procedure was established. 
The resulting final concentrations of active drug and excipients in liposomal formulations for 
production of MBs are given in Table 11. 
 
 
 
 
 
 106
Component Molar concentration, [mM] Mass concentration, [mg/ml] 
DOX 0.60 0.35 
DPPC 2.37 1.74 
DPPG 0.60 0.45 
DPPE-PEG2000 0.03 0.08 
Glucose 0.28 50.00 
EDTA 0.01 0.003 
Table 11: Constitution of “optimized” DOX-loaded liposomal formulations for the production of MBs by 
mechanical agitation. 
 
Briefly, depending on the charge volume, appropriate amounts of DPPC, DPPG and DPPE-
PEG2000 were dissolved in chloroform. Following, the organic solvent was removed and the 
phospholipid thin-film was allowed to dry under vacuum at a temperature of 60 °C for 
60 min. 
Accordingly, DOX, EDTA, and glucose were dissolved in highly purified electrolyte-free 
water (Purelab Plus®, USF Elga Ionpure GmbH, Germany). The phospholipid film was 
hydrated with the DOX solution for 60 min under continuous stirring under light protection 
and nitrogen atmosphere. During the hydration the temperature was maintained above the gel- 
to liquid-crystalline phase transition temperature of the DOX / phospholipid complex (42 °C). 
Prior to characterization and further proceeding, the liposomes were allowed to equilibrate for 
at least 12 hours at 4 °C. The total molar concentration of phospholipid (PLT) in final 
liposomal formulations was 3 mM (2.27 mg/ml). The mass ratio of DOX to total phospholipid 
has been calculated to be 15.3%. 
 
4.2. Characterization of doxorubicin-loaded liposomes 
4.2.1. Size distribution and Zeta potential 
In standard preparations according to Table 11 DOX-loaded liposomes had an average size of 
530 ± 83 nm (PdI = 0.382±0.051) and a Zeta potential of -22.58 ± 0.56 mV at a medium 
conductivity of 0.0014 mS/cm2.  
The successful binding of DOX to anionic liposomes was also confirmed by the increase of 
their negative Zeta potential caused by the compensation of anionic charges by DOX. The 
Zeta potential of unloaded liposomes containing from 10 mol% to 50 mol% DPPG decreased 
rather linearly from -14.8 ± 0.20 mV to -38.4 ± 0.46 mV. After loading with 100 eq% DOX 
the Zeta potential in all samples increased by about 12.00 ± 0.75 mV to -27.45 ± 0.73 mV. 
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4.2.2. Measuring the DOX concentration 
The characteristic peak of DOX appeared at a retention time of 7.82 ± 0.3 minutes (26.06% of 
the total elution time). The slope of the UV-spectrometric calibration line in the DOX 
concentration range from 0.5 µg/ml to 100 µg/ml was 13,952.670 ± 350.563 with an intercept 
of 1,372.91 AU (R2 = 0.9974). The HPLC method was not significantly influenced by the 
presence of phospholipids in the studied concentration range. The recovery rate of DOX from 
liposome samples was 99.59 ± 0.07% (Cm = 0.3486 ± 0.0174 mg/ml) after admixing of 20 µl 
liposomal dispersion with 1 ml acidified isopropanol. 
4.2.3. Association of DOX with liposomes 
In the described concentration range DOX showed a very high affinity to anionic 
phospholipid bilayers. The fraction of free DOX, found in liposomal preparations, was 
2.76% ± 3.2% of the total amount of drug used.  
4.2.4. Electrolyte-induced liposomal leakage of DOX 
According to the literature, next to the weaker hydrophobic interaction, the major component 
of DOX complexation is the electrostatic attraction [165]. Increased electrolyte concentrations 
shield the Coulomb interactions between charges in an electrostatic complex which are 
separated by more than roughly a Debye screening length [190] (Equation 12). 
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Equation 12: Debye length equation in an electrolyte solution or in a colloidal dispersion.  
 
where I is the ionic strength of the electrolyte, ε0 is the permittivity of free space, εr is the 
solvent’s dielectric constant, k is the Boltzmann’s constant, T is the absolute temperature in 
Kelvin, NA is Avogadro’s number, and e is the elementary charge. When increasing the ionic 
strength the Debye length i.e. the distance, over which significant ion charge separation can 
occur, decreases. Because of the shrinking Debye spheres opposite ion charges interact 
weaker and the electrostatic component between DOX and anionic phospholipid bilayer 
looses on magnitude.  
On their turn the sodium cations also exert an effect on the ionization state of DPPG by 
binding and compensating negative charges [95]: 
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>O3POH ↔ >O3PO – + H + 
>O3PO – + Na+ ↔ >O3PONa 
>O3PO DOX + Na+ ↔ >O3PONa + DOX + 
 
However, literature data indicates an association constant (Ka) of about 0.2 M-1 (by 
interpreting the surface potential) [95] or somewhat lower from 0.005 M-1 to 0.02 M-1 (by 
interpreting the surface pressure data) [191], for binding of Na+ to phosphatidylglycerols. For 
comparison the association constants between anionic phospholipids (cardiolipin) and DOX 
are much greater and are in the order of 105-106 M-1 [192]. Apparently the salt-induced 
dissociation of the DOX-anionic bilayer complex is rather governed by Debye-shielding 
effects than by changing the phospholipid ionization state.  
Experimental data revealed that the influence of increased ionic strength on DOX-anionic 
bilayer complex shows a strong dependency on whether the complex has already been formed 
or not. Prior to complex formation the effect of monovalent ion concentrations in the range of 
0 mM to 100 mM almost completely inhibited the binding of DOX. Even at low ion 
concentrations of 10 mM DOX complexation was reduced from 87-90% to 21-28% of the 
total input amount (Figure 29). By increasing the ion concentration to 100 mM the amount of 
DOX, bound to liposomes, decreased gradually further to 7-9%. 
The salt-induced dissociation of DOX-anionic phospholipid complex was far less pronounced 
when the electrolyte was added to the pre-formed complex. In this case small salt 
concentrations of 10-20 mM provoked the dissociation of only 7-13% of the total DOX 
amount used. The dissociation at 100 mM ion concentration reached 34-42% DOX. 
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Figure 29: Electrolyte-induced leakage of DOX from anionic liposomes at increasing concentration of single-
charged ions – sodium chloride, from 0 mM to 100 mM (n = 3). The concentration of free DOX in the 
supernatants is plotted as per cent according to the total DOX concentration in whole samples. 
 
As found under “3.2.1 Differential scanning calorimetry studies” on p.81, the hydrophobic 
interactions of DOX with neutral phospholipids appear to be much weaker than the 
electrostatic attractions with anionic phospholipids. However, the present study allowed 
exerting the theory that electrostatic attractions only play an earlier role during the complex 
formation than hydrophobic interactions. Long-range electrostatic forces apparently attract the 
DOX molecules to such proximity where shorter-ranged hydrophobic interactions can occur.  
This hypothesis has been implicated by the fact that shielding the electrostatic interactions by 
monovalent sodium cations prior to the complex formation results in almost total inhibition of 
the complexation (Figure 29, solid line). Apparently the hydrophobic attractions additionally 
stabilize the complex when the molecule is located in an approximate reach to the bilayer. 
This is supported by the fact that detaching of DOX upon electrolyte shielding of electrostatic 
attractions after the formation of the complex (Figure 29, dashed line) is about three times less 
pronounced than prior to that. 
It appears that the electrostatic interaction is only a necessary prerequisite for the formation of 
DOX-phospholipid complex which further on is stabilized by hydrophobic interactions with 
the phospholipid acyl chains or / and the formation of stacked aglycon associates (Figure 22, 
p. 77). One indication for this event sequence is the fact that DOX interacts very scarcely with 
zwitterionic phospholipid layers of DPPC, where only hydrophobic interactions are possible. 
In contrast to that more lipophilic cationic anthracyclines such as pirarubicin [193] and N-
trifluoroacetyladriamycin-14-valerate [179] are indeed able to form such complexes.  
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4.2.5. Chemical stability of DOX during the production of liposomes 
In the early stages of formulation development the concentration loss of DOX due to chemical 
degradation during liposome production using the thin-film method with a following US-
homogenization step was up to 10.4% ± 6.19% of the input DOX amount. US 
homogenization alone had a great impact to the chemical decay making up about 
4.8% ± 1.53% of the total degradation rate. 
After spontaneous formation of small liposomes was achieved by the addition of PEGylated 
phospholipids the highly energetic step of US horn-type homogenization was excluded from 
the processing lane (see “4.1.3 Effect of third phospholipid compounds”, p.101). Additional 
protection measures from air oxygen and light helped reduce DOX chemical decay to 
statistically insignificant values.  
4.2.6. Photochemical stability of DOX 
The photochemical degradation of DOX revealed a single exponential- to nearly linear order 
kinetics. Both aqueous and liposomal formulations showed significant concentration 
losses (correspondingly 27.16% ± 0.37% and 12.81% ± 2.76% according to the initial 
concentration) due to thermal effects in obscured samples (Figure 30 and Figure 31, solid 
lines). Interestingly, although the temperature, measured during the whole time range, in 
obscured samples of both liposomal and aqueous formulations did not deviate 
significantly (25.94 °C ± 3.21 °C), liposomal DOX appeared to be more stable in absence of 
light.  
 
 
Figure 30: Photochemical stability of DOX in 0.6 mM aqueous solutions in obscured (solid line, R2 = 0.9738) 
and light exposed samples (dashed line, R2 = 0.9975), n = 9. 
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Figure 31: Photochemical stability of DOX in liposomal dispersions, containing 0.6 mM DOX and 3 mM total 
phospholipid concentration, in obscured (solid line, R2 = 0.9738) and light exposed samples (dashed line, 
R2 = 0.9975), n = 9. 
 
The temperature difference between light exposed and obscured samples was moderate – 
3.51 % ± 1.37 %. After 72 hrs exposure to light aqueous DOX solutions showed a total decay 
of 47.80 % ± 2.78 %, while in liposomal samples the DOX loss was higher – 
58.59 % ± 1.97 % (Figure 32). The half-life times of DOX are represented in Table 12. 
 
 
Figure 32: Comparison between the photochemical degradation of DOX in light-exposed aqueous 
solutions (solid line) and liposomal samples (dashed line). 
 
However, if the more pronounced thermal decay be subtracted from the total degradation rate, 
liposomal formulations demonstrate a 2.22-fold lower photochemical stability than aqueous 
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solutions with 45.78% (in liposomes) vs. 20.64% (in solution) photochemical loss after 
72 hrs. 
 
Half-life (τ) of DOX, [hours] 
Formulation 
Exposed samples Obscured samples 
Aqueous solution 22.38 ± 1.13 29.18 ± 1.28 
Liposomal dispersion 29.87 ± 2.01 37.26 ± 1.21 
Table 12: Half-life (τ) of DOX in aqueous solutions and in liposomal dispersions  
 
The increased photochemical instability of DOX in liposomal formulations can be attributed 
mainly to their increased turbidity compared to aqueous solutions. Furthermore, the DOX 
stability is possibly influenced through the increased specific absorption constant when the 
aglycon persists in less polar medium between the phospholipid acyl chains [165]. 
In summary, in order to preserve the chemical stability of DOX, primary packages must be 
selected which provide an adequate light protection. 
 
4.3. Pre-formulation studies on doxorubicin-loaded microemulsions 
and acoustically active lipospheres 
The formulation strategy of DOX-loaded acoustically active lipospheres (AALs) was based 
on the production of foamable microemulsions, containing the active drug in their oil-phase. 
After mechanical agitation these drug-loaded microemulsions produce AALs, comprising 
DOX in the oil layer, covering the inner surface of the phospholipid monolayer (Figure 
2, C, p.19). Drug-loaded AALs were first described by Unger et al. (1998) [122] in the case of 
paclitaxel. Several injectable oil excipients such as castor oil, soybean oil, or triacetin have 
been used to prepare drug-loaded AALs [194, 195]. Among them triacetin-containing AALs 
were found to provide the best acoustic destructibility, apparently because of its about four 
times lower viscosity of 28 cP vs. 110 cP in the case of soybean oil at 25 °C [194]. For this 
reason triacetin was preferred in the following pre-formulation studies. 
During the pre-formulation development several main pharmaceutical challenges were 
addressed:  
a) colloidal stability of DOX-loaded microemulsions;  
b) retention of DOX in the lipophilic phase; 
c) ability of microemulsions to form AALs (foamability); 
d) US echogenicity and destructibility of AALs. 
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4.3.1. Partition equilibrium of DOX-base between triacetin and water 
The distribution of DOX-base between the non-polar triacetin phase and the outer aqueous 
phase is a solubility- and pH-dependent process. Others than paclitaxel [122] which has a very 
high octanol / water partition coefficient of 99 and is barely soluble in water [122], DOX has 
a rather high water solubility and a low partition coefficient of 0.45 to 1.85 [180-182]. In 
addition, its molecule has an amphotheric character owing to the basic daunosamine primary 
amine group and the deprotonable phenol function of the aglycon. Depending on the pH DOX 
molecules are prone to self-association and formation of fiber-like aggregates [196], as well 
as to chemical degradation [175].  
Triacetin is a rather non-polar medium with a dielectric constant of 6.2 which is over 10-fold 
lower than that of water – 78.48 (1 MHz, 25 °C). Because of its small molecule, triacetin is 
slightly soluble in water and has an equilibrium saturation concentration of 
61.2 g/l (52.7 µl/ml) [197]. 
The above chemical parameters draw a rather challenging perspective for the formulation 
development which firstly needs to overcome the partitioning problems of DOX between 
triacetin and water. 
The chemical transformation of DOX from its hydrochloride salt form into the free-base 
form (DOX-base) has increased its solubility in triacetin from undetectable concentrations to 
4.37 ± 0.31 mg/ml (equilibrium saturation concentration at 4 °C). After the DOX-
base / triacetin solution was brought in contact with aqueous phase, part of DOX migrated 
into it on a pH dependent manner.  
The triacetin / water partition of DOX is an equilibrium process, depending on the 
lipophilicity values of DOX-base and triacetin, on the pH value in the aqueous phase, and on 
the DOX concentrations in both phases. The retention of DOX in the lipophilic phase was 
evaluated in terms of the apparent partition coefficient (P): 
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where [DOX-NH2]lip is the molar concentration of DOX-base in the lipophilic phase while 
[DOX-NH2]aq and [DOX-NH3+]aq are the concentrations of DOX-base and protonated DOX 
in the aqueous phase. 
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In the aqueous phase DOX-base is protonated on a pH-dependent manner and its 
concentration is reduced according to the equilibrium: 
 
DOX-NH2 + H+ ↔ DOX-NH3+  
 
][
]][[
3
2
+
+
−
−
=
NHDOX
HNHDOXKe  
Equation 14 
 
The theoretical plot of DOX ionization state [150] reveals a minimum protonation above a pH 
of 7. Between pH of 8 and 9 a maximum of 70% of all DOX molecules persist in uncharged 
form. Above a pH of 8 a steep increase of the deprotonated DOX species takes place.  
As a result of its diffusion out of the triacetin phase and its protonation in the aqueous phase, 
DOX continuously migrates out of the AAL carriers which decreases their efficient loading. 
In order to ensure the stability of the loaded DOX amount, the control of pH and increasing 
the concentration of DOX-base are expectably effective levers for enhancing the retention of 
DOX in the lipophilic triacetin phase. The influence of surfactant / co-surfactant monolayer 
on the partition was not considered in this study. 
At lower pH values between 5 and 7 nearly all DOX migrated from the non-polar triacetin 
into the aqueous phase (Figure 33, dashed line). Increasing the pH to 8.5 increased the 
concentration of DOX-base in the aqueous phase at the expense of the protonated DOX form 
which led to an increased retention in triacetin (P = 45.43% ± 2.35%). Further increase up to a 
pH of 9 caused complications due to reduced solubility and precipitation of DOX.  
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Figure 33: Experimental apparent partition coefficients of DOX between triacetin and aqueous buffers with 
various pH.  
 
In a following study, DOX in a concentration of 30 µg/ml was added to the aqueous buffer in 
order to shift the above acid-base and diffusion equilibria towards the triacetin phase. As 
expected, the apparent partition coefficient at a pH of 8.5 has raised to 
58.30% ± 2.31% (Figure 33, solid line) which value was accepted for further progress.  
The above results were consistent with previous studies of Tewes et al. (2007) [150], who 
determined the apparent partition coefficients of DOX for two organic phases – methylene 
chloride (P ~ 90-95% at pH 8.5) and ethyl acetate (P ~ 10-15% at pH 8.5). Interestingly, these 
results do not correlate with the dielectric constants of these two solvents, being 
correspondingly 9.8 and 6.02. However, the influence of additional factors must be also taken 
into account such as the ionic strength, solute concentration, etc. 
4.3.2. Optimal formulation procedures for DOX-loaded microemulsions and 
AALs 
The resulting final concentrations of active drug and excipients in microemulsion and AAL 
formulations are given in Table 13 below.  
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Component Molar concentration, [mM] Mass concentration, [mg/ml] 
DOX-base in triacetin 0.121 0.065 
DOX in aqueous phase 0.051 0.030 
DPPC 4.63 3.40 
DPPG 0.57 0.38 
DPPE-PEG2000 0.45 1.20 
Lutrol F68 approx. 0.794 10 
Triacetin --- 15 
Triacetin-saturated phosphate buffer, pH 8.5 ad 50 ml 
Table 13: Final concentrations of DOX and excipients in standard formulations of DOX-loaded MBs. 
 
In summary, according to the above calculated DOX partition, from the total amount of 
0.172 mM DOX in the microemulsion, 41% (0.0705 mM or 35.814 µg/ml) were entrapped in 
the triacetin phase and 59% (0.1015 mM or 51.562 µg/ml) were situated in the outer aqueous 
phase.  
 
4.4. Characterization of doxorubicin-loaded microemulsions 
4.4.1. Particle size distribution and colloidal stability of DOX-loaded 
microemulsions 
Directly after their production, both high-pressure homogenized and horn-type sonication 
homogenized microemulsions showed rather similar particle size distributions of 
correspondingly 102.0 nm ± 12.0 nm and 114.7 nm ± 13.5 nm. The polydispersity index (PdI) 
of both formulations was correspondingly 0.276 and 0.312 (n = 3).  
After storage for 14 days, DOX-loaded triacetin microemulsions, produced by horn-type 
sonication showed an over 2-fold increase of particle size (from 82.8 ± 9.3 nm to 
175.3 ± 31.5 nm) and resulted in coarse dispersions after 30 days. Within the first two weeks 
their polydispersity increased by about 2-fold from a PdI of 0.206 to 0.405, reaching the 
maximum value of 1.000 after 30 days. 
In contrast, under the same storage conditions microemulsions, produced by high-pressure 
homogenization, showed no significant size increase over 30 days. Therefore, the high-
pressure homogenization was chosen for a standard preparation method for microemulsions in 
order to prepare drug-loaded AALs. 
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4.5. Characterization of doxorubicin-loaded microbubbles and 
acoustically active lipospheres 
4.5.1. Structure analysis of DOX-loaded MBs and AALs 
CLSM microscopic images of DOX-loaded MBs (Figure 34, A) revealed their spherical shape 
with intensive fluorescence of the drug, included in the phospholipid shell. The DOX-bearing 
shell encompasses a dark core, comprising the octafluoropropane gas. 
In the case of DOX-loaded AALs (Figure 34, B), the drug was also included into the 
surrounding shell which was thicker and its fluorescence often masked the dark core shadow. 
 
 
Figure 34: CLSM micrographs of DOX-loaded phospholipid MBs (A) and DOX-loaded AALs, containing 
triacetin (B). DOX (in red) is localized mainly in the anionic phospholipid MB shell and in the triacetin layer of 
AALs. 
 
4.5.2. Particle size distribution 
Concerning the formulation of DOX-loaded MBs and AALs in this work, the surface-
weighted particle size distribution was considered most significant, especially with regard to 
the efficient loading (refer to “II. Ch. / 4.1 Characterization of microbubbles”, p. 43).  
DOX-loaded MB formulations revealed a bimodal size distribution with a more 
intensive (~ 80%) peak between 800 nm and 4 µm with a mean size of 
1.0165 µm ± 0.0218 µm. Another size peak with an intensity of about 20% smeared between 
20 µm and 100 µm. In order to quantitatively determine the number of MBs, larger than 
10 µm, additional particle size and counting measurements using light blockage accomplished 
covering the size range from 800 nm µm to 200 µm. According to them only between 0.06% 
and 0.40% of the total MBs number surpassed the size limit of 10 µm.  
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In the case of DOX-loaded AALs, the size distribution by laser diffraction also revealed a 
bimodal surface-weighted size distribution with a mean peak (~ 70% intensity) at 
1.2036 µm ± 0.1319 µm and a higher-sized peak (~ 30% intensity) between 30 µm and 
110 µm. Particle counting analysis revealed that between 0.98% and 1.22% of the overall 
AAL number are larger than 10 µm. 
4.5.3. Particle concentration 
Particle concentration in freshly prepared samples of DOX-loaded MBs was 7.85 ± 0.51 x 109 
MB/ml. Compared to that, the average yield of DOX-loaded AAL was four decimal orders 
lower: 4.73 ± 0.74 x 105 AAL/ml. 
4.5.4. Effectiveness of DOX loading into MBs and AALs 
Following, the effectively loaded amounts of DOX in phospholipid MBs and triacetin AALs 
will be outlined and the excipient burden of both formulations will be compared. Excipient 
burden will be defined as the mass ratio between the total formulation drug amount and the 
comprised excipients. Effective loading amount will be defined as the ratio between drug 
amount, encapsulated in MBs or AALs after their production, and the total drug amount in the 
formulation.  
The experimentally determined effective DOX loading amounts of MBs and AALs are 
represented in Table 14. While in the case of MBs the larger part of the total drug amount was 
efficiently encapsulated in liposomes and consequently transferred into MBs, in AALs the 
encapsulation was not as effective. Since the DOX-base partitioning between triacetin and 
aqueous phase was rather unadvantageous only a small part of the entrapped amount was 
transferred into the AALs.  
 
 DOX-loaded MBs DOX-loaded AALs 
Total drug amount, [µg/ml] 350 95 
Effective loaded amount, 
[% of the total drug amount] 
87.30 ± 2.78 22.53 ± 1.89 
Unbound DOX, 
[% of the total drug amount] 
10.65 ± 3.1 
(~ 6% in residual liposomes and 
~ 4.7% as free DOX) 
78.14 ± 2.73 
(in form of free DOX or as 
residual triacetin droplets) 
Table 14: Phase distribution of DOX in optimal formulations of DOX-loaded MBs and DOX-loaded AALs. 
 
The excipient burden of DOX-loaded AALs was about fifty times greater than for MBs. In the 
case of MBs the excipient burden was calculated to 6.49 and approximates the value of the 
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commercial DOX-loaded liposomes (Doxil®, Ortho Biotech, Bridgewater, USA) having an 
excipient burden of 6.15. In the case of AALs, the excipient burden approached 312.51. 
In summary, with regard to the loading efficiency phospholipid MBs were definitely more 
appropriate as targeted carriers for DOX than triacetin AALs. This can be mostly attributed to 
the low lipophilicity of DOX which made necessary complex formulation measures to be 
taken in order to retain the drug in the particles. Like in the case of paclitaxel [134] AALs 
might be appropriate carriers for more lipophilic anti-tumor drugs. 
4.5.5. In-vitro acoustic destructibility of DOX-loaded MBs and AALs 
The acoustic destructibility of DOX-loaded MBs and DOX-loaded AALs was compared with 
unloaded MBs and the commercial standard SonoVue® in order to select the better candidate 
formulation for further in-vivo studies. The corresponding single exponential decay curves of 
particle concentration vs. sonication time are represented on Figure 35.  
 
 
Figure 35: Ultrasound-mediated destruction of DOX-loaded MBs and AALs, compared to unloaded MBs and 
the commercial standard SonoVue®. 
 
After calculation of the sonication half-lives (t1/2) for individual MB and AAL 
formulations (Table 15) they could be compared (Figure 36). The highest acoustic decay pace 
with a t1/2 of about 41 s was shown for the commercial standard SonoVue®. In comparison to 
that, the decay of unloaded MBs (t1/2 = 60.15 s) and drug-loaded MBs (t1/2 = 60.18 s) was less 
rapid, having a small, but statistically significant difference to SonoVue® (p<0.0005 for 
unloaded MBs and p<0.0001 for DOX-loaded MBs). Interestingly, the difference between t1/2 
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of unloaded and drug-loaded MBs was statistically insignificant (p = 0.9893). In this case, the 
presence of drug loading had no considerable effect on the MB acoustic destructibility. 
 
Formulation R2 Initial population, a Decay coefficient, b Half-life, t1/2, [s] 
Blank measurement 0.8220 1.048 x e5 3.622 x e-4 1913 ± 0.9 
DOX-loaded AALs 0.9605 1.073 x e5 3.769 x e-3 184.02 ± 3.12 
Unloaded MBs 0.9363 1.030 x e5 1.530 x e-2 60.15 ± 2.63 
DOX-loaded MBs 0.9450 1.053 x e5 1.152 x e-2 60.18 ± 1.32 
SonoVue® 0.9894 9.693 x e4 1.688 x e-2 41.05 ± 1.83 
Table 15: Coefficient of determination R2, decay function parameters, and half-life of different MB formulations 
during sonication at a frequency of 1 MHz and output intensity of 4 W/cm2 (number of experiments, n = 5, 
number of measurements per experiment, m = 3). 
 
In contrast, DOX-loaded AALs with t1/2 = 184.02 s were 4.5-fold less destructible than 
SonoVue®, and 3.06-fold less destructible than DOX-loaded MBs which limited their 
applicability as potential drug-carrier candidates.  
The loss of MBs due to stress factors in the in-vitro setup e.g. shear-stress, compression by the 
peristaltic pump, etc. was about a decimal order slower (t1/2 = 1913 s) than the slowest US-
induced decay (those of triacetin AALs) and was considered negligible. 
The observed slightly greater half-life of own DOX-loaded and unloaded MB formulations 
compared to SonoVue® might be explained with their different mean particle size maxima (2-
3 µm for SonoVue® [132] and 0.9-1.0 µm for own formulations).  
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Figure 36: Half-life during US exposure of drug-loaded MBs compared to unloaded MBs, triacetin AALs and 
the commercial standard SonoVue®. 
 
In conclusion, during the early formulation development and characterization of DOX-loaded 
phospholipid MBs and triacetin AALs, MB formulations obviously surpassed AALs with 
regard to their loading potential and acoustic destructibility. For this reason, DOX-loaded 
AALs were abolished from further studies.  
4.5.6. In-vivo evaluation of the acoustic properties of DOX-loaded MBs 
In rat’s myocardium model DOX-loaded MBs produced a strong backscatter signal and 
allowed quantitative evaluation of the blood vessel replenishment (Figure 37).  
 
 
Figure 37: Backscattered signal contrasted image of rat’s myocardium prior to MB destruction and immediately 
afterwards. The solid outline represents the approximate left myocardium margins. 
 
DOX-loaded MBs possessed very good backscattering ability comparable to this of the 
commercial standard SonoVue® (Table 16). Their acoustic destructibility in-vivo was 1.75-
fold higher than SonoVue® which correlated well with previous in-vitro results (refer to 
“4.5.5 In-vitro acoustic destructibility of DOX-loaded MBs and AALs”, p. 119). 
 
 SonoVue® DOX-loaded MBs DOX-loaded AALs Unloaded MBs 
Opacification intensity, [dB]  39.70 35.76 35.20 39.20 
Destructibility A, [%] 40.74 70.01 58.85 63.73 
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Table 16: Opacification intensity, [dB] and acoustic destructibility A, [%] of DOX-loaded MBs compared to the 
marketed US contrast agent SonoVue®. 
4.5.7. In-vivo / in-vitro acoustic destructibility correlation 
The acoustic destructibility data of in-vitro and in-vivo studies on DOX-loaded MBs, DOX-
loaded AALs, unloaded MBs, and the marketed standard SonoVue® were ranked as shown on 
Table 17. The ranking coefficients ranged from 1 (best destructibility) to 4 (worst 
destructibility). In in-vitro studies the destructibility of DOX-loaded MBs did not significantly 
differ from that of unloaded MBs. Therefore, both formulations were ranked a coefficient 
of 2.  
 
Formulation 
In-vitro acoustic 
destructibility half-life, [s] 
In-vitro 
ranking 
In-vivo acoustic 
destructibility, A, [%] 
In-vivo 
ranking 
SonoVue® 41.05 ± 1.83 1 40.74 4 
DOX-loaded MBs 60.18 ± 1.32 2 70.01 1 
DOX-loaded AALs 184.02 ± 3.12 4 58.85 3 
Unloaded MBs 60.15 ± 2.63 2 63.73 2 
Table 17: Ranking of in-vivo and in-vitro acoustic destructibility data on DOX-loaded MBs and AALs, 
compared to unloaded MBs and the commercial standard SonoVue®. 
 
Within the properly formulated DOX-loaded MBs, DOX-loaded AALs, and unloaded MBs 
the ranking correlation was fulfilled with a coefficient of determination (R2) of 0.7500 (Figure 
38). SonoVue® deviated from own formulations and was therefore excluded from the 
correlation. Under physiologically close in-vitro conditions SonoVue® revealed the shortest 
half-life i.e. the highest acoustic destructibility, and was rendered a ranking coefficient of 1. 
In the animal model SonoVue® was the least destructible formulation and was ranked a 
coefficient of 4.  
The difference of the acoustic behavior of SonoVue® under in-vitro and in-vivo conditions 
could be attributed to three major differences to the own formulations. Firstly, the mean size 
of SonoVue® is greater (2.5 µm) than that of the own MB and AAL formulations (1.2 µm). 
Furthermore, properly formulated MBs and AALs comprise gas cores of octafluoropropane, 
while in SonoVue® the gas is sulfur hexafluoride (SF6). At last, the phospholipid composition 
of SonoVue® comprises a mixture of C16 (DPPG) and C18 phospholipids (DSPC) as well as 
single-chain surfactants (palmitic acid), while DOX-loaded MB shells consist solely of C16 
phospholipids (DPPC, DPPG, and DPPE-PEG2000). The discrepancy could be possibly 
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overcome by employing a marketed standard which is closer to the tested formulations, e.g. 
Definity® (Bristol-Myers Squibb Medical Imaging, USA). 
 
 
Figure 38: In-vivo / in-vitro ranking correlation between properly formulated DOX-loaded MBs (●), DOX-
loaded AALs (▼), unloaded MBs (■), and the commercial standard SonoVue® (×).  
 
Despite the deviating ranking data of SonoVue®, the correlation between the properly 
developed DOX-loaded MBs, DOX-loaded AALs, and unloaded MBs was a substantial 
indication for the applicability of the physiological conditions acoustic transmission 
line (PCATL) in-vitro model as a useful tool for the early pre-clinical prediction of the in-vivo 
acoustic destructibility of newly established formulation candidates. 
 
4.6. Therapeutic evaluation of doxorubicin-loaded microbubbles 
4.6.1. Intracellular distribution of DOX after treatment with DOX-loaded MBs 
The aim of the present study was to compare the intracellular uptake and partition of free 
aqueous DOX and DOX in complex with anionic phospholipids, as it is present in the MB 
shell. The complexation constant between DOX and anionic phospholipids is rather high in 
the order of 105 - 106 M-1 [192] and is comparable to the DOX association constant with 
DNA – 2.4 x 106 M-1) [165]. Therefore, it could be presumed that in cells the complex of 
DOX with anionic phospholipids will have a less pronounced affinity to the nucleus than 
DOX in free form. 
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Mhawi et al. (2007) [198] observed the intracellular partition of DOX and demonstrated its 
localization in the nucleus, whereby the signal was concentrated at the nuclear periphery and 
on nucleoli. Furthermore, the authors suggested that DOX associates with the perinucleolar 
chromatin and the heterochromatin present near to the nuclear membrane.  
In the present study similar results were observed with free DOX using comparable 
concentrations and incubation times as Mhawi et al. DOX was nearby thoroughly located in 
the cell nucleus as confirmed by the overlapping of DOX fluorescence and nuclear staining 
with Hoechst 33342 in 2D and 3D projections. Within the nucleus, DOX revealed a 
heterogeneous distribution, mostly near the nuclear membrane. At the middle of nuclei, 
numerous darker compartments were observed, corresponding apparently to the nucleoli. 
 
  
  
Figure 39: Confocal laser microscopy images of fluorescence labeled adherent cell cultures, treated with DOX-
loaded MBs and US. A) Overlay image; B) Cell membrane staining; C) Intracellular partition of DOX; 
D) Nuclear staining. 
 
Surprisingly, the DOX intracellular partition after application of DOX-loaded MBs and 
US (Figure 39) was not significantly differing from that of DOX in free form. The cell 
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membrane staining with Concanavalin A - Alexa Fluor® 488 conjugate (in green) allowed 
discriminating the cells’ outlines. Cell nuclei were stained in blue with Hoechst 33342.  
The intracellular partition of DOX (in red) in MB-treated cells coincided with the nuclear 
staining and no significant fluorescence was found in the cytosol.  
These data also for the first time reveal the ability of DOX, complexed to anionic 
phospholipids, to enter the cell nucleus.  
4.6.2. In-vitro evaluation of the anti-proliferative efficacy of DOX-loaded MBs 
The purpose of this study was the proof of three concepts on human cell tumor cultures in an 
in-vitro model system: 
a) Does the complexation of DOX to anionic phospholipids inhibit its release and 
consequently its therapeutic efficacy? 
b) Do the DOX-loaded MBs provide a greater therapeutic activity than DOX alone or 
DOX-loaded liposomes? 
c) Provided there is an augmentation of the therapeutic activity through the interplay of 
US and DOX-loaded MBs, is this an additive or a synergistic interaction? 
According to preliminary studies, applying US with a frequency of 1 MHz delivered a better 
efficacy than a higher frequency of 3 MHz. As expected, the cell viability also decreased with 
US intensity rising from 1 MHz to 4 MHz (data not shown). At the given US settings of 
1 MHz frequency and 1 W/cm2 output intensity the acoustic pressure, applied to the wells, 
was 0.283 ± 0.027 MPa without absorbing gel pad and sank to about 0.087 ± 0.32 MPa after 
the pad was laid under the well plate.  
Experimental data revealed several comparisons, outlined in Figure 40. US alone did not have 
any effect on cell viability. Unloaded MBs in combination with US diminished cell viability 
to about 69.02% ± 5.93% apparently because of cavitation effects. In the case of free DOX 
and DOX-loaded liposomes, the anti-tumor effect on cells was not affected by US and 
reduced cell viability in all cases to approximately 62-64%. The same impact was 
demonstrated also by DOX-loaded MBs without US. DOX-loaded MBs in combination with 
US produced a viability decrease down to 17.87% ± 1.95%. 
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 Figure 40: Metabolic activity in human tumor cell cultures, treated with aqueous, liposomal, and MBs-
encapsulated DOX with or without application of US (n = 10). 
 
In comparison, the combination of DOX-loaded MBs and US produced a 5.71 ± 1.48 fold 
reduction of cell viability (Figure 41). Free DOX produced only a moderate 
reduction (1.77 ± 0.46 fold) of cell viability. DOX-loaded liposomes had 1.68 ± 0.56 fold 
effectiveness and there was no statistically significant difference to free DOX. Nearby same 
activity as for DOX and DOX-loaded liposomes was found in the case of DOX-loaded MBs 
too (1.62 ± 0.43 fold), if they are not combined with US.  
 
 
Figure 41: In-vitro anti-proliferative activity of DOX-loaded MBs with and without application of US compared 
to free DOX and DOX-loaded liposomes. 
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The obtained data indicated that there was no apparent reduction of DOX anti-tumor activity, 
resulting from its complexation to the anionic phospholipids. This was though expectable, 
regarding the high association constant (Ka) between cardiolipin and DOX (1.6 x 106 M-1 at 
25 °C) which is comparable to Ka between DOX and DNA (2.4 x 106 M-1) [165]. Therefore, a 
mass transfer competition of DOX between the anionic phospholipid and cell DNA and hence 
a reduced anti-proliferative efficacy were expectable. 
Although unloaded MBs in combination with US possessed an intrinsic cell inhibition 
activity (1.49 ± 0.37 fold), the anti-proliferative effect of DOX-loaded MBs and US was about 
1.75-fold greater than the additive inhibiting effect of aqueous DOX and unloaded MBs with 
US. Therefore, an about 150% mutual synergistic enhancement of DOX therapeutic activity 
has been achieved through its combination with US and MB carriers.  
4.6.3. In-vivo evaluation of the targeting efficacy of DOX-loaded MBs 
The ability of DOX-loaded MBs to specifically release and accumulate DOX in the target 
tumor site in-vivo after destruction with diagnostic US was evaluated. Briefly, rat models 
were implanted with two pancreas xenograft tumors on each back side. The test animals were 
infused intraarterially one dose unit of DOX-loaded MBs, comprising 140 µg active drug. 
Simultaneously, one of the back-side tumors was treated with diagnostic US in order to 
destroy MBs and to release DOX on the target site. The tumor on the other back-side became 
no US. Five minutes after the treatment the animals were sacrificed and the tumors were 
harvested along with the liver, the lungs, and the kidneys. The tumors and organs were 
homogenized and the amount of DOX was quantitatively determined by RP-HPLC with 
combined UV/Vis and fluorescence detection. 
A total amount of 35.07% ± 5.14% of the total injected dose of 140 µg DOX could be 
recovered from the analyzed tumors and organs. In sonicated tumors 7.65% ± 2.21% of the 
injected DOX dose per gram tissue, [ID/g] were found, in contrast to 1.14% ± 1.02% ID/g in 
tumors without US. Totally 23.59% ± 5.43% ID/g of DOX were recovered from lungs, 
kidneys, and liver (spleen was not harvested). On the targeted tumor site a concentration of 
10.15 ± 2.96 µg/g DOX was achieved. Although DOX-loaded MBs have perfused US-
negative tumors too, the drug concentration there was about 12-fold lower than in US-treated 
tumors (p < 0.005, Figure 42). 
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Figure 42: DOX distribution in US treated and untreated subcutaneous xenograft tumors in rats (n = 6). DOX 
concentrations in particle clearing organs such as kidneys, lungs, and liver are also represented. Average tumor 
weight was 194 mg to 511 mg. 
 
In summary, DOX distribution could be effectively targeted towards the tumor site through 
US-triggered MB destruction. In tumors which became no US, DOX-loaded MBs promoted 
no significant drug release and accumulation. Thus, US has been proved as a necessary 
prerequisite for drug release and tissue accumulation from MBs. Upon interaction with 
diagnostic US, DOX-loaded MBs oscillate and are driven to fragmentation, if the US intensity 
surpasses their cavitation threshold. As a result of that, MB shell is fragmented [14]. The 
intensive mechanic effects of MB cavitation cause capillary fenestration and leakage of small 
MBs and shell debris into the interstitium, where they accumulate and exert their therapeutic 
effect.  
Recently Tartis et al. (2008) [199] revealed that MBs demonstrate a specific pharmacokinetic 
profile different than that of liposomes. It was known that MBs can be actively taken up by 
phagocyting cells such as monocytes, macrophages, Kupffer cells, etc. and captured in the 
organs of the reticulo-endothelial system – lung, spleen, and liver [200]. With regard to MBs, 
the spleen is one of the major clearing organs, since the typical MB diameter of 1-5 µm 
exceeds that of 200-500 nm narrow spleen channels [100, 201, 202]. Furthermore, a 
pronounced affinity to accumulation in the spleen and the liver could be expected from DOX-
loaded MBs, since this is characteristic for the related anionic DOX liposomes [203]. 
Therefore, although the spleen was not considered for analysis in this study, a significant 
portion of DOX could be expected to be found there. 
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Similarly to the spleen, the lungs also have the property to size-specifically clear larger MBs 
which could be the reason the small portion of larger MBs, present in the formulations, to be 
retained there.  
It is extremely difficult to make conclusions about the MB pharmacokinetics based only on 
this limited study, mainly because of the different distribution and uptake mechanisms of 
MBs and shell fragments. Nevertheless, next to its main goal, the above in-vivo study helped 
identify some of the important elimination sites for DOX-loaded MBs.  
The obtained in-vivo and in-vitro data revealed the excellent acoustic properties of the novel 
DOX-loaded MBs, developed in this work, which were comparable with clinically recognized 
MB products (SonoVue®). Furthermore, the own DOX-loaded MBs possessed an over 3.2-
fold increase of the therapeutic activity in cell cultures due to the synergistic action between 
DOX and US. The targeting efficacy of the combination of DOX-loaded MBs and diagnostic 
US was demonstrated in-vivo by the over 12-fold accumulation of DOX into US-treated 
tumors in comparison to tumors which became no US. These promising results give green 
light to further-going clinical studies which could demonstrate the therapeutic efficacy of this 
novel targeted tumor therapy by assessing the progression of tumor growth and the survival 
rate of animal models. 
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5. Summary and outlook 
In the present chapter, two drug delivery systems for targeted tumor therapy which release 
their active load in response to US, have been developed and evaluated. Soft-shelled 
phospholipid MBs and triacetin AALs, having a more robust shell, were loaded with DOX 
and their acoustic destructibility was tested using an optimized in-vitro model. Since the 
acoustic properties and loading ability of DOX-loaded MBs exceeded these of the triacetin 
AALs, the development of phospholipid MBs was promoted into in-vitro tissue culture 
studies and accordingly into in-vivo studies.  
Within the phospholipid monolayer-shelled MBs, the cationic doxorubicin (DOX) was 
complexed by electrostatic interactions to an anionic phospholipid – dipalmitoyl 
phosphatidylglycerol (DPPG). Furthermore, the complex was stabilized by additional 
hydrophobic attractions. In the case of DOX-loaded AALs the drug was turned more 
lipophilic by transforming its hydrochloride salt into free base. DOX was further included into 
the oil layer of glycerol triacetate (triacetin), comprising the AALs. Both candidates – DOX-
loaded MBs and DOX-loaded AALs, were compared under in-vitro and in-vivo conditions 
and the more appropriate of them – the phospholipid MBs, was launched into clinical studies. 
DOX-loaded MBs were preferred rather than the triacetin AALs mainly for their much better 
echogenicity and acoustic destructibility, demonstrated in-vitro as well as in-vivo.  
Anionic phospholipid MBs possessed superior loading potential for DOX reaching almost 
90% of the total drug amount. The excipient burden, calculated on the basis of the mass 
concentrations of DOX and total phospholipid, was 6.49 which value approximates that of the 
commercially available DOX-loaded liposome product Doxil® (Ortho Biotech, Bridgewater, 
USA). The in-vivo US contrasting efficacy of DOX-loaded MBs was close to that of the 
commercial US contrast agent SonoVue® (Bracco International, B.V., The Netherlands) while 
their acoustic destructibility even surpassed the positive control by 175%. 
In-vitro studies on the therapeutic efficacy of DOX-loaded MBs in tissue cultures revealed a 
3.2-fold increase of therapeutic activity compared to free DOX and DOX liposomes (n = 10). 
In-vivo studies in subcutaneous xenograft tumor models in rats demonstrated an about 12-fold 
accumulation of DOX in US-treated tumors, compared to tumors which became DOX-loaded 
MBs but no US (n = 6, p < 0.005).  
Further in-vivo studies in rat tumor models are foreseen in order to assess the therapeutic 
potential of DOX-loaded MBs by monitoring the pace of tumor growth. As a step forward, 
DOX-loaded MBs will be tested in large animal models. 
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In summary, DOX-loaded MBs brought at least three important advantages in comparison to 
current administration forms for this anti-tumor agent. Firstly, because of their backscattering 
properties DOX-loaded MBs can act as contrast agents and aid tumor visualization. 
Furthermore, DOX-loaded MBs provide specific drug targeting which can be externally 
controlled by the clinician. Furthermore, apparently because of the ability of MBs in 
combination with US to enhance the permeability of capillary endothelium and cell 
membranes, DOX-loaded MBs demonstrated an about 150% synergistic augmentation of the 
therapeutic efficacy in-vitro compared to free DOX and DOX-loaded liposomes. At last, MBs 
are generally considered blood-pool agents because of their size. Therefore, similarly to 
liposomes they obviously can reduce the distribution volume of DOX to that of blood plasma. 
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V. CHAPTER: Ultrasound targeted gene therapy 
1. Abstract 
Microbubbles (MBs) have become an established instrument as injectable contrast agents in 
diagnostic ultrasound (US) imaging. More recently, their potential as carriers for the targeted 
gene therapy has been revealed. After intravenous injection MBs can be destroyed by 
applying US, thus releasing their bioactive load directly at the target site. In the following 
work newly developed MB gene carriers will be presented, having phospholipid shells 
decorated with DNA-bearing polyplexes.  
Polycationic amphiphilic conjugates (bPEI-PA) of palmitic acid (PA) and branched 
polyethylenimine (bPEI) were synthesized through covalent amide binding. Conjugates were 
synthesized using bPEI with various molecular weights of 1.8 kDa, 10 kDa, and 25 kDa. 
Furthermore, the conjugates were grafted with different amounts of PA. After purification, the 
successful conjugation of polyethylenimine and palmitic acid was confirmed by 1H and 13C 
NMR. The complexing capacity of bPEI-PA for plasmid DNA was demonstrated by an 
ethidium bromide fluorescence quenching assay and the optimal nitrogen-to-phosphorus ratio 
was determined for each conjugate.  
In order to formulate MBs, polycationic liposome precursors were produced from C16-
phospholipids (DPPC and DPPE) and bPEI-PA. The liposomes were loaded with plasmid 
DNA by incubation at room temperature. Following, they were placed into appropriate vials, 
covered with octafluoropropane gas and mechanically agitated at a high speed. The resulting 
polyplex-associated MBs were characterized in their particle size distribution (using laser 
diffraction), concentration (using light blockage) and structure (using confocal scanning laser 
microscopy). The anchoring of bPEI-PA conjugates into the MB shell and the successful 
loading of pDNA onto the MB surface were confirmed by fluorescence confocal laser 
scanning microscopy observations. Polyplex-loaded MBs had a size-distribution from 800 nm 
to 4 µm and concentration of approximately 7 x 109 MB/ml. 
MB transfection efficacy upon exposure to US was demonstrated in comparison to 
polyplexes, polycationic liposomes on human tissue cultures using the luciferase assay. 
Additionally, cell metabolic activity after transfection was assayed. Comparative in-vitro 
studies on the polyplex transfection efficacies of bPEI-PA conjugates with various molecular 
weights and PA grafting ratios were carried out next. One candidate out of seven – 
bPEI 10 kDa, grafted with 12 PA molecules, showed appropriate transfection rates which 
were comparable to the positive standard bPEI 25 kDa, and superior cell viability.  
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The optimal candidate bPEI10-PA12 was used to produce polyplex-loaded MBs which were 
also tested on human cell cultures under exposure to US. However, no significant increase of 
transfection was observed which confirmed the findings of previous studies that colloidal 
particles such as the polyplexes cannot be transported across the cell membrane by means of 
sonoporation [33]. 
 
Keywords: gene therapy, drug targeting, polyplexes, ultrasound contrast; 
 
Abbreviations: bPEI – branched polyethylenimine, PA – palmitic acid, RES – reticulo-
endothelial system, SC – secondary carriers, scMBs – secondary-carrier associated 
microbubbles, UTMD – ultrasound-targeted microbubble destruction, US – ultrasound, PCL – 
polycationic liposomes, DPPC – dipalmitoyl phosphatidylcholine, DPPE – dipalmitoyl 
phosphatidylethanolamine;
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2. Introduction 
Initially, gene therapy had the purpose to treat inherited diseases by replacing defective genes 
with their normal copies. Nowadays the scope of potential applications has broadened to 
include also defeating of many “civilization diseases” like cancer and atherosclerosis. 
Modern gene therapy puts several requirements on the development of gene delivery 
approaches which are on the first place supposed to achieve therapeutically relevant levels of 
gene expression, as well as to provide optimal spatial and temporal profiles of gene 
expression in the organism. Under in-vitro and ex vivo conditions gene transfection by means 
of physical, chemical and viral methods has become routine, however in-vivo 
implementations remain a hurdle. On its way to the nucleus, the genetic material encounters 
several specific physical and chemical barriers such as the digestion by serum nucleases, the 
capillary endothelium and the cell membrane, the endosomal degradation, and at last the 
nuclear membrane.  
Various procedures have been established for the in-vivo gene transfer [204] which are ideally 
supposed to meet the following criteria: 
• to carry and protect the genetic material from elimination by the reticulo-endothelial 
system (RES), degradation by serum nucleases, or endosomal degradation; 
• to attain adequate cell transfection rates and a relevant therapeutic response; 
• to enable site-specific gene delivery through targeting; 
• to have an optimal safety profile including carrier agglomeration through serum 
proteins, immunological aspects, cytotoxicity, etc. 
Despite the versatility of the nowadays known gene delivery approaches, only 2.4% from over 
1,300 clinical trials conducted worldwide since 1989 have been moved into phase III, and to 
date no gene therapy product has been approved [205]. Although gene therapy holds the 
promise for ameliorating and curing diseases which are resistant to conventional treatments it 
is still limited by the lack of effective and safe gene carriers. 
Up to now, the most effective and sustainable gene expression has been attained by using 
attenuated viruses that cannot replicate and cause diseases, but remain capable of delivering 
exogenous DNA into cells. Viral vectors, however, still bear considerable safety concerns 
because of the possibility of genetic mutations, immunogenic reactions and potential 
pathogenicity [206]. Furthermore, many viral vectors have only a limited capacity to envelop 
larger transgene molecules [207] and lack target specificity [56].  
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These drawbacks of viral vectors led to an increasing interest in developing nonviral gene 
carriers, such as gelatin nanoparticles, lipoplexes, and polyplexes [208]. The colloidal 
nonviral gene carriers are widely considered biologically safe compared to the efficient, but 
risky viral vectors. On the other side many nonviral carriers still lack targeting potential and 
transfection activity. Particularly the complexes of DNA with polycationic polymers – 
polyplexes, are currently considered the most effective nonviral gene carriers, approaching in 
some applications the activity of viral vectors. 
About nine years ago Shohet et al. (2000) [209] demonstrated for the first time the 
outstanding targeting potential of a novel class of nonviral gene carriers – the 
microbubbles (MBs) which can be specifically targeted to target tissues and organs through 
external triggering by diagnostic ultrasound (US). This approach was denoted in the literature 
as ultrasound-targeted microbubble destruction (UTMD). 
Numerous authors have shown the effective gene targeting and optimal in-vivo safety profile 
of MBs, obtaining a therapeutic effect over time periods as long as thirty days or more [73, 
128, 227, 228]. As a further advantage the MBs enable the visualization of the target site as 
they backscatter diagnostic US and act as contrast agents. However, MBs are still limited in 
their loading capacity, since more than 80-90% of their volume comprises of gas (Table 18). 
Therefore, it is a challenge for the current research to find solutions to enhance the MB gene 
loading and / or to improve their in-vivo transfection efficacy.  
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Author 
Approximate 
amount of DNA 
loading, [pg/µm2] 
MB type Therapeutic/reporter transgene 
Frenkel  
et al. (2002) [210]  2.4 PESDA CMV-LacZ pDNA 
Borden  
et al. (2007) [113]  0.1 
PLL/DNA layer-by-layer 
phospholipid-MBs SV40-Luc pDNA 
0.023 DPPC/DPPE-based  phospholipid-MBs Bekeredjian  
et al. (2003) [56] 
0.011 HSA-shelled MBs 
CMV-Luc pDNA 
Chen  
et al. (2003) [211] 0.018 
DPPC/DPPE-based  
phospholipid-MBs CMV-Luc pDNA 
Chen  
et al. (2006) [212]  0.004 
Lipofectamine 2000-associated 
DPPC/DPPE-based  
phospholipid-MBs 
RIP-Luc and RIP-human 
insulin pDNA 
Lentacker  
et al. (2006) [66]  0.004 
Poly-allylamine 
hydrochloride/DNA layer-by-
layer HSA MBs 
SV40-Luc pDNA 
Christiansen  
et al. (2003) [117]  0.002 
DSPC/DPTAP-based cationic 
phospholipid-MBs CMV-Luc pDNA 
Table 18: Amounts of DNA loaded on MBs by a number of research groups. The loaded amounts are 
represented as mass per MB surface area. PESDA – perfluorocarbon-exposed sonicated dextrose albumin MBs; 
LacZ – nuclear localized β-galactosidase; SV-40 – simian virus 40 promoter; CMV – cytomegalovirus 
promoter; RIP – rat insulin 1 promoter; Luc – luciferase coding plasmid; HSA – human serum albumin; 
DPPC – dipalmitoyl phosphatidylcholine; DSPC – distearoyl phosphatidylcholine; DPPE – dipalmitoyl 
phosphatidylethanolamine; DPTAP – dipalmitoyl phosphatidyltrimethylaminopropane; PLL – poly-L-lysine. 
 
In the present work a promising novel concept was developed for the first time. It combines 
the targeting potential of US triggered gene delivery with MBs with the high loading and 
transfection efficacy of polyplexes. A novel MB construct of the structure class of secondary-
carrier associated MBs (Figure 2 D, p. 19) was developed. Its phospholipid shell is decorated 
with DNA-loaded polyplexes, comprising an amphiphilic conjugate of polyethylenimine and 
palmitic acid. The polyethylenimine conjugate is able to bind and condense DNA and to 
protect it from serum degradation, as well as to mediate its cellular uptake and delivery into 
the cytosol and the nucleus. The polyplexes are anchored onto the MB shell due to the 
hydrophobic interaction between their palmitoyl residues and the phospholipid acyl chains of 
the shell monolayer. In this way the interplay of MBs and diagnostic US is responsible for the 
target site visualization, for the overcoming of the capillary endothelium, and for the site 
specific gene delivery. On their side, the polyplexes protect the gene material from serum 
degradation, and mediate the cell uptake on the endosomal pathway, as well as the endosomal 
escape and trafficking of DNA into the nucleus. 
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2.1. Amphiphilic conjugates of polyethylenimine 
The polycationic polymer polyethylenimine (PEI) was originally introduced as gene 
transfection agent by the research group of Jean-Paul Behr [213] and represents one of the 
most significant excipient for polyplex compositions at the moment. Compared to other 
polycations, PEI has the distinct advantage of the highest positive charge density since every 
third atom in its structure is potentially protonable. 
Like the most non-viral gene carriers PEI polyplexes have their optimal transfection efficacy 
when the particles present an overall net positive Zeta potential. This is provided by the 
excess of cationic charges through protonated PEI nitrogen atoms with respect to the anionic 
DNA phosphate groups and is expressed as the molar ratio of nitrogen to phosphor (N/P 
ratio).  
Although the polyplex net cationic charge is assumed to be necessary for interactions with 
cell membranes [214, 215], it also poses problems when polyplexes are administered 
systemically. Cationic complexes are not only able to agglutinate erythrocytes [216], but also 
interact with many anionic blood proteins such as albumin [217]. Additionally, the positive 
charge of PEI/DNA complexes triggers their opsonization by the RES and leads to their rapid 
clearance from circulation within a few minutes. As a result polyplexes accumulate mainly in 
RES organs such as the liver, the spleen, and the lungs [218, 219].  
As known, the ability of PEIs to condense DNA increases with their molecular weight within 
certain limits with an optimum between 5 kDa and 25 kDa [220]. However, especially high 
molecular weight PEIs are hardly biodegradable [221] which in turn increases their 
cytotoxicity and renders them dubious for repeated in-vivo application [222, 223]. In contrast, 
low-molecular weight PEIs possess a low cytotoxicity in-vitro [224], but mostly cease to 
condense DNA and form small polyplexes. 
In order to improve the biodegradability of PEI-based vectors, attempts were made to bundle 
several PEI molecules with lower molecular weight (in the order of 600 to 10,000 Da) to 
larger structures which are yet biodegradable and less toxic, but possess a better ability to 
condense DNA. This have been done by either forming of biodegradable covalent 
bridges [221, 225] or by forming of non-covalent associates. These strategies increase the 
capability of low-molecular weight PEIs to condense DNA by bundling several small 
molecules into a larger associate and lower the polyplex cell toxicity since the associates are 
better biodegradable than the high-molecular weight PEI. 
Recently, numerous authors have developed amphiphilic conjugates of low-molecular weight 
PEI which are able to form micelles and liposomes by either self-association or by co-
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association with phospholipids. For the first time Yamazaki et al. (2000) [226] developed 
polycationic liposomes comprising cetylated branched PEI and demonstrated that they 
surmounted conventional cationic liposomes in terms of higher transfection activity and lower 
cytotoxicity. Further on, both water soluble and hydrophobic conjugates with 
cholesterol [236-238], palmitic acid [227], myristic acid [228], lauric acid [229], or cetyl 
alcohol [230] of linear and branched PEI (bPEI) were developed. In many studies, bundling of 
low-molecular weight PEIs into micellar or liposomal associates increased the transfection 
activity up to a factor of 400 [229] or lowered the in-vitro cytotoxicity down to 10-fold [231]. 
However, since the research data on amphiphilic PEI conjugates and polycationic liposomes 
is still insufficient, a broad scope to develop their potential as gene carries is available. 
 
2.2. Microbubble-mediated gene therapy 
Gene transfer with MBs is widely considered safe and organ specific [3, 232]. Numerous in-
vitro and ex vivo studies have shown that ultrasound-targeted microbubble 
destruction (UTMD) can enhance transfection rates from 10-fold [18] up to 3,000-fold [233] 
compared to naked plasmid DNA (pDNA). High transfection rates of approximately 1,000-
fold over pDNA were measured with reporter genes under in-vivo conditions [234]. However, 
therapeutically relevant in-vivo transfection is more difficult to achieve. 
Most in-vivo transfection studies focus on tissues and organs that have already been studied 
previously using US contrast imaging, including the heart [18, 56, 229, 254], the brain [48, 
50], the kidneys [235, 236], the pancreas [212], skeletal muscles [127, 259-261], the 
liver [237, 238], and solid tumors [239]. Many experimental treatments were also directed 
against vascular dysfunctions, such as intimal hyperplasia or ischemia (Table 19). A rather 
intensive gene expression could be achieved in-vivo and even therapeutically relevant levels 
were reached [238]. However, in most applications the gene expression persisted for a 
relatively short time period of several days up to a month. In contrast to virus-mediated 
transfection, sonoporation with MBs is considered to deliver genetic material only to the 
cytoplasm where the plasmid copies are not replicated, and either vanish during cell 
proliferation or are fragmented by enzymes [42]. A greatly prolonged and specifically 
targeted transfection has been achieved through combining of adeno-associated viral vectors 
with phospholipid MBs [42, 65]. So far, expression levels and sustainability are still under 
investigation, and the clinical applicability of gene therapy with MBs has not yet been proven. 
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Author Target disease MB / transgene 
Animal 
model 
Therapeutic 
effect Duration 
Porter 
et al. (2001) [240] 
Carotid 
intimal 
hyperplasia 
PESDA /  
synthetic antisense 
oligodeoxynucleotide 
Pig 
Significantly 
reduced stenosis 
formation 
n.a. 
Lipoplex-coupled MBs / 
RIP-hexokinase I pDNA  
30% decrease of 
serum glucose  ≥ 5 days 
Chen 
et al. (2006) [212]  Diabetes Lipoplex-coupled MBs / 
RIP-human insulin pDNA 
Rat 20% decrease of 
serum glucose at 
day 5, 10% at day 
10 
≥ 10 days 
Akowuah 
et al. (2005) [233]  
Saphenous 
vein 
hyperplasia  
BR-14® / TIMP-3 pDNA  
(co-administration) Pig 
60.5-65.6% 
enhancement of 
lumen area 
≥ 28 days 
Korpanty 
et al. (2005) [241]  
Myocardial 
ischemia 
Lipoplex-coupled MBs / 
hVEGF165 pDNA 
Rat 
33% increased 
capillary density, 
86% increased 
alveolar density 
30 days 
Leong-Poi 
et al. (2007) [118] 
Skeletal 
muscle 
ischemia 
Cationic phospholipid-MBs /  
hVEGF165 pDNA 
Rat 
Approximately 2-
fold increase in 
normalized 
microvascular 
blood flow 
42 days 
Zhigang 
et al. (2004) [242] 
Myocardial 
ischemia Quanfuxian / VEGF pDNA Rat 
80% increase in 
capillary density n.a. 
Lan  
et al. (2003) [236] 
Tubulo-
intestinal 
renal fibrosis 
Optison® /  
SMAD7-encoding pDNA 
(co-administration) 
Rat 
85% reduced 
tubulointerstitial 
myofibroblast 
accumulation,  
60 to 70% 
reduced collagen 
synthesis 
≥ 7 days 
Sakakima 
et al. (2005) [237]  
Hepato-
cellular 
carcinoma 
BR-14® / IFNβ pDNA 
(co-administered 
intratumoral injection) 
Mice 
3 to 4 times 
reduced tumor 
growth 
≥ 42 days 
Miao 
et al. (2005) [238]  Hemophilia 
MBs / human Factor IX-
encoding pDNA Mice 
66-fold increase 
vs. naked pDNA, 
up to 63 ng/ml 
Factor IX (near 
therapeutic range) 
n.a. 
Negishi 
et al. (2008) [243] 
None (model
expression of 
GFP) 
Phospholipid MBs / GFP-
targeting siRNA Mice 
Gene silencing in 
the tibialis muscle 
after intradermal 
injection of 30 µg 
siRNA 
≥ 21 days 
Table 19: In-vivo UTMD-mediated gene therapy for specific diseases and estimations of the therapeutic effects. 
PESDA – perfluorocarbon-exposed sonicated dextrose albumin MBs; TIMP-3 – tissue inhibitor of 
metalloproteinase 3, hVEGF165 – human vascular endothelial growth factor 165, RIP – rat insulin 1 promoter, 
SMAD7 – an intracellular key-mediator of signaling, IFNβ - interferon beta, GFP – green fluorescent protein, 
siRNA – small interfering RNA; n.a. – not available. 
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In conclusion, several recent studies have demonstrated the therapeutic potential of MB-based 
gene therapy. However, the in-vivo application of UTMD still requires a greater 
understanding of the optimal US parameters, MB pharmacokinetics, and the applicability of 
the co-administration of genetic material and MBs compared to the gene-loading of MBs. The 
pharmaceutical formulation of disease-specific therapeutic MBs could make advanced clinical 
studies and product development possible. 
 
2.3. Gene delivery by secondary carrier-associated microbubbles 
About three years ago the idea of using drug-loaded nanoparticles, liposomes, or lipoplexes, 
associated with MBs, has been introduced by Lum et al. (2006) [64]. For the first time this 
particular hybrid class of MB carriers has been denoted as secondary-carrier associated 
MBs (scMBs) in several recent review articles [244, 245]. Secondary-carrier MBs are 
believed to have an increased loading capacity and to protect genetic material from 
degradation by serum enzymes. 
The secondary carriers (SC) are usually nanometer-sized particles such as liposomes, solid 
nanoparticles, lipoplexes, polyplexes, etc., decorating the outer MB surface and bearing the 
effective payload of e.g. oligonucleotides, siRNA, or pDNA. Previous research suggests that 
nanoparticles can hardly be introduced into the cytosol using sonoporation due to their large 
size (Table 2, p.21), but they can pass through the UTMD-perforated capillary endothelium. 
Therefore nanoparticulate SCs are supposed to possess an intrinsic transfection potential in 
order to further mediate the transfection on a cellular level. 
The idea behind the concept of scMBs is to make use of the MB potential to produce capillary 
perforations and facilitate the extravasation of colloidal particles (Figure 43). After the 
intravenous application of scMBs they can be excited by low-intensity US (black solid lines) 
and back-scattered signal (grey dashed lines) can be detected, aiding the visualization of 
scMBs on the target site. A subsequent higher-intensity US pulse (red solid lines) destroys the 
MBs, thus releasing the SCs (red dots) and perforating capillary walls at the same time. 
Further on, SCs are promoted into tissue interstitium by the hydrodynamic blood pressure and 
get in contact with tissue cells. Due to their intrinsic transfection capacity, SCs can be taken 
up by the cells and deliver the genetic material into the cytosol and the nucleus. The 
intracellular SC trafficking and endosomal release may follow different pathways depending 
on the nature of the particular carrier.  
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Figure 43: Mechanism of action of secondary carrier-associated MBs (scMBs). After their application, the MBs 
can be excited by low-intensity US (black solid lines) and visualized by their US backscattered signal (grey 
dashed lines). Following, they can be “burst” by high-intensity US (red solid lines), perforate capillary walls and 
simultaneously release the secondary carriers (red dots). Following, the nanoparticles penetrate the interstitium 
and can be taken up by tissue cells. Transfected cells are represented in green. 
 
The in-vivo action mechanism of scMBs combines advantages of both MBs and 
nanoparticulate gene carriers. On the one hand, MBs are echogenic i.e. they act as US contrast 
agents and can be visualized on the target site using diagnostic US. Furthermore, the release 
of genetic material can be externally triggered and directed with high precision, allowing an 
effective site targeting. In addition to that, the utilization of SCs can increase the loading 
capacity of MBs. SCs can also protect the genetic material from serum degradation, facilitate 
its endosomal escape, and direct the gene transfer into the nucleus. 
Up to now, several authors have described MB constructs, carrying several orders of 
magnitude smaller particles which can be denoted as scMBs. For the first time 
Lum (2006) [64] demonstrated the loading of phospholipid MBs with fluorescent latex 
nanobeads as model drug carriers. The authors showed the ability of the new construct to 
induce deposition of the model nanoparticles under in-vitro conditions. 
Kheirolomoom et al. (2007) [246] described phospholipid MBs associated with liposomes, 
loaded with a model fluorescent substance and studied their oscillation behavior during 
exposure to US using high-speed photography. Furthermore, the authors demonstrated that 
liposome-associated MBs can be focused on a cell culture monolayer and the fluorescent dye 
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can be internalized into the cells within the US field. All of the above strategies of direct 
loading of particles to pre-formed MBs exploit the linking either through avidin-biotin 
couples, or by neutravidin-biotin linkage. Although this is a very efficient approach, it bears 
concerns for in-vivo applications due to the significant immunogenicity of the avidin-biotin 
pair [247]. 
In their patent Schneider et al. (2007) [248] also described phospholipid MBs associated by 
electrostatic attractions with micelles or liposomes which may carry active drug substances.  
A MB structure design, related to the scMBs, was implemented by 
Lentacker et al. (2006a and b) [249, 250] and Borden et al. (2007) [113] through layer-by-
layer covering with poly-L-lysine and DNA of pre-formed albumin- or phospholipid-shelled 
MBs. Though this is in fact no nanoparticle loading on MBs, the biological mechanism of 
action of such MBs would be similar to scMBs since biologically active shell fragments are 
shed off during the MB destruction. 
Lentacker et al. (2007) [251] thoroughly fulfilled the concept of scMBs by developing 
lipoplex-associated phospholipid MBs, loaded with plasmid DNA. The lipoplexes were 
loaded with gene material and possessed own transfection activity, demonstrated in cell 
cultures. 
Several other authors like Korpanty et al. (2005) [241] and Chen et al. (2006) [212] combined 
phospholipid MBs with lipoplexes of Lipofectamine® (Invitrogen Molecular ProbesTM, 
Eugene, USA) and tested them in rat models. However, the authors did not provide evidence 
if the lipoplexes were physically attached to the MB shell.  
In the present work, a novel hybrid gene vector comprising polyplex-associated scMBs has 
been developed for the first time. In this case, the polyplexes play the role of SCs, as they 
possess an intrinsic transfection activity and are able to condense and protect the DNA. While 
the MBs are responsible for the site specific targeting and the permeabilization of small blood 
vessels, the MB shell fragments mediate the further cellular uptake, the endosomal escape, 
and the gene transfection. The proposed MB structure design circumvents the in-vivo 
concerns related with the use of avidin-biotin complexes.  
The polyplexes comprise an amphiphilic covalent conjugate of branched PEI with palmitic 
acid (bPEI-PA) and are associated to the MB shell through hydrophobic interactions between 
the PA residues and the phospholipid acyl chains in the shell monolayer.  
Different branched PEIs with molecular weights of 1.8 kDa, 10 kDa, and 25 kDa were 
considered in this study. The bPEIs were covalently conjugated with various amounts of 
palmitic acid and the chemical structure of the bPEI-PA conjugates was characterized.  
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For the formulation of polycationic liposomes (PCL) comprising bPEI-PA, an established 
combination of two zwitterionic phospholipids – dipalmitoyl phosphatidylcholine (DPPC) 
and dipalmitoyl phosphatidylethanolamine (DPPE), was implemented. Since the colloidal 
stability of mixed bilayers of DPPC and DPPE was impaired by their net negative lyotropic 
curvature, formulation studies were performed to improve the stability of such liposomes. The 
miscibility of bPEI-PA and binary DPPC / DPPE mixtures was characterized and polycationic 
liposomes were formulated as precursors for the production of scMBs. The ability of the 
bPEI-PA / phospholipid liposomes to condense DNA and protect it from degradation by 
serum nucleases was further demonstrated. The bPEI-PA candidates, having different 
molecular weights and substitution rates with palmitic acid, were then screened for their 
capability to form small complexes with pDNA, as well as for their high transfection activity 
and low cytotoxicity. The most suitable candidate was used to formulate pDNA-loaded 
polyplex-associated scMBs. In prospective development, the optimal formulation of pDNA-
loaded polyplex-associated MBs will be launched into in-vivo studies in order to prove their 
US backscattering ability, biocompatibility, transfection activity, and targeting potential.  
A novel formulation strategy for MBs was also described in this work, called liposomal-
controlled microbubble production (LCMP). It implicates the direct one step production of 
gene-loaded MBs through pre-formulation of liposomal intermediates, comprising both the 
necessary gene material and the excipients, covered with the core gas within a single vial. The 
MBs are produced by a short high-speed mechanical agitation and are immediately ready for 
administration.  
The LCMP strategy involves the establishing of a relation between the pharmaceutical 
properties of the liposomal intermediates and the MBs, produced from them. This allows the 
tuning of the MB properties such as size, yield, loading, and stability, by manipulating the 
pharmaceutical features of the liposomal precursor formulations. The major advantage of this 
approach is that the resulting product allows an straightforward application on the patient’s 
bed side in contrast to the loading of pre-formed MBs, bringing considerable complications 
such as MB instability, microbial contamination, etc. 
The biological action mechanism of the bPEI-PA polyplex-loaded scMBs on the tissue level 
is identical with the other scMBs, described above (Figure 43, p.141). Nevertheless, on the 
cellular level the action of small polycationic liposomes and micelles, produced after the US-
mediated “bursting” of the MB shell, is rather complex. 
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Figure 44: Endosomal uptake and delivery to the cell nucleus of secondary polyplex carriers, delivered by 
ultrasound-mediated MB destruction. Bottom left the surface of a scMB is represented which is decorated with 
polyplexes. The scMB is fragmented by US and the shell material in the form of DNA-loaded bPEI-
PA / phospholipid liposomes is taken up by cells. In the cell, osmotic endosome degradation and polyplex 
release take place. 
 
After the MBs are fragmented through diagnostic US, the shell monolayer rearranges and 
forms shell fragments which are apparently complexes of phospholipid, bPEI-PA, and 
DNA (Figure 44). A possible mechanism for the intracellular trafficking of such complexes 
was proposed by Sugiyama et al. (2004) [252]. The suggested pathway implies several 
similarities as well with the mechanisms of DNA release from lipoplexes [253] as with the 
endosomal escape of polyplexes [254].  
Both polyplexes and lipoplexes are internalized into cells via the endosomal pathway, but 
within the cytosol they follow different mechanisms to escape the endosome. In the case of 
lipoplexes, comprising cationic phospholipids and DNA, a mechanism for endosomal release 
was proposed by Xu et al. (1996) [253]. On the basis of their studies, they proposed that the 
destabilization of endosomal membrane is induced by electrostatic attraction between anionic 
phospholipids (phosphatidylserine) of its outer layer and the cationic phospholipid, forming 
the lipoplexes. The flip-flop of anionic phospholipid within the endosomal membrane and 
towards the lipoplex neutralizes its positive charge and detaches the DNA which is then 
released through the fusion of the lipoplex and the surrounding endosomal membrane [255]. 
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On the other hand, the escape from polyplexes between PEI and DNA follows a different 
mechanism. PEI has a number of amines which can be protonated over a broad pH range. 
Within the endolysosome, the pH usually approaches values of about 5 [256]. The high proton 
concentration is buffered by PEI resulting in protonation of about 45% of PEI nitrogen 
compared to approximately 20% protonation at a pH of 7.4 [257]. The proton excess induces 
an electrostatic gradient and an influx of chloride ions, followed by an increase of osmotic 
pressure in the endolysosome. The latter effect is compensated by an influx of water, leading 
to the degradation of the endosome. This so-called “proton-sponge” effect [258] causes the 
delivery of the intact polyplex into the cytosol. Furthermore, the PEI has the ability to 
accelerate the nuclear uptake of DNA, known in the literature as nuclear trafficking [259-
261]. Recently, the hypothesis is being discussed that the PEI/DNA complexes, having a basic 
character, feature a similarity with several nuclear localizing signal peptides [252] which also 
contain numerous basic amino acids [262]. 
The intracellular transfer of polycationic liposomes, comprising DNA, amphiphilic PEI 
conjugates, and phospholipids, apparently combines characteristics which are specific for 
both lipoplexes and polyplexes. Similarly to lipoplexes and polyplexes DNA-encapsulating 
polycationic liposomes are taken up by the endosomal pathway. During the further 
intracellular trafficking the phospholipid is detached from the complex and remains in the 
cytosol. On its side the complex of PEI and DNA is preferentially transferred into the nucleus 
and processed towards gene expression [252]. It still needs to be clarified which of the two 
mechanisms – membrane fusion or “proton sponging” governs the endosomal escape after 
cellular uptake of polycationic liposomes. Nonetheless, since the gene transfer was successful 
not only in the presence of non-bilayer phospholipids such as DOPE [252], but also with 
liposomes, composed of bilayer-forming phospholipids [226, 230], the mechanism of osmotic 
endosome bursting apparently was claimed the prevailing role for the DNA release.  
However, no in-vivo data is yet available in the literature and therefore no reliable conclusions 
are possible concerning the therapeutic effectiveness or possible biological concerns 
regarding the application of scMBs. 
One possible challenge to scMBs is their integrity in terms of detaching of nanoparticles from 
the MB surface due to e.g. shear stress or electrolyte effects. The loss of SCs is even more 
likely during the visualization procedure when MBs perform intensive linear or non-linear 
oscillations, causing surface microstreaming effects accompanied by considerable shear stress 
for the MB surface. 
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Summarizing, the concept of the present research project aims on the establishing of 
polyplex-associated MBs, fulfilling the following advantages to related nonviral carriers: 
a) Site specific gene delivery through targeting by diagnostic US; 
b) Protection of the genetic material from digestion by serum nucleases through 
condensation to polyplexes; 
c) Facilitation of cellular uptake and endosomal escape through the osmotic endosome 
degradation; 
d) Promotion of nuclear delivery and expression of the genetic material through nuclear 
trafficking. 
Further in-vivo studies are necessary in order to establish the therapeutic value and safety 
profile of the newly developed polyplex-loaded scMBs. 
Within the following research work the chemical structure analysis of bPEI-PA conjugates 
was done in cooperation with Mr. Lars Allmendinger, Ph.D. from the Department of 
Pharmacy, Pharmaceutical Chemistry at the Ludwig-Maximilians-University – Munich, 
Germany. Gene transfection studies and agarose gel assays were carried out in cooperation 
with Mr. Martin Meyer, Ph.D. and Mr. Alexander Philipp from the Department of Pharmacy, 
Pharmaceutical Biology – Biotechnology, Ludwig-Maximilians-University – Munich. 
Confocal laser scanning microscopy imaging was done in co-work with Mr. Stefan 
Zahler, Ph.D from the Department of Pharmacy, Pharmaceutical Biology at the same 
university. Studies involving measurements of peak-negative acoustic pressure in US fields 
were made together with Mr. Rainer Pecha, Ph.D. from the University of Stuttgart, Germany.  
In-vivo clinical studies were performed in cooperation with Mr. Raffi Bekeredjian, MD, Ph.D. 
from the Internal Medicine III, Ruprecht-Karls-University – Heidelberg, Germany. The 
research work was funded through a research grant by the NanoforLife initiative of the 
Federal Ministry of Education and Research, Germany in cooperation with Mr. Raffi 
Bekeredjian, MD, Ph.D. 
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3. Materials and Methods 
3.1. Reagents 
Substance Abbreviation Purchased from 
Agarose, HEEO, ultra quality Agarose Carl Roth GmbH, Karlsruhe, Germany 
Boric acid --- Sigma-Aldrich GmbH, Munich, Germany 
Coumarine-6® (laser grad, 98%) --- Acros Organix, Geel, Belgium 
Chloroform, HPLC-grade --- Sigma-Aldrich GmbH, Munich, Germany 
Chloroform, deuterated --- Euriso-Top SA, Gif sur Yvette, France 
1,4-Diazabicyclo[2.2.2]octane DABCO Sigma-Aldrich GmbH, Munich, Germany 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide MTT Sigma-Aldrich GmbH, Munich, Germany 
Dimethyl sulfoxide DMSO Sigma-Aldrich GmbH, Munich, Germany 
Dipalmitoyl phosphatidylcholine DPPC Lipoid AG, Ludwigshafen, Germany 
Dipalmitoyl phosphatidylethanolamine DPPE Lipoid AG, Ludwigshafen, Germany 
DNAse I, type IV from bovine pancreas DNAse I Sigma-Aldrich GmbH, Munich, Germany 
Dulbecco´s modified Eagle´s medium, 
activated with 10% fetal calf serum DMEM 
Invitrogen Molecular ProbesTM, Eugene, 
USA 
Ethylene diamine tetra-acetic acid EDTA Sigma-Aldrich GmbH, Munich, Germany 
Ethylene diamine tetra-acetic acid, 
trisodium salt EDTA.3Na Sigma-Aldrich GmbH, Munich, Germany 
1,2,3-Propanetriol, water free Glycerol Sigma-Aldrich GmbH, Munich, Germany 
Ethidium bromide --- Invitrogen Molecular Probes
TM, Eugene, 
USA 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid HEPES Sigma-Aldrich GmbH, Munich, Germany 
Loading buffer for agarose gel 
electrophoresis --- 
Kindly provided by Martin Meyer, Ph.D., 
Department of Pharmacy,  
Pharmaceutical Biology – Biotechnology,  
Ludwig-Maximilians-University - Munich 
Lysis buffer for cell cultures --- Cell signaling Technology, Inc, Danvers, USA 
Magnesium chloride --- Merck-Schuchardt OHG,  Hohenbrunn, Germany 
N,N-dicyclohexylcarbodiimide DCC Sigma-Aldrich GmbH, Munich, Germany 
Octafluoropropane --- Sauerstoffwerk Friedrich Guttroff GmbH, Wertheim, Germany 
Palmitic acid, p.a. PA Sigma-Aldrich GmbH, Munich, Germany 
Polyethylenimine, branched, 1.8 kDa bPEI1.8 Polysciences Europe GmbH, Eppelheim, Germany 
Polyethylenimine, branched, 10 kDa bPEI10 Polysciences Europe GmbH, Eppelheim, Germany 
Polyethylenimine, branched, 25 kDa bPEI25 Sigma-Aldrich GmbH, Munich, Germany 
Potassium acetate --- Sigma-Aldrich GmbH, Munich, Germany 
Propidium iodide --- MoBiTec GmbH, Göttingen, Germany 
Pyridine --- Sigma-Aldrich GmbH, Munich, Germany 
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Continued from p. 147 
Texas Red® sulfonyl chloride Texas Red® Invitrogen Molecular Probes
TM, Eugene, 
USA 
Tris(hydroxymethyl)-aminomethan base Tris base Carl Roth GmbH, Karlsruhe, Germany 
Trypan blue stain, 0.4 mass% in saline Trypan blue Invitrogen Molecular Probes
TM, Eugene, 
USA 
Membrane tubing for dialysis,  
MW cut-off: 1 kDa --- 
Spectra/Por®, VWR International GmbH, 
Darmstadt, Germany 
 
3.2. Synthesis of branched polyethylenimine palmitate (bPEI-PA) 
conjugates 
Covalent conjugates of branched PEI with molecular weights of 1.8 kDa, 10 kDa, and 
25 kDa and palmitic acid (PA) were synthesized through pyridine-catalyzed nucleophilic 
substitution after chemical activation of PA with N,N-dicyclohexyl-
carbodiimide (DCC) (Figure 45). The molar degrees of substitution between number of PA 
residues and PEI monomer units per molecule were varied between 2 mol% and 50 mol%. 
Branched PEI was dissolved in HPLC-grade chloroform at a concentration of 20 mg/ml and 
500 µl pyridine were added. Separately, the required amounts of PA and DCC were dissolved 
in chloroform and both solutions were mixed. The reaction mixture was stirred for 24 h at 
room temperature under nitrogen atmosphere and light protection.  
The stoichiometric ratio between bPEI and PA in the final reaction mixture corresponded to 
the desired degree of substitution of the final product bPEI-PA plus an excess of 5 mol% PA. 
DCC was added in a 50% higher molar concentration than PA to ensure complete activation 
of the fatty acid. Conjugates of bPEI with a molecular weight of 1.8 kDa were synthesized 
with substitution rates of 2, 5, and 12 PA residues per bPEI molecule. Conjugates of bPEI 
with molecular weight 10 kDa were substituted with 10, 30, and 60 PA moieties. Branched 
PEI of 25 kDa was grafted with 10, 20, 30, 70, 100, and 200 PA moieties per molecule.  
After the reaction time, the precipitated N,N-dicyclohexylurea was removed by filtration 
through a Schott filter, the product was concentrated under vacuum and purified by extensive 
dialysis in chloroform over a week using a recycled cellulose membrane dialysis tubing with a 
molecular weight cut-off of 1 kDa. Traces of water in the dialysis phase were absorbed with 
granulated water-free calcium chloride. 
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Figure 45: Chemical synthesis of amphiphilic bPEI-PA conjugates from branched polyethylenimine (bPEI) and 
palmitic acid (PA). 
 
Following, the bPEI-PA solutions were adjusted with chloroform to a concentration of 
25 mg/ml (0.581 M nitrogen concentration) based on the input amount of bPEI. The stock 
solutions were stored in dark at -20 °C. 
The approximate number of primary amine groups per conjugate molecule was calculated 
based on the polymerization degree of bPEI, the proportion of 33.33 mol% of primary vs. 
secondary, and tertiary amines [263], and on the number of PA grafts per conjugate molecule.  
The hydrophilic-lipophilic balance (HLB) for each conjugate was calculated according to the 
Griffin’s method [264]. 
3.2.1. Chemical structure analysis of bPEI-PA 
The chemical structure of the bPEI-PA conjugates was characterized by 1H and 13C 
NMR using a Jeol JNMR-GX400 (Jeol GmbH, Eching, Germany) operating at 400 MHz in 
order to prove the covalent bonding of PA to the backbone of bPEI and to determine the 
number of PA residues per bPEI molecule. Deuterated chloroform was employed as solvent. 
The approximate number of PA residues per molecule bPEI-PA was calculated as the ratio 
between the intensity of PA hydrogen and bPEI hydrogen in the 1H NMR spectra. 
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3.3. Characterization of bPEI-PA 
3.3.1. Particle size distribution of bPEI and bPEI-PA in polar and non-polar 
solvents 
The particle size distribution of bPEI and of bPEI-PA conjugates was measured both in 
chloroform and in water by dynamic light scattering using Zetasizer Nanoseries Nano-ZS 
(Malvern Instruments Ltd., Worchestershire, UK). The concentration in all measured samples 
was adjusted to 25 mg/ml bPEI. For the production of aqueous bPEI-PA dispersions, the 
chloroform was eliminated from the stock solution using a Büchi Rotavapor R-114 (Büchi 
Labortechnik GmbH, Essen, Germany) for 60 min at 60 °C. Following, the bPEI-PA 
conjugate was hydrated with a medium, consisting of 30 mM HEPES, 1 mM EDTA, 15 mM 
sodium chloride, 50 vol% Glycerol, and highly-purified electrolyte free water (Purelab Plus®, 
USF Elga Ionpure GmbH, Germany), having a pH between 4.8 and 5.0. After hydration, the 
dispersion was US homogenized for 60 s using a horn-type US homogenizer (Branson 
Sonifier®, Branson Ultrasonics Corp., USA). The samples were allowed to equilibrate for at 
least 24 h at 4 °C in dark. 
To prepare aqueous samples for measurements, 200 µl of the bPEI-PA dispersion or bPEI 
solution were diluted in electrolyte free water and the pH was controlled. The medium 
viscosity of samples for measurements (containing 7.7 vol% glycerol in water) was 
determined by falling ball viscosimetry using an Automated Micro Viscosimeter 
AMVn (Anton Paar GmbH, Ostfildern, Germany). The refractive index of the aqueous 
dispersant was set to 1.341, for chloroform – to 1.446, and for the bPEI-PA particles – to 
1.450, with an absorption index of 0.01. 
 
3.4. Formulation and characterization of polycationic liposomes with 
bPEI-PA 
3.4.1. Mixing behavior of DPPC and DPPE 
The mixing behavior between DPPC and DPPE in different proportions were studied by 
differential scanning calorimetry (DSC) using a Mettler Toledo DSC821e (Mettler-Toledo 
GmbH, Giessen, Germany). The molar ratio between DPPC and DPPE was varied from 
100 mol% DPPC to 100 mol% DPPE with an increment of 25 mol% DPPE.  
The phospholipids were separately dissolved in chloroform and mixed to achieve the desired 
proportions. Liposome dispersions with a total phospholipid concentration of 20 mM were 
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produced using the thin-film hydration method by hydrating the phospholipid film with highly 
purified water. Samples for measurements were prepared by placing 30 µl of the liposomal 
formulations in 40 µl aluminum DCS pans and sealing them. Samples were prepared in 
triplicate and three scanning runs were performed against air with each sample (n = 9). The 
scans were performed in a temperature range from 20 °C to 85 °C with a heating rate of 
5 °C/min. Between every heating and cooling segments an isotherm segment of two minutes 
was set. Measured data were accordingly normalized against the sample weight and 
phospholipid molar concentration. 
3.4.2. Effect of glycerol on the colloidal stability of DPPC / DPPE liposomes 
The influence of increasing amounts of glycerol on the colloidal stability and sedimentation of 
DPPC / DPPE liposomes was monitored over a week during storage at 4 °C in dark. 
Consequently, the miscibility of DPPC and DPPE at increasing glycerol concentration was 
monitored by differential scanning calorimetry (DSC).  
Samples were prepared with 20 mol% DPPE and 80 mol% DPPC at a total concentration of 
20 mM. The concentration of glycerol in the hydration medium varied from 0 vol%, to 
100 vol% with an increment of 25 vol%, corresponding to 0 mol%, 7.6 mol%, 19.8 mol%, 
42.5 mol%, and 100 mol% glycerol concentration. The conversion from vol% into mol% was 
made in order to simplify comparisons with the literature. Sample preparation, DSC 
measurements, and data weighing were carried out as described above under “3.4.1 Mixing 
behavior of DPPC and DPPE”. Samples were stored for 14 days in dark at 4 °C and the 
phase separation and formation of sedimentation layer was monitored. 
3.4.3. Mixing behavior of bPEI-PA with DPPC / DPPE bilayers 
Formulations of polycationic liposomes for analysis were prepared according to the thin-film 
method, whereby bPEI25-PA20 was blended together with the phospholipid and included into 
the thin-film. The bPEI25-PA20 / phospholipid blends were hydrated with 30 mM HEPES 
and, if necessary, adjusted with 0.5 N hydrochloric acid or 0.5 N sodium hydroxide to a pH 
of 7. 
Samples contained a total phospholipid concentration of 20 mM, consisting of 20 mol% 
DPPE and 80 mol% DPPC and comprising bPEI25-PA20 at various nitrogen concentrations 
from 0 mM to 40 mM with an increment of 10 mM. The miscibility of bPEI25-PA20 with 
DPPC / DPPE bilayers was studied with DSC following the same measuring setup as 
described in “3.4.1 Mixing behavior of DPPC and DPPE”.  
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3.4.4. Determination of bPEI-PA buffer capacity 
Sample preparation for titration measurements followed the same procedure as in 
“3.3.1 Particle size distribution of bPEI and bPEI-PA in polar and non-polar solvents”, 
p.162. Polycationic liposomes comprising 20 mol% DPPE and 80 mol% DPPC at a total 
phospholipid concentration of 5 mM, as well as bPEI25-PA20 at a nitrogen concentration of 
190 mM were prepared. Samples for positive control were prepared with bPEI25 at the same 
nitrogen concentration as the PCL in highly purified water. Samples for negative control were 
prepared, comprising DPPC / DPPE liposomes with the same phospholipid constitution as the 
PCL, in water.  
Titration was carried out using a Malvern Multi Purpose Titrator MPT-2, connected to a 
Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., Worchestershire, UK). Shifts in the 
pH were measured by potentiometry. Parallel to pH the Zeta potential was measured also 
during the titration. Titration excursions were carried out with 0.05 N hydrochloric acid from 
a pH of 7.5-7.8 down to 2.3.  
The titration started from the existing pH value of the formulation and was left unadjusted. 
This was done in order to keep samples’ conductivity low and to not influence Zeta potential 
measurements. 
3.4.5. Zeta potential of polycationic liposomes with bPEI-PA 
Three studies on the Zeta potential of polycationic liposomes were performed. The first study 
explored the influence of the substitution rate of bPEI25 with PA. Therefore, polycationic 
liposomes were produced comprising 20 mol% DPPE and 80 mol% DPPC at a total 
phospholipid concentration of 5 mM and a total nitrogen concentration of 20 mM. The 
formulations comprised bPEI25-PA with various substitution rates of PA per molecule 
bPEI25 ranging from 10 to 200. The pH value was buffered with 30 mM HEPES to 7.4. The 
Zeta potential was measured by electrophoretic light scattering using Zetasizer Nanoseries 
Nano-ZS (Malvern Instruments Ltd., Worchestershire, UK).  
The aim of the second study was the determination of the effect of different bPEI-PA 
concentrations on the Zeta potential of polycationic liposomes at a constant pH, ionic strength 
and phospholipid concentration. Samples were prepared at a total phospholipid concentration 
of 3 mM and with an increasing concentration of bPEI25-PA20, corresponding to nitrogen 
concentrations ranging from 0 mM to 100 mM with an increment of 20 mM. The dispersant 
medium was highly-purified water buffered at a pH of 7 with 30 mM HEPES. 
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The third study examined the influence of pH excursions in the range of 7.5-7.8 down to 2.3 
on the Zeta potential of PCL. The measurements were carried out simultaneously with the 
study under “3.4.4 Determination of bPEI-PA buffer capacity”, p.152, but will be discussed 
in this section. 
For all Zeta potential measurements the dispersant dielectric constant was set to 78.5. The 
optical measurement settings were the same as used for size distribution measurements by 
dynamic light scattering. Sample conductivity during the titration was kept below 1.8 mS/cm2. 
 
3.5. Studies on the loading of bPEI-PA liposomes with pDNA 
Various studies were performed in order to achieve small polyplex size distribution and an 
acceptable polydispersity by manipulating such formulation parameters as pH, electrolyte 
concentration, and the influence of triple-charged anions.  
3.5.1. Complexation capacity of bPEI-PA liposomes for pDNA 
The plasmid binding strength of the PEI-PA conjugates was assessed by exclusion of 
ethidium bromide of its complex with DNA [265]. Loading studies were performed with 
luciferase-encoding plasmid DNA bearing cytomegalovirus promoter (pCMV-LUC) and 
having a size of 7,040 base-pairs [266]. According to the chemical structure of DNA, two 
phosphorus atoms were assigned per base pair. The mass concentration of pDNA was 
determined using an automated spectrophotometer Eppendorf BioPhotometer (Eppendorf AG, 
Hamburg, Germany) at 260 nm wavelength. The molar concentration of DNA phosphorus 
was calculated based on an average molecular weight of 660 Da per DNA nucleotide pair. 
Based on the average molecular weight of bPEIs, used for the synthesis of amphiphilic 
conjugates, an average number of 581 nitrogen atoms was assigned per molecule of bPEI25, 
233 atoms per molecule of bPEI10, and 42 atoms per molecule of bPEI1.8. Accordingly, the 
nitrogen-to-phosphorus (N/P) ratios were calculated based on the molar concentration of bPEI 
and molar concentration of DNA phosphorus. 
The fluorescence of 20 µg/ml solution of pDNA (corresponding to 60.61 µM 
DNA phosphorus) containing 400 ng/ml ethidium bromide in HEPES-buffeted glucose was 
initially measured and set to 100% (λex = 510 nm, λem = 590 nm, slit width = 10 nm) using a 
Varian Cary Eclipse fluorescence spectrophotometer (Varian, Inc., Palo Alto, USA). 
Liposome solutions with a nitrogen concentration of 1.5 mM and a phospholipid 
concentration of 3 mM were prepared with bPEI1.8 and its conjugates with 2 and 5 PA 
residues, bPEI10 and its conjugates with 12 and 30 PA residues, and with bPEI25 and its 
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conjugates with 10, 20, and 30 PA residues. Portions of 20 µl PCL were added to 1 ml 
solution of pDNA, resulting in titration steps of 0.5 N/P.  
Aliquots of bPEI-PA liposomes were added stepwise to the solution and the decrease of 
fluorescence was measured (n = 3) as indication for the interaction between complexing 
compound and nucleic acid.  
3.5.2. Effect of pH on the polycationic liposome size 
Polycationic liposomes were formulated containing 3 mM total phospholipid, of which 
20 mol% were DPPE and 80 mol% DPPC, and bPEI25-PA20 at a nitrogen concentration of 
20 mM. The liposomes were aliquoted in three portions and the pH was adjusted with 0.5 N 
hydrochloric acid to approximately 3.5, 5.5, and 8.5. The liposomes were loaded with pDNA 
under gentle vortexing and incubation at room temperature. DNA-loaded polyplex-liposomes 
were diluted to a proportion of 1:10 with electrolyte-free water and their particle size and 
polydispersity were determined by dynamic light scattering using Zetasizer Nanoseries Nano-
ZS (Malvern Instruments Ltd., Worchestershire, UK). 
3.5.3. Polycationic liposome size according to bPEI molecular weight, PA 
substitution, and loading with pDNA 
Polycationic liposomes were produced via the thin-film hydration method as described above. 
The concentration of bPEI-PA nitrogen was kept constant at 20 mM, the final total 
phospholipid concentration was 3 mM. The pH was adjusted to 4.5-4.2 with 1 M hydrochloric 
acid, and the ion concentration was set to 30 mM by sodium chloride. The loading with 
pDNA was carried out at an N/P ratio of 10. Liposomes were prepared for measurements as 
described above. Particle size and polydispersity were determined by dynamic light scattering 
using Zetasizer Nanoseries Nano-ZS (Malvern Instruments Ltd., Worchestershire, UK).  
 
3.6. Formulation and characterization of polyplex-associated MBs, 
loaded with pDNA 
3.6.1. Effect of electrolytes on the MB production and liposome aggregation 
Polycationic liposomes loaded with pDNA were produced as described above. The ion 
concentration was adjusted with sodium chloride and trisodium citrate, assuming a complete 
dissociation of salts to two moles ions for sodium chloride and four moles ions for trisodium 
citrate and an ion activity, linearly corresponding to the ion concentration. The ion 
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concentration was varied from 0 mM, 30 mM, 50 mM, 70 mM, and 100 mM. Accordingly, 
MBs were prepared by mechanical agitation at 4,500 oscillations / minute for 20 s of 400 µl 
liposome dispersion with 1.6 ml octafluoropropane gas in a sealed tube. The MB 
concentration was determined by light blockage using a PAMAS SVSS-C (PAMAS GmbH, 
Rutesheim, Germany). MB size distribution was monitored by laser diffraction using a Partica 
LA-950 (Horiba Ltd., Kyoto, Japan). Particle size and polydispersity of polycationic 
liposomes were measured by dynamic light scattering using Zetasizer Nanoseries Nano-
ZS (Malvern Instruments Ltd., Worchestershire, UK). 
3.6.2. Optimal formulation for polyplex-associated MBs for in-vivo studies 
The production of polycationic liposomes was performed according to the thin-film hydration 
method. The appropriate amounts of dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl 
phosphatidylethanolamine (DPPE), and bPEI-PA were blended under heating at 60 °C in 
HPLC-grade chloroform and the organic solvent was removed for 60 min at 65 °C under 
vacuum using a Büchi Rotavapor R-114 (Büchi Labortechnik GmbH, Essen, Germany). The 
bPEI-PA / phospholipid film was hydrated at gentle conditions at 50 °C under nitrogen 
protection, for 15-20 min. The medium for phospholipid hydration contained 30 mM HEPES, 
1 mM EDTA, and 15 mM sodium chloride, dissolved in a mixture of 50 vol% water-free 
glycerol in highly-purified water (Purelab Plus®, USF Elga Ionpure GmbH, Germany).  
 Accordingly, the raw phospholipid dispersion was shortly homogenized with low-frequency 
US using a horn-type homogenizer (Branson Sonifier®, Branson Ultrasonics Corp., USA). 
The resulting clear yellow phospholipid dispersion was adjusted with 1 M hydrochloric acid 
to pH 4.5-4.2 and allowed to equilibrate at 4 °C in dark for at least 12 hours. Potentiometric 
pH measurements were performed as control prior and after the equilibration. The liposomes 
were stored at -4 °C at dark without any evident signs of aggregation and sedimentation over 
months. 
In order to produce polyplex-associated MBs 160 µl of 1 mg/ml solution of pDNA were 
added to 240 µl polycationic liposomes in a 2 ml safe-lock tube (Eppendorf AG, Hamburg, 
Germany) and gently mixed with the pipette. The mixture was incubated for 15 min at room 
temperature, then covered with octafluoropropane and agitated for 20 s at 4,500 oscillations 
per minute using a mechanical agitator CapMixTM (3M Deutschland GmbH, Neuss, 
Germany). Prior to their application MBs were diluted with octafluoropropane-saturated 
5 mass% solution of glucose in highly-purified water. 
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3.6.3. Structure analysis of polyplex-associated MBs 
Fluorescence confocal scanning laser microscopy (CLSM) studies were performed using an 
inverted Zeiss LSM 510 (Carl Zeiss Microimaging, Göttingen, Germany) in order to confirm 
the loading of pDNA on the MBs and to examine the colloidal structure of the MB dispersion. 
A pinhole of 118 µm was exerted with an oil-immersion objective producing optical slices of 
about 225 µm thickness. 
Microbubbles were double fluorescent labeled in order to localize the phospholipid, the bPEI-
PA conjugates, and the pDNA. Phospholipids were labeled with the hydrophobic dye 
Coumarine-6® (Table 20, p.156) which emits light mostly when intercalated between the acyl 
chains, while it is practically quenched in water [267]. Coumarine-6® was included in the 
organic solution of bPEI-PA and phospholipids during the production of liposomes at a final 
concentration of 3 µg/ml. 
In unloaded MB formulations the bPEI-PA conjugates were covalently labeled with 
TexasRed® sulfonyl chloride. The amino-reactive TexasRed® dye was incubated in 
chloroform solution with bPEI25-PA30 at a molar ratio, corresponding to about 150 dye 
molecules per molecule bPEI. Incubation was carried out for 24 hours at 4 °C in dark and 
under nitrogen protection. Following, the fluorescently labeled conjugate was purified from 
unbound dye by extensive dialysis in chloroform over two weeks at 4 °C in dark using a 
recycled cellulose dialysis tube with a molecular weight cut-off of 1 kDa. The TexasRed® 
labeled bPEI-PA conjugate was included in MB formulations as described in the standard 
formulation production. 
 
Fluorescent dye 
Excitation wavelength 
maximum, [nm] 
Emission wavelength 
maximum, [nm] 
Coumarine-6® 420-450 490-520 
Propidium iodide (nucleic acid bound) 535 617 
Texas Red® sulfonyl chloride 596 615 
Concanavalin A- 
Alexa Fluor® 488 conjugate 
495 519 
Hoechst 33342 350 461 
Table 20: Fluorescent dyes and their excitation and emission laser wavelengths, used here for fluorescent 
staining of polyplex-associated MBs.  
 
In DNA-loaded MB formulations the TexasRed®-labeling was substituted by staining of 
pDNA with propidium iodide. To the freshly prepared MB 20 µg propidium iodide and 1 ml 
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highly-purified water were added. The MBs were accordingly incubated for 15 min at room 
temperature.  
Prior to the microscopy, the labeled MBs were mounted in a medium, containing 2 mass% 
DABCO, 80 vol% water-free glycerol and 20 vol% water. The mounted sample was then 
introduced by a syringe into a thin-bottom Ibidi µ-slide IV (Ibidi GmbH, Munich, Germany) 
and observed. 
3.6.4. Protection of pDNA against enzymatic degradation 
The plasmid sensitivity to degradation by DNAse I was evaluated using changes in plasmid 
migration on agarose gel electrophoresis. The DNAse stress assay and the agarose gel assay 
were performed according to the protocols of Lentacker et al. (2006) [119] with some 
modifications. Briefly, polyplex-associated MBs loaded with pDNA were mixed with 
DNAse I, type IV from bovine pancreas and incubated for 30 min at 37 °C under shaking 
using Eppendorf Thermomixer Comfort (Eppendorf AG, Hamburg, Germany). The final 
concentrations of DNAse and pDNA during incubation were held constant in all samples at 
accordingly 200 U/L DNAse activity and 198 µg/ml pDNA. The concentration of bPEI25-
PA30 nitrogen was varied from 3 mM, 6 mM, and 9 mM in order to produce N/P loading 
ratios of 5, 10, and 15. Furthermore, the samples contained magnesium chloride in a final 
concentration of 2.04 mM which is necessary for the activation of DNAse I. The pH was 
maintained at 7.4 by addition of HEPES and potassium acetate at final concentrations of 
correspondingly 2 mM and 22 mM. 
Seven setup combinations were prepared and tested. Firstly, the plasmid alone was used as 
positive control. MB dispersions were also incubated with DNAse, inhibited in advance with 
EDTA.3Na in order to test its quenching activity on DNAse. Furthermore, naked pDNA was 
incubated with DNAse as a control of its digesting activity. As a negative control unloaded 
MBs were examined. At last, the DNA-loaded MBs were challenged with DNAse at N/P 
loading ratios of 5, 10, and 15. After the incubation, the DNAse I was quenched by the 
addition of 10 µl 100 mM solution of EDTA.3Na. The pDNA was detached from its complex 
with bPEI-PA in order to examine whether it survived the challenging with DNAse. 
Therefore, MBs were incubated with sodium chloride at a final concentration of 5 M at 50 °C 
for 30 min under shaking using Eppendorf Thermomixer Comfort (Eppendorf AG, Hamburg, 
Germany).  
Agarose gel pads were prepared from 1 mass% agarose solution in tris / borate / EDTA buffer 
containing 10.8 g/l tris base, 5.5 g/l boric acid, and 0.58 g/l EDTA.3Na, and the 0.5 µg/ml 
ethidium bromide were added to enable the visualization of DNA. 
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Accordingly, 50 µl of each sample were mixed with 10 µl loading buffer comprising 
2.5 mg/ml bromophenol blue and 400 mg/ml sucrose in water, the samples were shortly 
vortexed, centrifuged, and loaded onto the agarose gel pad.  
The samples were subjected to electrophoresis at 120 V for 80 min, and the pDNA was 
visualized under UV light prior to photography. 
3.6.5. Effective loading of pDNA in polycationic liposomes and in polyplex-
associated MBs 
The partition of pDNA between free-form and polycationic liposomes was determined by a 
gel retention assay. The polycationic liposomes were loaded with pDNA at N/P ratios of 15, 
13, 10, 7, 5, 3 and 1 and incubated for 15 min at room temperature. The samples were treated 
with loading buffer and subjected to agarose gel electrophoresis as described above. The 
intensity of fluorescence through leaked pDNA was evaluated using the software 
ImageJ v.1.41o (National Institute of Health, USA).  
Accordingly, the binding of pDNA to polyplex-associated MBs was evaluated by 
fluorescence spectrometry. Freshly prepared samples of pDNA-loaded MBs were diluted with 
octafluoropropane-saturated 5 mass% glucose in highly-purified water. The bubbles were 
gently centrifuged for 5 min at 1,000 rpm using NeoLab 16/18 centrifuge (Hermle 
Labortechnik GmbH, Wehingen, Germany). Portions of the underlying liquid phase were 
drawn by piercing through the tube wall with a syringe needle. In order to detach pDNA from 
its complex with bPEI-PA the obtained samples were incubated with 5 M solution of sodium 
chloride at 50 °C for 30 min under continuous shaking using an Eppendorf Thermomixer 
Comfort (Eppendorf AG, Hamburg, Germany). Propidium iodide was added at a final 
concentration of 1 µg/ml and the samples were centrifuged for 15 min at 14,000 rpm using a 
NeoLab 16/18 centrifuge (Hermle Labortechnik GmbH, Wehingen, Germany) in order to 
remove insoluble particles. The fluorescence of the pDNA / propidium iodide complex was 
determined using a Varian Cary Eclipse fluorescence spectrophotometer (Varian, Inc., 
Palo Alto, USA). 
The fluorescence data was displayed in per cent according the fluorescence, obtained from 
whole pDNA-loaded liposomal formulations. The effective loading of polyplex-associated 
MBs was calculated by subtracting the amount of unbound pDNA from the total input amount 
of pDNA.  
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3.7. Comparative in-vitro transfection / cell viability studies with 
pDNA-loaded polycationic liposomes and polyplex-associated 
microbubbles 
The transfection efficacy of pDNA-loaded polycationic liposomes and polyplex-associated 
MBs were examined in B16F10 human melanoma cell cultures and compared to polyplexes 
of bPEI with various molecular weight and naked plasmid.  
The cells were treated with naked pDNA, bPEI polyplexes, bPEI-PA nanoparticles, as well as 
with polycationic liposomes and polyplex-associated MBs with US application. Thereby, 
various polycations and conjugates were tested also in the presence and absence of 
phospholipid. The candidates involved in this study, were bPEI1.8, bPEI1.8-PA2, bPEI1.8-
PA5, bPEI10, bPEI10-PA12, bPEI10-PA30, as well as bPEI25 and its conjugates bPEI25-
PA10, bPEI25-PA20, and bPEI25-PA30. The purposes of the current studies were to select 
the bPEI-PA candidate with the greatest transfection potential and to compare the transfection 
activities of bPEI25 as a positive control, and polyplex-associated MBs comprising it. 
Treatment with technical US was done using a Sonitron-2000 (RichMar Corp., 
Chattanooga, USA) equipped with a 3 mm probe by directly immersing the probe into the 
culture medium. According to preliminary studies US parameters were set to 1 MHz 
frequency, 1 W/cm2 output intensity, 50% duty cycle and a sonication time of 20 s. The 
bubble-to-cell ratio was set to about 80. The peak-negative acoustic pressure, [MPa] in the 
wells was measured using a 250 µm fiber-optic probe hydrophone (FOPH 2000, RP 
Acoustics, Germany) [29].  
Cell cultures were cultivated in T75 flasks in DMEM medium with 10% fetal calf serum at 
37 °C in 5 vol% CO2-enriched atmosphere. Prior to each experiment, the adherent cells were 
harvested with trypsin / EDTA solution. Dead cells were distinguished under microscope by 
staining with 0.4 mg/ml Trypan blue. Non-stained cells were counted using the modified 
Neubauer chamber. Cell concentration was adjusted with DMEM medium and suspension 
was placed into 96-well plates (Greiner Bio-one GmbH, Frickenhausen, Germany) with a 
final number of 6 x 104 cells/well. Provided a treatment with US was carried out, a 3.5 cm 
thick gelatin gel tissue phantom was placed beneath the well plate in order to absorb US and 
prevent standing US waves.  
After the transfection agent was added to the culture medium and eventually US treatment 
was applied, the cells were incubated for 24 hours. Accordingly, the overlying medium was 
removed and the adherent cells were solubilized with cell lysis buffer. The samples were 
analyzed using a luminometer Lumat LB 9507 (Berthold Technologies GmbH, Bad Wildbad, 
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Germany), whereby a solution of luciferin and ATP was automatically added to provide 
luminescence. The experimental data was represented as an average of n = 8. 
The metabolic activity assay was carried out simultaneously to the gene reporter assay. 24 
hours after transfection the metabolic activity of cells was determined by a 
methylthiazoletetrazolium (MTT) / thiazolyl blue assay as follows: 10 µl of a 5 mg/ml 
solution of MTT in phosphate-buffered saline were added to each well. The cells were 
incubated for 2 hours at 37 °C, the medium was accordingly removed and 50 µl of DMSO 
were added. The optical absorbance of thiazolyl blue, produced by cells, was measured at 
590 nm (reference wavelength 630 nm) using a microplate reader (Fluostar Omega, BMG 
Labtech GmbH, Offenburg, Germany). The cell viability was expressed in percent against 
phosphate-buffered saline-treated control cells. The results are presented as means of n = 15. 
 
4. Results and Discussion 
4.1. Synthesis of branched polyethylenimine palmitate (bPEI-PA) 
conjugates 
The synthesized conjugates of bPEI and PA appeared as yellowish to orange-red colored 
waxy substances. Lesser substituted conjugates were good soluble in organic solvents such as 
chloroform and isopropanol. In water they formed opalescent colloidal dispersions. Higher 
substituted bPEI-PA conjugates were poorly soluble in a series of organic solvents including 
isopropanol, chloroform, cyclohexane, acetonitril, acetone, and mixtures of them. The 
solubility in organic solvents was impaired by traces of water. Due to their scarce solubility 
the higher substituted conjugates bPEI1.8-PA12, bPEI10-PA60, bPEI25-PA70, bPEI25-
PA10, and bPEI25-PA200 were excluded from following research.  
The approximate calculated number of primary amine groups in bPEI 1.8 kDa was 
14 mol/mol, for bPEI10 – 78 mol/mol, and for bPEI25 – 194 mol/mol bPEI. Consumption of 
primary amine groups through binding of amide groups with PA reduces the number of 
primary amines per bPEI molecule (Table 21). Generally, the bPEI-PA conjugates remain 
very hydrophilic with HLB-values in the range of O/W emulsifiers. 
 
Mr (bPEI), [kDa] 
PA residues / 
PEI molecule 
Hydrophilic-
lipophilic balance1 
Mr (bPEI-PA), 
[kDa] 
Approximate number of 
primary amine groups per 
bPEI molecule 
                                                 
1 According to the Griffin’s method; 
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2 15.57 2.31 12 
1.8 
5 11.68 3.08 9 
12 15.29 13.08 66 
10 
30 11.30 17.69 48 
10 18.14 27.56 184 
20 16.60 30.13 174 25 
30 15.29 32.69 164 
Table 21: Basic characteristics of bPEI-PA conjugates. 
 
 
4.1.1. Chemical structure analysis of bPEI-PA 
Representative NMR spectra of the conjugate bPEI-PA are shown in Figure 46. In the 
1H NMR spectrum (Figure 46, A) following peaks were observed. The triplet at 0.78-
0.83 ppm corresponds to the terminal –CH3 groups of PA. The multiplet between 1.12 ppm 
and about 2.00 ppm corresponds to the =CH2 protons of PA. The triplet at 2.3 ppm 
corresponds to the =CH2 group of PA which is adjacent to the carbonyl moiety. The multiplet 
between 2.45 ppm and 2.70 ppm corresponds to the =CH2, =NH, and –NH2 protons of the 
bPEI. The amide protons were not detectable since they overlap this multiplet. The quartet at 
3.5 ppm apparently matches the =CH2 groups of bPEI which are located next to the amide 
nitrogen. These findings were well conformed with previous literature data [268, 269]. 
In the 13C NMR spectrum (Figure 46, B) the amide moiety –CONH– of the bPEI-PA 
conjugate was successfully identified, giving the proof of successful covalent grafting. The 
amide group was identified by the chemical shifting of the carbonyl peak in PA from 
180.6 ppm to 173.8 in bPEI1.8-PA5 [270]. The multiplet between 52.16 ppm and 55.57 ppm 
corresponds =CH2 groups of the bPEI. The multiple peaks between 22.8 ppm and about 
35 ppm correspond to the =CH2 groups of the PA moiety. The singlet at 14.14 ppm 
corresponds to the terminal –CH3 of PA [227]. 
The NMR analysis was hampered by the polymeric nature of the conjugates. Polymeric 
molecules typically have short relaxations in NMR which leads to peak broadening and 
flattening. On the other hand, the signal intensity of amide carbons was rather weak compared 
to the rest of the molecule. Due to the strong peak broadening only bPEI-PA conjugates with 
lower molecular weight and higher substitution degree with PA have provided appropriate 
spectral data for analysis. 
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From the 1H NMR-spectra of bPEI1.8-PA5 the approximate number of PA per bPEI-PA 
molecule was calculated to 5.6 which roughly corresponded to the stoichiometric amounts of 
reagents used in the synthesis.  
 
4.2. Characterization of bPEI-PA 
4.2.1. Particle size distribution of bPEI and bPEI-PA in polar and non-polar 
solvents 
In order to determine the particle sizes of bPEI and bPEI-PA conjugates in molecular 
solutions and in colloidal dispersions, they were measured in non-polar solvents such as 
chloroform, and in polar solvents such as water.  
The viscosity of the aqueous sample medium, containing 7.7 vol% glycerol in water, was 
1.1203 ± 0.0103 cP at 25 °C and was applied in all measurements settings. 
Comparing the particle size distribution of bPEI and bPEI-PA in non-polar solvents such as 
chloroform (dielectric constant, τ = 4.8 at 20 °C) and in polar solvents such as 
water (τ = 78.48 at 25 °C) revealed the strong affinity of bPEI-PA to self-associate in polar 
solvents, as might be presumed from their amphiphilic nature. 
In chloroform, most bPEI-PA conjugates were well soluble depending on their PA 
substitution rate. Conjugates’ solubility in a number of solvents was strongly impaired at high 
ratios between PA grafting and bPEI molecule weight as in the cases of bPEI1.8-PA12 and 
bPEI10-PA60. The solubility was further aggravated by traces of water in the solvent which 
presumably can deliver protons and / or hydrate the bPEI moiety and contribute to the 
molecule association. 
Nevertheless, the particle size distribution in chloroform was comparable for bPEI10 and 
bPEI10-PA12 (Figure 47). Regarding the low polarity of the solvent, the molecular dispersion 
state of the solution was assumed and the measured particle sizes were attributed to the single 
molecules. 
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Figure 46: 1H and 13C NMR characterization for bPEI-PA synthesis, carried out on bPEI1.8-PA5 in deuterated 
chloroform. The polymerization degree of bPEI1.8 is 41.86, corresponding to 167.44 H from bPEI methylene 
units and 41.86 H from =NH units. Each of the five palmitic acid residues provides a single –CH3 terminal 
group, 14 =CH2 units, and a single amide moiety. A: Chemical structure and 1H NMR spectrum of bPEI1.8-PA5; 
B: 13C NMR spectrum of bPEI1.8-PA5. Explanations are given in the text. 
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Figure 47: Size distribution of bPEI10 and bPEI10-PA12 measured by dynamic light scattering in chloroform 
solution. bPEI10 showed a monomodal distribution with peak maximum at 6.544 ± 0.08 nm. bPEI10-PA12 
demonstrated a bimodal distribution with a mean peak at 7.675 ± 0.11 nm (82.6% intensity) and a smaller peak 
at 946.9 ± 65.7 nm (17.4% intensity). The polydispersity of bPEI10-PA12 was higher with a PdI of 0.261, while 
bPEI10 had a PdI of 0.150. 
 
The average hydrodynamic diameter of bPEI10 molecules in chloroform was 6.544 ± 0.08 nm 
with a rather low PdI of 0.150. As expected, the grafting of PA residues led to a moderate but 
reproducible diameter increase of about 1.21 ± 0.06 nm. This was apparently due to an 
increase of molecule volume and / or due to altering the solvation state of bPEI-PA in 
chloroform. A second less intensive peak was observed with bPEI10-PA12 at about 950 nm, 
indicating the formation of molecule associates such as inverted micelles probably due to 
partially protonation and hydration of the polar bPEI10 moiety by traces of water. 
In water, the particle size distribution of all bPEI-PA conjugates suggested a strong tendency 
to form particulate self-associates (Figure 48). Generally, the grafting of PA increased the 
particle size by several orders compared to non-grafted bPEI. On the other side, in the main 
case it lowered the polymer polydispersity.  
Generally, the hydrodynamic diameters of non-conjugated bPEIs, measured in water, 
outweighed these, measured in chloroform, by about three- to five-fold. This can be attributed 
to the abundant hydration shell and polymer swelling in water. 
The measured particle size of non-grafted bPEIs was nearly linearly dependent on their 
molecular weight. Furthermore, a rather high polydispersity, reaching a PdI of 1.00, was 
found in these samples. In low-substituted conjugates such as bPEI1.8-PA2, bPEI10-PA12, 
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and bPEI25-PA10 a steep decrease of PdI was observed which continuously grew up with 
increasing the substitution rate. This is most apparent in the case of bPEI25 and its conjugates 
on Figure 48. Even in highly substituted conjugates the PdI remained below this of the non-
grafted polymer.  
It can be hypothesized that the attaching of hydrophobic PA rests leads to the formation of 
thermodynamically stable associates such as micelles, cylinders, etc., comprising a number of 
molecules. In this manner, bPEI-PA molecules with diverging sizes can be bundled to 
particles which sizes are dictated by the highest energetic loss and have therefore a lower 
polydispersity than the single molecules themselves.  
 
 
Figure 48: Hydrodynamic diameter and polydispersity index of bPEI with various molecular weights and their 
amphiphilic conjugates with various amounts of PA in water (n = 3). 
 
In general, the particle size of the bPEI-PA associates increased together with the substitution 
rate up to a certain limit, where particle size slightly decreased. The smallest particle sizes 
combined (144.13 nm) with the lowest PdI (0.257) were achieved with bPEI25-PA10, 
corresponding to a hydrophilic-lipophilic balance (HLB) of 18.14. Less polar conjugates 
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having HLB values between 16.60 and 11.68 produced associates, sized between 200 nm and 
290 nm.  
 
4.3. Formulation and characterization of polycationic liposomes with 
bPEI-PA 
In order to formulate polycationic liposomes as precursors for the production of polyplex-
associated phospholipid MBs, the physico-chemical properties of the system have to be 
discussed. Based on this, the possible formulation problems can to be identified, and a design 
concept can be elaborated. 
The composition of the MB shell was based on zwitterionic phospholipids with an acyl chain 
length of 16 carbon atoms, corresponding to the palmitoyl residues of amphiphilic bPEI-PA 
lipopolymers. The non-covalent interactions, stabilizing the MB structure are the hydrophobic 
– between the bPEI-PA / DNA polyplexes and the phospholipid acyl chains, and prevailing 
electrostatic – between the bPEI-moiety and DNA. Additional interactions such as hydrogen 
bonding between phospholipids and bPEI-PA could also play a role in the MB organization.  
Dipalmitoyl phosphatidylcholine (DPPC) has been well established in the literature as 
constituting component of the MB shell [59, 113]. However, DPPC alone cannot form MBs 
and needs a second phospholipid such as the DPPE. The combination of phosphatidylcholine 
and phosphatidylethanolamine was selected for its ability to form stable and narrow-sized 
MBs [58] and for its lack of electrostatic net charge at physiological pH. 
As an initial formulation step, the miscibility between DPPC and DPPE was studied by means 
of their melting behavior. Accordingly, the miscibility of DPPC / DPPE binary mixtures with 
bPEI-PA was explored and concentration ranges were selected for further formulation 
research.  
Precursor liposomes comprising DPPC and DPPE lacked colloidal stability and were prone to 
sedimentation which was one substantial formulation problem of this work. Therefore, next 
studies were directed towards improving the colloidal state of DPPC / DPPE liposomes by 
replacing water with hydrophilic solutes such as glycerol. Following research focused on the 
loading of bPEI-PA liposomes with pDNA and controlling the size and Zeta potential of 
liposomes, as well as obtaining appropriate MB yields upon agitation. This was done by 
handling formulation parameters such as the pH, ionic strength, N/P ratio, etc. 
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In the final pre-formulation stage, the developed MB formulations were tested in their ability 
to condense and protect DNA against enzymatic degradation, as well as in their in-vitro 
transfection activity and cytotoxicity. 
In their works Naumann et al (2001a and b) [271, 272] and Foremal at al. (2003) [273] 
demonstrated that numerous amphiphilic lipopolymers can form two-dimensional gels when 
grafted on condensed phospholipid monolayers on the air-water surface. These monolayer-
supported polymer networks were stabilized by two different types of associative 
interactions – hydrophobic association of the phospholipid acyl chains, and hydrogen bonding 
between adjacent hydrophilic polymer clusters on the top of the monolayer. Considering the 
abundant hydrogen bonding capacity of bPEI, this hypothesis should be considered when 
thinking about the organization of the bPEI-grafted MB shell. 
4.3.1. Mixing behavior of DPPC and DPPE 
The thermotropic behavior of pure DPPC and DPPE revealed symmetrical sharp peaks 
centered correspondingly at 41.5 °C and 64.31 °C (Figure 50). The mean transition peak 
temperature of the binary mixtures changed rather linearly (R2 = 0.9827) between the melting 
temperatures of the single phospholipids.  
The high ratios between peak half-height width (W0.5) and peak height (H) of pure 
phospholipids were indicative for their high cooperativity [274, 275] (Figure 49). In mixed 
bilayers a pronounced peak broadening and flattening was observed which was indicative for 
decrease of cooperation and membrane fluidization. On the concentration scale this effect did 
not follow a symmetrical progression, but was more pronounced in the low-DPPE region. 
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Figure 49: Transition peak flattening and broadening in binary mixtures of DPPC and DPPE, expressed as the 
ratio of peak width at half peak height (W0.5) vs. peak height (H). The more pronounced peak broadening in the 
low-DPPE range indicates higher membrane fluidity and was beneficial for MB formulations with a high yield 
and an optimal size distribution.  
 
The miscibility of phospholipid components constituting the MB shell is an important 
formulation parameter which determines the lateral shell homogeneity of the shell monolayer. 
Therefore, it was evaluated in the present study based on the melting behavior of mixtures 
comprising DPPC and DPPE. 
In binary mixtures at various molar proportions DPPE and DPPC demonstrated an ideal 
miscibility in the liquid-crystalline phase, indicated by the appearance of a single transition 
endotherm (Figure 50). Miscibility limitations in the gel phase in the low-DPPE concentration 
region were indicated in DSC studies by Blume et al. (1974) [276].  
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Figure 50: Phase shift diagrams of binary mixed phospholipid bilayers composed of DPPC and DPPE in various 
proportions in water. The concentration of DPPE increases from 0 mol% to 100 mol% with an increment of 
25 mol%, while the total phospholipid concentration remains 20 mM (n = 9). 
 
Due to the ideal miscibility of DPPC and DPPE, the identification of an optimal concentration 
region, based on this premise, was purposeless. However, macroscopic observations of the 
formulations during storage over a week in refrigerator showed that their colloidal stability 
decreases with rising DPPE concentration. Later experiments further revealed that liposomal 
precursors, containing 10-20 mol% DPPE at a total phospholipid concentration of 3 mM, 
produce the highest MB yields with an optimal size distribution. Higher molar ratios of DPPE 
led to an increase of the MB size, while DPPC and DPPE alone failed to produce MBs (data 
not shown). 
Based on these observations, the concentration region of 10 mol% to 20 mol% DPPE in 
DPPC was selected for further development.  
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4.3.2. Effect of glycerol on the colloidal stability of DPPC / DPPE liposomes 
The colloidal state of aqueous DPPE / DPPC dispersions is greatly impaired through the 
intrinsic negative curvature (towards the polar head group) of the DPPE molecules which is 
incompatible with the positive curvature in the outer bilayer leaflet of liposomes [277].  
While DPPC molecules possess a “cylindrical” form and occupy the energetically most stable 
lamellar (Lα) lyotropic phase, these of DPPE are “cone-shaped” and adopt the inverted 
hexagonal (HII) phase. The relatively high percentage of DPPE in liposomal formulations 
(20 mol% of the total phospholipid amount) apparently confers the mixed bilayer a net 
negative curvature [278]. The slow lyotropic transition, facilitated by the nearly to zero Zeta 
potential of liposomes, leads to their aggregation, coalescence, and sedimentation within 
several hours up to a day during storage of 3 mM dispersions at 4 °C. 
Liposomal stability could be greatly increased by including bPEI-PA to the bilayer apparently 
due to electrostatic and steric repulsions. Nevertheless, the sterically large polar group of 
bPEI-PA could “unbend” the negative layer curvature caused by DPPE. Anyway, the 
liposome size could not be confined in the desired low nanometer range and a substantial 
increase of their size and polydispersity was observed on storage.  
One possible opportunity to further stabilize the liposomal size and probably to increase the 
MB yield is posed by the replacing of water molecules from the hydration shell of the grafted 
phospholipid bilayer. 
Glycerol has several important effects on phospholipid dispersions including viscosity 
increase, water substitution, decrease of solvent polarity and membrane relaxation and finally 
lowering of the surface tension. In the above engineered phospholipid system, DPPC is the 
component responsible for the high collateral cohesion [93], while DPPE possesses a higher 
hydration state [93, 279] and mediates therefore the interaction with the outer aqueous phase. 
While the methylated headgroup of DPPC is rather hydrophobic, DPPE intensively interacts 
with water mainly through hydrogen bonding [280]. However, glycerol has a greater 
hydrogen bonding capacity than water and can partially replace it from the hydrating shell of 
phospholipid headgroups [281]. Furthermore, since its molecule has an about 3.7-fold higher 
volume (109.6 Å3 [282]) compared to water (29.89 Å3 [283]), glycerol can enhance the 
hydration volume of phospholipid headgroups. Hence, it can increase the headgroup 
interfacial area [184, 281] which apparently can result in a positive bending effect, 
compensating the negative layer curvature due to DPPE.  
Corresponding to its modulating effect on headgroup hydration, glycerol can relax 
phospholipid membranes by lowering the collateral adhesion between molecules. A relaxation 
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effect in the headgroup region in DPPC bilayers was reported by McDaniel et 
al. (1983) [281]. Furthermore, a relaxation in the acyl tail region could be explained through 
the lowering of dispersant polarity with increasing glycerol amount [282]. While pure water 
has a dielectric constant (τ) of 78.48 at 25 °C, for pure glycerol τ has a substantially lower 
value of 42.48 [284]. 
A further effect of glycerol is the reduction of the surface tension in aqueous systems which 
could be of major importance for the formation of MBs during mechanical agitation. At 
50 mol% glycerol in water about 92% of the air-water interface area is occupied by glycerol 
molecules [285]. It is possible that the reduced surface pressure promotes the dislocation of 
phospholipid molecules onto the gas-liquid interface during agitation and shifts the existing 
equilibrium between liposomes and MBs towards the MB formation. 
Another stabilizing contribution of glycerol in liposomal dispersions is the increase of their 
viscosity, limiting the Brownian motion, particle impact events, and therefore the probability 
for agglomeration and coalescence.  
Several interesting effects were observed in the thermal transition behavior of DPPC / DPPE 
mixtures upon increasing the glycerol amount. In the range of lower glycerol concentrations 
from 0 mol% to 19.8 mol% glycerol (corresponding to 50 vol%) an significant increase of the 
melting peak temperature from about 45.2 °C to about 48.6 °C, followed by a steep drop to 
42.5 °C when reaching 42.5 mol% glycerol (Figure 51, solid line) could be detected. Since 
under fully hydrated conditions the main phase transition characteristics of phospholipids are 
determined by their acyl chains [286] this effect can be mainly contributed to perturbations in 
the hydrophobic region. 
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Figure 51: Influence of glycerol concentration on the melting temperature (Tm) of 80 mol% DPPC / 20 mol% 
DPPE with total phospholipid concentration 20 mM (n = 9). 
 
In complementary follow-up experiments, implementing the same concentration range of 
glycerol, but at a phospholipid concentration of 5 mM which is suitable for the production of 
MBs, the progress of MB yield has been studied. Generally, the MB yield followed the 
progression of DSC events (Figure 51, dashed line). An about 5-fold increase of MB 
concentration was denoted upon addition of 19.8 mol% glycerol. When the amount of 
glycerol was further increased to 42.5 mol% the MB concentration dropped by about 104-fold.  
Interestingly, 42.5 mol% is the lowest glycerol concentration at which a interdigitation peak 
differentiates from the broad mean transition at 44.2 °C and sharpens and migrates to 42.1 °C 
in water-free medium (Figure 52). The interdigitated state of phospholipid of phospholipid 
bilayers [184, 281] can be induced by small alcohols, drug molecules [287], etc. In 
interdigitated phospholipid bilayers, the acyl chains of the one bilayer sheet completely 
interpenetrate the hydrocarbon chains of the apposing monolayer. In this manner the terminal 
methyl groups of acyl chains are closely positioned to the phosphate groups of the opposite 
monolayer sheet and the bilayer sheets are fully “zipped”.  
The glycerol induced interdigitation is typical for phosphatidylcholines at low water 
concentrations, yet the described main transition temperature shift has not yet been observed 
in pure DPPC [281, 288] and can apparently be denoted as a specific property of the binary 
mixture of DPPC and DPPE.  
Finally, the melting thermograms in the concentration range up to 19.8 mol% (50 vol%) 
glycerol revealed a single transition peak for the binary phospholipid mixture, indicating that 
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no significant phase separation occurs due to the altered phospholipid hydration caused by 
glycerol. 
 
 
Figure 52: Phase transition diagrams of binary systems of 20 mol% DPPE and 80 mol% DPPC at a total 
phospholipid concentration of 20 mM and various concentrations of glycerol ranging through 0 mol%, 
19.8 mol%, 42.5 mol%, and 100 mol% (curve of 7.6 mol% glycerol not shown for sake of clarity, n = 9). 
 
One possible reason for that effect could be attributed to the onset of acyl chain 
interdigitation. Since the phospholipid bilayer needs to be “unzipped” in order to form the MB 
monolayer shell, the phospholipid condition in liposome intermediates need to combine a high 
lateral cohesion and collateral fluidity, together with a weak interaction between the bilayer 
sheets. The major effects of phospholipid interdigitation are the integration of the bilayer 
sheets and the enhancing of the lateral distance between phospholipid molecules.  
Another hypothesis can be developed based on the increase of mean phase transition 
temperature. During the mechanic agitation of liposomes, temperature in glycerol free 
samples increases from about 25 °C to about 34 °C during the first 20 s, and may reach 45-
50 °C after 60 s (see Figure 6, p.43). As the pace of temperature increase is viscosity 
dependent (yet, not linearly), the temperature during the agitation generally rises faster with 
increasing viscosity (see Figure 8, p.45). When tube temperature reaches the phospholipid 
melting temperature the lateral cohesion between molecules abruptly decreases upon phase 
transition from gel- to liquid-crystalline. Since the phospholipid monolayer is not stable in 
this phase state, the MB degradation apparently through shear forces surmounts the formation 
process, leading to low MB yields. 
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4.3.3. Mixing behavior of bPEI-PA with DPPE / DPPC bilayers 
Following, the miscibility of bPEI-PA in binary mixtures of 20 mol% DPPE and 80 mol% 
was studied in the concentration range from 0 mM to 40 mM bPEI nitrogen with an increment 
of 10 mM.  
 
 
Figure 53: Phase shift diagrams of ternary mixed bilayers composed of 20 mol% DPPC, 80 mol% DPPC und 
various amounts of bPEI25-PA20 in water. 
 
For the pure DPPE / DPPC mixture, the mean transition endotherm was broad and 
symmetrically centered at 45.31 °C. After addition of 17.2 µM bPEI25-PA20 (corresponding 
to 10 mM nitrogen and about 344.2 µM palmitic acid), the peak sharpened, shifted to about 
43.3 °C and became a shoulder. Upon increasing the nitrogen concentration to 
20 mM (corresponding to 34.4 µM) the peak retained its position and the shoulder, but 
became flatter and broader. Further increase of bPEI-PA concentration to 30 mM and 40 mM 
nitrogen depressed the transition to 42.1 °C and 41.3 °C, as well as led to further peak 
broadening and flattening.  
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Figure 54: Transition peak flattening and broadening in ternary mixtures of 20 mol% DPPE, 80 mol% DPPC 
and bPEI25-PA20 in concentrations varying from 0 µM to 68.8 µM with an increment of 17.2 µM. Peak 
broadening is expressed as the ratio between the peak width at half peak height (W0.5) and the peak height (H). 
 
As indicated by the progression of peak broadening, expressed as the ratio between the peak 
width at half height and the peak height, the addition of low amounts bPEI25-PA20 increases 
the membrane lateral order, while amounts of above 17.2 µM bPEI25-PA20 (corresponding to 
10 mM nitrogen) increase membrane fluidity.  
Generally, the phospholipids demonstrated a good miscibility with bPEI-PA in all 
proportions. The occurring shouldering at nitrogen concentrations of 10 mM and 20 mM 
could be either due to a moderate phase separation, or because of the occurring of a second 
fluid crystalline phase of hydrogen-bridged bPEI-moieties above the phospholipid layer, as 
suggested in the literature for other systems of hydrogen-bonding lipopolymers and 
phospholipids [271-273, 289].  
4.3.4. Determination of bPEI-PA buffer capacity 
The buffering capacity of amphiphilic PEI conjugates has been demonstrated in previous 
studies [290-292] and has been confirmed for own bPEI-PA conjugates in PCL formulations. 
Similarly to the corresponding bPEI, the conjugates successfully buffered the pH range 
between 4 and 6. 
The behavior of the negative control samples comprising water and DPPC / DPPE liposomes 
was identical. In the absence of buffering chemical moieties it revealed a rapid pH drop down 
to about 3 yet at as low proton concentrations as 0.67 mM. In spite of the obvious DPPE 
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protonation ability at pH beneath 4, demonstrated by Zeta potential studies below, no 
buffering effect has been observed in its case. 
Generally, the substitution rate wit PA showed a moderate influence on the buffering 
capacity. Compared to bPEI, amphiphilic conjugates mostly showed a slightly lower buffering 
ability, more pronounced for highly substituted conjugates such as bPEI10-PA60. The data 
point out that chemical grafting of hydrophobic PA residues plays only a marginal role on the 
buffering capacity of the bPEI moiety of the conjugate. 
 
 
Figure 55: Buffering capacity of polycationic liposomes comprising bPEI25-PA20 compared to bPEI25 and 
zwitterionic DPPC / DPPE liposomes. Blank measurement was carried out with water. The buffering capacity of 
bPEI25-PA20 was close to that of bPEI25.  
 
The persisting acid buffering capacity in the pH range from 6 to about 4 of bPEI-PA suggests 
that it will be able to leverage the acidic conditions in endolysosome, where the pH 
approaches 5, and to mediate their osmotic rupture. 
4.3.5. Zeta potential of polycationic liposomes with bPEI-PA 
The Zeta potential of bPEI-PA comprising PCL was significantly influenced by the 
substitution rate of bPEI with PA, showing a non-linear dependency (Figure 56). At lower 
substitution rates such as 10, 20, and 30 PA grafts per bPEI molecule the Zeta potential 
declined by about 3 mV and fell by further 7 mV with increasing the substitution to 100 PA 
grafts per molecule. At further increase of the substitution rate from 100 to 300 PA grafts per 
molecule bPEI there was no major change in the PCL Zeta potential.  
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It is possible to hypothesize that increasing the ratio between PA grafts per bPEI molecule 
causes a stronger interaction with the phospholipids. Therefore, the bPEI residue is denser 
enveloped with phospholipids shielding the outwards Zeta potential. Another explanation for 
this effect could be the consumption of protonable primary and secondary amine groups 
which are converted to amide moieties through the grafting with PA. 
 
 
Figure 56: Effect of bPEI25 substitution with PA on the Zeta potential of polycationic liposomes at pH 7.4. At 
lower substitution rates of 10 to 100 PA grafts per bPEI molecule, the Zeta potential sloped steeply down from 
about 35 mV to about 23 mV. Further increase of the substitution rate to 300 PA grafts per molecule produced 
no significant changes in the Zeta potential (n = 3, p < 0.05).  
 
The effect of increased bPEI-PA concentration on the Zeta potential of polycationic 
liposomes was non-linear, resulting in a rapid increase from 5-6 mV, if no polycation is 
present, to about 35 mV at a nitrogen concentration of 20 mM. Further increase of the bPEI-
PA concentration to 40 mM nitrogen raised the Zeta potential only moderately to 40-43 mV, 
while no significant further increase followed at higher polycation amounts of up to 100 mM 
nitrogen. Nevertheless, the increasing concentration of bPEI25-PA20 significantly increased 
the viscosity of the formulations and made them inapplicable for the production of MBs. 
The behavior of polycationic liposomes Zeta potential during acid titrations in the pH range 
from 6 to about 4 was studied simultaneously with the buffering capacity of bPEI-PA (Figure 
57). The Zeta potential of polycationic liposomes showed no proportionality to the 
protonation rate of the bPEI residue during the pH titration (see Figure 55). Similarly to 
bPEI25, the amphiphilic conjugate bPEI25-PA20 effectively buffered the pH range from 6 to 
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about 4. However, the pH interval of buffering the Zeta potential of PCL initially increased 
from 70 mV (at a pH of 6.53) to about 88 mV (at a pH of 5.3). A similar behavior was 
observed with non-substituted bPEI25, where the Zeta potential rose from 73 mV (at a pH of 
6.7) to about 86 mV (at a pH of 3.96). 
 
 
Figure 57: Effect of pH change on the Zeta potential of bPEI25-PA20 liposomes, compared to bPEI25 and 
DPPC / DPPE liposomes. At lower pH values the Zeta potential was depressed by the increasing conductivity of 
the sample medium (n = 3).  
 
The negative control sample, comprising DPPC / DPPE liposomes, demonstrated a pH 
dependent shift of Zeta potential, too. In the pH interval from about 4.3 to 2.3, the Zeta 
potential rapidly increased from 11 mV to 56.5 mV. This could be contributed to the 
protonation of the phosphate group of DPPE, having in bilayers a transition in the protonation 
state at a pH of approximately 3 [293].  
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4.4. Studies on the loading of bPEI-PA liposomes with pDNA  
In following formulation studies, the loading capacity of PCL was examined with regard to 
their size, Zeta potential and capacity to produce MBs upon mechanical agitation.  
The pDNA loading studies were aimed at the formulation of small polyplexes, sized in the 
lower nanometer range which after loading possess a residual net positive Zeta potential, and 
produce appropriate yields of MBs upon agitation.  
4.4.1. Complexation capacity of bPEI-PA liposomes for pDNA 
The ability of PCL to bind pDNA was scrutinized using the ethidium bromide exclusion 
assay [265]. The fluorescent dye ethidium bromide intercalates between the base pairs of 
DNA. The degree of access to the binding sites is mainly dependent on the condensation state 
of DNA. The fluorescence quantum yield of ethidium bromide is also significantly enhanced 
by intercalation between nucleotide pairs. When a polycation binds to the nucleic acid, 
intercalated ethidium bromide is displaced and a fluorescence intensity drop can be noticed. 
The maximum curve slope (first derivative) indicates the N/P-ratio, at which maximum DNA 
binding occurs and the polycation affinity to DNA. 
Experimental data revealed a general trend of decreasing of the bPEI-PA capacity to bind and 
condense pDNA with increasing rate of chemical substitution with PA (Figure 58). This effect 
was clearly observed in the case of bPEI1.8 and its conjugates.  
For non-substituted bPEIs further binding of pDNA was no more possible beyond N/P ratios 
of between 1.2 and 2. Substituted bPEI-PA conjugates showed less complexation ability and 
had higher saturation N/P ratios of about 3.0-3.4 for bPEI1.8-PA2, bPEI10-PA12, bPEI10-
PA30, bPEI25-PA10, and bPEI25-PA20. Even lower binding capacities of N/P 4.5-5.0 were 
observed in the cases of bPEI1.8-PA2 and bPEI25-PA30. Phospholipid liposomes, 
comprising no polycation, did not bind and condense pDNA. 
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Figure 58: Fluorescence decrease slope curves of 
DNA-intercalated ethidium bromide upon titration 
with bPEI25-PA20 polycationic liposomes. The degree 
of curve slope is indicative for the polycation affinity 
to DNA. Generally, increasing PA substitution rate 
reduces the capacity of bPEI-PA to bind and condense 
pDNA (n = 3). 
 
The decreasing complexation ability of amphiphilic conjugates compared to the non-
substituted bPEI species can be attributed to their interaction with the phospholipid phase. 
Provided the hydrated bPEI moieties build a hydrophilic core, where the hydrophobic 
PA rests are directed outwards, they can interact with phospholipid molecules and build 
liposome- and micelle-like structures. Similar to the structures, proposed by 
Ko et al. (2009) [294], in the so formed core-shell associates the bPEI-PA could be enveloped 
in phospholipid molecules rather than exposed at the liposome surface, as suggested by 
Oku et al. (2001) [230]. 
Further hypotheses can be considered with regard to conformational changes of bPEI and the 
occurring of steric tension after the lipopolymer molecule has been deformed by the 
hydrophobic association with other bPEI-PA molecules and phospholipids. It is also probable 
that the consumption of primary amino groups by the chemical grafting plays a role, too. 
4.4.2. Effect of pH on the polycationic liposome size 
In aqueous dispersions polyplexes of pDNA and bPEI-PA do not exist as distinct structures, 
but are associated by phospholipid into polycationic liposomes or other lyotropic structures. 
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On the other hand, polycationic liposomes are dissipated during the production of polyplex-
associated MBs while the polyplexes presumably retain their size. For this reason, particle 
size measurements in dispersions of polycationic liposomes do not represent the real size of 
the secondary-carrier particles, but a higher value. Although one of the important aims of the 
current formulation research was to obtain smaller polyplex liposomes as an indirect sign for 
smaller polyplexes.  
The size of polyplex liposomes and their polydispersity could be successfully influenced by 
changes of the pH prior to the complexation with pDNA (Figure 59).  
 
 
Figure 59: Effect of the pH value on the diameter of polycationic liposomes comprising bPEI25-PA20 at a 
nitrogen concentration of 20 mM and an N/P loading ratio of 15. A decrease of both particle size and 
polydispersity was achieved by reducing the pH value. After lowering the pH from 8.3 to 3.5 the liposome 
hydrodynamic diameter decreased from about 1,900 nm to about 300 nm, while the polydispersity index 
declined by about 0.2 units. 
 
The size of DNA-loaded polyplex liposomes was successfully reduced by lowering the pH 
value. A pH decrease from 8.3 to 3.5 led to a 6.3-times decrease from 1,900 nm to about 
300 nm of the hydrodynamic diameter. The polydispersity index decreased by approximately 
2.4-fold from about 8.3 to 3.5. As the pH range below 4 approaches extreme acidic 
conditions, a pH span of 4.5 to 4.0 was selected as best suitable for formulations. 
The observed effect of particle size decrease can be explained with electrostatic effects caused 
by the protonation of bPEI-PA and DPPE. As depicted in the titration curves on Figure 55 on 
p.176 and on Figure 57 on p.178, with decreasing pH bPEI is progressively protonated and 
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the positive charge density per molecule grows. Up to a pH of about 3.5 the negative charge 
number of pDNA is not affected, hence each bPEI molecule provides more binding sites for 
pDNA and thus, less molecules polycation are necessary to condense a single plasmid. 
4.4.3. Polycationic liposome size according to bPEI molecular weight, PA 
substitution, and loading with pDNA 
In the following study, a more extensive comparison will be made between the particle size 
and polydispersity of polycationic liposomes, comprising bPEI with various molecular 
weights and bPEI-PA conjugates with different substitution rates. Following, the bPEI-PA 
will be compared according to their particle size growth after loading with pDNA at an 
N/P ratio of 15. 
Generally, unloaded polycationic liposomes had hydrodynamic diameters of 100-160 nm with 
no apparent influence caused by bPEI different molecular weights. Comparing particle sizes 
in aqueous dispersions of bPEI-PA conjugates in absence of phospholipid (Figure 48, p.165), 
and the corresponding polycationic liposomes (Figure 60) it is obvious that the complexation 
of bPEI-PA with phospholipid has contributed to decreasing particle size. Under equal 
conditions, phospholipid-free dispersions of bPEI-PA have particle sizes of 200-230 nm, 
whereby the particle size and polydispersity are dependent on the bPEI molecular weight and 
substitution rate with PA.  
The particle size of polycationic liposomes after loading with pDNA was influenced by the 
molecular weight of the bPEI used. Neu et al. (2005) [218] demonstrated that low-molecular 
weight bPEI in the order of 1.8 kDa provides only over a limited capacity to condense pDNA 
and to form small polyplexes. In the current study these findings were confirmed since in 
absence of phospholipid polyplexes, formed with bPEI1.8 were sized about 9,000 nm, 
compared to about 500 nm sized polyplexes, produced from bPEI25. The extensive 
discrepancy between polyplex size can be explained with the inability of small bPEI to 
complex all neutral charges of the plasmid molecule. For this reason, one plasmid can be 
bound to two or more polyplexes at the same time and act as a inter-particle cross-
bridge [295]. 
In the presence of phospholipid the size of polyplexes with bPEI1.8 was stabilized at about 
500 nm. However, in average polyplexes and DNA-loaded polycationic liposomes comprising 
bPEI1.8-PA were still bigger sized than formulations with bPEI10 and bPEI225 and their 
conjugates.  
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Figure 60: Hydrodynamic diameter and polydispersity index of polycationic liposomes, comprising 
phospholipids and bPEI with various molecular weights and their amphiphilic conjugates with various amounts 
of PA in water prior to (on the left side) and after their loading with DNA (on the right side), n = 3. 
 
There was no significant difference between polyplexes, comprising bPEI10 and its 
conjugates which were all about 300 nm sized. DNA-loaded polycationic liposomes with 
bPEI25-PA conjugates had somewhat lower sizes of around 200 nm, independently from the 
rate of PA grafting. 
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As expected, when loading of increasing amounts of DNA the Zeta potential of polycationic 
liposomes was turned more negative with decreasing N/P ratio, and reached highly negative 
values of about -40 mV at an N/P of about 7 (Figure 61, solid line). Simultaneously the 
particle size distribution of polycationic liposomes (dashed line) reached a maximum when 
the Zeta potential approached zero and the electrostatic repulsing forces between particles 
were practically neutralized. Under these conditions, polyplexes tend to aggregate [296] due 
to the prevalence of attractive such as hydrophobic interactions and van-der-Waals 
forces [297]. 
 
 
Figure 61: Zeta potential of polycationic liposomes with bPEI25-PA30 at various N/P DNA loading ratios. 
 
Interestingly, the cationic bPEI charges were shielded by DNA at an N/P ratio of about 10. 
However, according to Figure 58 on p.180 the saturation of bPEI25-PA30 lies much lower 
between N/P ratio values of 3.0-3.5. Though the higher protonation of bPEI25-PA30 during 
the current loading study its loading capacity was limited not by the rate of DNA 
condensation, but by the depression of Zeta potential and the particle size growth. Therefore, 
according to the above data, the binding ability of bPEI seems to be higher than its loading 
capacity, determined by its Zeta potential. Indeed, the binding of DNA is thought to be driven 
by entropic forces arising from the release of counter ions or hydrating water, rather than by 
electrostatic interactions [218, 298]. However, the observed progress of particle size and Zeta 
potential was not typical for all bPEI-PA conjugates tested. Accordingly, loading with pDNA 
with N/P ratios of down to 10 was achieved in later studies. 
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A comparison of the Zeta potential shift of polyplexes, comprising various bPEI conjugates, 
and loaded at a constant N/P ratio of 15 is given in Figure 62. The shift of Zeta potential upon 
loading with DNA was dependent from the molecular weight and from the degree of 
substitution with PA. Generally, the Zeta potential was stronger influenced in polycationic 
liposomes comprising bPEI1.8 and bPEI10 than in the case of bPEI25. On average the Zeta 
potential of loaded polyplexes approached values of about 30 mV. 
 
Figure 62: Zeta potential of polycationic liposomes 
comprising bPEI of various molecular weights with 
regard to its substitution with PA and presence (dashed 
line) or absence (solid line) of DNA loading at an N/P 
ratio of 15 (n = 3). 
 
Comparing the particle size data in Figure 60 on p.183 with findings about the Zeta potential 
of polycationic liposomes, the degree of polyplex aggregation was again corresponding to the 
reduction of Zeta potential.  
In summary, polycationic liposomes are explicitly prone to aggregation owing to features of 
the lyotropic state, hydrophobicity, etc. Repulsing electrostatic interactions seem to play an 
important role for their colloidal stability, particularly with regard to loading with DNA. 
Colloidal stability of DNA-loaded polycationic liposomes can be successfully influenced by 
adjustments of the pH, dispersant viscosity and polarity, phospholipid hydration state, as well 
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as by selection of appropriate molecular weight of bPEI and a suitable rate of substitution 
with PA. 
 
4.5. Formulation and characterization of polyplex-associated MBs, 
loaded with pDNA 
Beyond the colloidal stability and DNA complexing capacity, polycationic liposomes, loaded 
with DNA must possess the ability to produce MBs with an appropriate size distribution and 
an acceptable particle yield upon mechanical agitation.  
4.5.1. Effect of electrolytes on the MB production and liposome aggregation 
One major problem, solved during the formulation studies, was the extremely limited 
“foamability” of polycationic liposomes, leading to low particle yields of 103-105 MB/ml. For 
the first time Borden et al. (2007) [113] identified the issue about the balance between surface 
charge and MB stability. They observed a monotonously declining stability of positively 
charged MBs when the concentration of cationic phospholipid increased. Furthermore, the 
authors successfully overcame the shell monolayer instability by employing the ionic strength 
as a formulation lever. The apparent reason for the MB instability was the lateral electrostatic 
repulsions between cationic charges in the bubble shell. Beyond a certain concentration limit 
of cationic charges per unit of area, the Coulomb repulsions between phospholipid 
headgroups exceed the hydrophobic attractions between acyl chains. This can lead to 
reduction of the co-lateral adhesion between phospholipid molecules, alter the lyotropic state, 
increase of the surface tension, and finally impair the MB structure. 
In the above mentioned paper the increasing electrolyte concentration was exploited as a 
formulation tool to prevent MB shell instability. According to the Debye length equation 
(Equation 12, p.107), when the ion concentration is increased the electrostatic repulsions are 
shielded and the tension in the shell monolayer is relaxed. 
There is also another direct effect of the electrolyte concentration on the collateral adhesion 
between zwitterionic phospholipid molecules in the shell monolayer. According to the study 
of Oncins et al. [299] sodium chloride in the concentration range of 10 mM to 100 mM 
increases the collateral cohesion between phosphatidylcholine molecules and raises the layer 
compactness. This effect is owing to the shielding of the electrostatic repulsions between 
phosphate groups as well as between quaternary ammonium groups which increase the 
distances between neighboring molecules. 
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Increasing the electrolyte concentration was successfully employed in the present work to 
reduce the electrostatic repulsions between polyplexes. However in this case the electrolyte 
conditions had to be very precisely selected since too high ion concentrations lead to 
aggregation of the polycationic liposomes. For this reason, the Coulomb interactions were 
only partially screened by adjusting with electrolyte, while trying to increase the MB yield 
causing a minimum increase of liposome size.  
Briefly, experimental data revealed an increasing tendency of polycationic liposomes to 
agglomerate upon increasing electrolyte concentration (Figure 63). This effect was more 
pronounced for triple-charged anions such as citrate compared to simple anions such as 
chloride. In the case of addition of triple-charged anions, the average hydrodynamic diameter 
of polyplex liposomes grew steeply from about 300 nm to about 7,600 nm after addition of 
30 mM electrolyte. This rapid size increase did not permit the particle size to be adjusted by 
means of citrate.  
On the other hand, a much more moderate effect was obtained by the use of single-charged 
anions such as the chloride. The ion concentration range between 0 mM and 50 mM provides 
opportunities to optimize the MB production without increasing the size of liposome 
precursors over 1,000 nm. 
 
 
Figure 63: Effect of electrolyte concentration and anion charge on the diameter of polycationic liposomes, 
comprising bPEI25-PA20. The ion concentration was varied from 0, 30, 50, 70, and 100 mM. 
 
Apparently the size increase of polycationic liposomes upon electrolyte shielding is governed 
by electrostatic Coulomb interactions. This is substantiated by the relation between particle 
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growth events and the shift of Zeta potential (Figure 64). While single-charged chloride 
anions caused a moderate decrease of positive Zeta potential of polycation liposomes, triple-
charged citrate neutralized the polyplex cationic charges much faster.  
 
 
Figure 64: Effect of electrolyte concentration and anion charge on the PCL Zeta potential. 
 
In the concentration range from 0 mM to 50 mM chloride anions shielded the Zeta potential 
from about 44 mV to about 25 mV, while liposomes shielded by citrate had only about 5 mV 
cationic Zeta charge. 
The concentration of MBs did not linearly increase together with the ion concentration, as was 
expected according to the findings of Borden et al. Both, for citrate and chloride anions there 
was a maximum in the MB yield at 30 mM to 70 mM (Figure 65), while at higher ionic 
concentrations the MB concentration decreased again.  
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Figure 65: Effect of electrolyte concentration and anion charge on the MB yield (n = 6). 
 
Generally, at equal ion concentrations sodium citrate produced a higher MB yield than 
sodium chloride. This corresponds well to the higher ability of citrate anions to shield Zeta 
potential (Figure 64) due to their triple charge. However, these positive features were 
connected with the greater liposome aggregation, caused by citrate (Figure 63). 
For this reason, sodium chloride was preferred to adjust the ionic strength in a controllable 
manner and was included in the formulation in amounts of 10-20 mM for the production of 
pDNA-loaded MBs. Because DNA additionally compensates positive charges on the MB 
surface, it also contributed to increase the MB concentration. In contrast to pDNA-loaded 
formulations, unloaded liposomes produced about 105-fold less bubbles. 
4.5.2. Optimal formulation for polyplex-associated MBs for in-vivo studies 
Following the research development of polyplex-associated MBs several important 
formulation factors were optimized and summarized into a standard formulation setup, 
described here. In Table 22 the amounts of pDNA and excipients in the final formulation are 
represented. 
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Component Molar concentration, [mM] Mass concentration, [mg/ml] 
DPPC 2.40 2.94 
DPPE 0.60 0.70 
bPEI25-PA30  
(20 mM nitrogen) 
Approx. 0.03442 Approx. 0.86 
HEPES 30 7.15 
Sodium chloride 15 0.875 
EDTA 1 0.292 
Hydrochloric acid  
(for adjusting of pH) 
Approx. 25 µl 
Glycerol, water-free 50 vol% 
Water, electrolyte-free 50 vol% 
DNA (N/P = 10) 0.40 mg/ml 
Table 22: Optimal constitution of final formulations of polyplex-associated MBs. The concentration of bPEI 
nitrogen can vary from 10 mM to 20 mM. Approx. – approximately. The represented concentration result from 
the mixing of polycationic liposomes and pDNA solutions. 
 
The total phospholipid concentration in final MB preparations was 3 mM, comprising 
20 mol% DPPE and 80 mol% DPPC. At an N/P loading ratio of 10 and 20 mM bPEI nitrogen 
one single dosage unit of polyplex-associated MBs contains 160 µg pDNA and about 
4 x 109 MBs. Control pH measurements revealed moderate deviations of ± 4.6% (n = 12) 
prior to and after the equilibration of polycationic liposomes. 
Successful loading of polycationic liposomes was observed from Zeta potential 
measurements, while the loading of polyplexes on the MBs was demonstrated through 
fluorescence confocal microscopic imaging below.  
4.5.3. Structure analysis of polyplex-associated MBs 
The fluorescent micrographs of unloaded MBs revealed equally stained spherical structures, 
possessing dark interiors and a fluorescent shell (Figure 66).  
Clearly the amphiphilic bPEI-PA remains associated to the phospholipid shell and does not 
penetrate the gas core, as confirmed by 3D-microscopic images. In unloaded MBs bPEI-PA 
appears equally distributed throughout the MB shell without obvious signs of lateral 
segregation. The conjugate is apparently incorporated mainly in the MB shell as little red 
fluorescence due to TexasRed® labeled bPEI25-PA30 was found in the background of Figure 
66 A.  
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Figure 66: Confocal fluorescence microscopy image of perfluoropropane microbubbles stabilized by a 
Coumarine-6® labeled phospholipid monolayer (in green) containing the amphiphilic bPEI25-PA30. The 
microbubbles are either unloaded (A) or loaded with pDNA (B). On image A (left) the bPEI25-PA30 is 
covalently labeled with TexasRed® (red), while on image B (right) the red staining indicates the partition of 
pDNA, labeled by propidium iodide. Depending on the position of the confocal plane the MBs appear either as 
filled circles (confocal plane at the top or bottom of the MB) or as fluorescent rings (confocal plane in the middle 
of the MB).  
 
In the case of polyplex-associated MBs loaded with pDNA (Figure 66 B) there was an 
condensation of phospholipid, bPEI-PA, and pDNA. Thereby, nanoparticles were 
spontaneously formed on the MB surface via condensation of pDNA by bPEI-PA. Between 
the bubbles some green (phospholipid) and red fluorescence (plasmid) is still detected 
indicating the presence of a residual amount of pDNA-bearing liposomes which was not 
transformed to MBs during the agitation. 
4.5.4. Protection of pDNA against enzymatic degradation 
The polyplex-loaded MBs were challenged with 200 U/l DNAse I which amount is about 45-
fold higher than the DNAse activity in human blood [300] and allows reliable conclusions 
about the protection capacity of the bPEI-PA polyplex secondary carriers. 
Figure 67 represents the gel electrophoresis results on polyplex-associated MBs loaded with 
pDNA at N/P ratios raging from 15 to 5. As shown, the unchallenged plasmid produces two 
bands in the gel (lane 1 on the left) according to the coil state of the DNA strain. In lane 2, the 
pDNA was successfully protected by inhibition of DNAse through EDTA.3Na, while the 
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plasmid was fragmented when fully exposed to the enzyme (lane 3). Unloaded MBs did not 
exhibit any intrinsic fluorescence as shown in lane 4. Furthermore, DPPE / DPPC 
phospholipid MBs without bPEI-PA failed to protect pDNA from degradation by 
DNAse (data not shown). 
In lanes 5, 6, and 7 on the right, no fragment bands were observed, demonstrating that in this 
loading range pDNA was mostly protected from enzymatic digestion by the condensation 
with bPEI-PA. Only trace amounts in the order of 1.0-1.5% from the total lane fluorescence 
were found using ImageJ software v.1.41o (National Institute of Health, USA) beyond the 
main plasmid band.  
 
 
Figure 67: Agarose-gel electrophoresis of polyplex-associated MBs, loaded with pDNA at various N/P ratios 
after DNAse challenge assay. In the N/P loading range from 15 to 5 the bPEI-PA conjugates were able to protect 
pDNA against enzymatic degradation, while naked plasmid was fragmented.  
 
Clearly the pDNA was not thoroughly detached from the complex with bPEI-PA and was 
retained in the slots of the agarose gel which makes further quantitative assumptions 
unreliable. Furthermore, comparing the mean band height of free untreated pDNA and of the 
plasmid, released from the polyplex-associated MBs, apparently no conformational change of 
pDNA was caused by the condensation in polyplexes.  
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4.5.5. Effective encapsulation of pDNA in polycationic liposomes and in 
polyplex-associated MBs 
According to the gel retention assay data the plasmid DNA was completely bound to 
polyplex-associated MBs at an N/P loading ratio of 15 (Figure 68). At higher loading amounts 
between N/P 13 and 5, a moderate pDNA leakage of between 3.00% and 7.84% (according to 
the total fluorescence of free pDNA) was observed.  
 
 
Figure 68: Gel retention assay of pDNA-loaded polycationic liposomes at various N/P ratios. Plasmid DNA 
remains fully bound to liposomes until an N/P of about 10 to 7, where the earliest smear is viewable. At higher 
pDNA amounts, particle leakage continuously aggravates.  
 
At high loading ratios of N/P 3 and 1 practically no pDNA was bound and the loss increased 
exponentially correspondingly to 15.81% and 31.54% from the total plasmid fluorescence. 
Further on, the effectiveness of DNA-encapsulation in polyplex-associated MBs was 
evaluated. MB formulations comprising bPEI25-PA20 were studied at an N/P-loading ratio of 
15. From the total amount of 160 µg pDNA about 76.68% were effectively encapsulated in 
the MB fraction (Table 23). This results in an effective amount of about 122.69 µg pDNA 
encapsulated in polyplex-associated MBs. 
 
 Mass amount, [µg] Percent amount, [%] 
Polyplex-associated MBs 122.69 ± 5.89 76.68 ± 3.68 
Residual polycationic liposomes 37.31 ± 5.89 23.32 ± 3.68 
Free pDNA Trace amount Trace amount 
Total pDNA input amount 160 100 
Table 23: Phase partition of pDNA in polyplex-associated MB formulations comprising bPEI25-PA20 in 
concentrations, corresponding to 20 mM nitrogen and loaded with pDNA at an N/P molar ratio of 10. 
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4.6. Comparative in-vitro transfection / cell viability studies with 
pDNA-loaded polycationic liposomes and polyplex-associated 
microbubbles 
 
4.6.1. The effect of bPEI molecular weight 
Gene transfection efficacy and cell viability after treatment with polyplexes comprising bPEI 
with molecular weight of 1.8 kDa, 10 kDa, and 25 kDa prepared without addition of 
phospholipid were compared below. Low-molecular weight bPEI 1.8 kDa produced rather 
low transfection rates of 3.6 x 103 ± 2.1 x 103 RLU (Figure 69). The low transfection activity 
of such polyplexes could be attributed to their large size of several micrometers in absence of 
phospholipid.  
In contrast, bPEI with a molecular weight of 10 kDa achieved about 103-fold higher 
transfection rates than bPEI 1.8 kDa.  
 
 
Figure 69: Transfection efficiency of unmodified bPEI with molecular weights of 1.8, 10, and 25 kDa, 
demonstrated by luciferase assay (n = 15, RLU – relative luminescence units). Cell viability is expressed in 
percents regarding untreated cells. 
 
Transfection efficacy of bPEI 10 kDa revealed no statistically significant difference to the 
transfection rates achieved with the positive standard bPEI 25 kDa (p = 0.9753).  
Polyplex toxicity of all polyplexes was moderate and generally increased with increasing 
bPEI molecular weight (Figure 69, solid line). There was no statistically significant difference 
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between the toxicity of bPEI 10 kDa and that of the positive standard 
bPEI 25 kDa (p = 0.7981).  
4.6.2. The effect of conjugation with PA 
In the following study, nanoparticles from amphiphilic conjugates of bPEI and PA without 
addition of phospholipids were examined. This was done in order to scrutinize the intrinsic 
transfection efficacy and the toxicity of the bPEI-PA conjugates. These were compared to 
unsubstituted bPEIs and the effect of grafting with PA was assessed. 
Chemical grafting of PA to bPEI delivered no uniform trend in cell cultures treated with 
different molecular weights of bPEI. In the case of bPEI 1.8 kDa and its conjugates low-grade 
substitution led to a small, but significant increase of transfection rates (Figure 70). 
Conjugates of bPEI 10 kDa demonstrated continuous decreasing transfection activity with 
increasing substitution grade. On the other hand, loss of transfection efficacy in bPEI 25 kDa 
and its conjugates was observed only between ungrafted and grafted polycations, while there 
was no significant difference between the particular conjugates. 
 
 
  
 
Figure 70: The effect of various degrees of substitution 
with PA on the in-vitro transfection efficacy and cell 
viability (n = 15). Grafting of PA on bPEI with molecular 
weights of 1.8 kDa, 10 kDa, and 25 kDa increased the 
complex toxicity in all cases (RLU – relative luminescence 
units). Cell viability is expressed in percents regarding 
untreated cells. 
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4.6.3. The effect of phospholipid 
In the next step of the study, polycationic liposomes were formed out of phospholipids (DPPC 
and DPPE) and amphiphilic bPEI-PA conjugates with various molecular weight and 
substitution grade. Their transfection activity and toxicity was then compared to that in 
absence of phospholipids (Figure 70).  
In all cases, addition of phospholipids to either unmodified bPEI or bPEI-PA resulted in a 
significant loss of transfection efficacy. This effect was most pronounced with conjugates of 
bPEI 25 kDa, where the activity was depleted by up to 300-fold. Interestingly, while 
bPEI 10 kDa was almost completely inhibited by the presence of phospholipid, its 
amphiphilic conjugate bPEI10-PA12 was only moderately influenced and retained about 65% 
of its intrinsic activity. At last, the addition of phospholipid to bPEI 1.8 kDa and its 
conjugates resulted in complete loss of transfection activity. 
  
  
 
Figure 71: Comparison of transfection efficacy of 
branched PEI with different molecular weights and their 
amphiphilic conjugates with (black columns) and 
without (grey columns) addition of 
phospholipids (n = 15, RLU – relative luminescence 
units).  
 
The lower transfection rates were not accordant with the data on cell viability. In several cases 
the addition of phospholipid did not affect the toxicity of bPEI-PA polyplexes e.g. bPEI10-
PA12, bPEI10-PA30, and bPEI25-PA30 (Figure 72). In others, polyplex toxicity was strongly 
increased by phospholipid as in the cases of bPEI1.8-PA2, bPEI1.8-PA5, and bPEI25-PA10. 
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Figure 72: Comparison of the cell viability in tissue 
cultures treated with bPEI of different molecular 
weight and their amphiphilic conjugates with (black 
columns) and without (grey columns) addition of 
phospholipid (n = 15). Cell viability is expressed in 
percents regarding untreated cells. 
 
Because of the complex interplay of bPEI molecular weight, substitution grade with PA, and 
the presence or absence of phospholipids the selection of a suitable candidate for in-vivo 
studies affords thorough monitoring. The bPEI-PA candidates were ranked after two selection 
criteria – high transfection efficacy and low cell toxicity, obtained in presence of 
phospholipid. Accordingly, they were compared to the positive standard – bPEI 25 kDa in 
absence of phospholipid (Figure 73).  
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Figure 73: Comparison of the transfection efficacy and toxicity of bPEI-PA conjugates in presence of 
phospholipid with the positive control – bPEI 25 kDa in absence of phospholipid (n = 15, RLU – relative 
luminescence units). Cell viability is expressed in percents regarding untreated cells. 
 
Amongst all tested bPEI-PA conjugates, bPEI10-PA12 provided the highest transfection rates. 
Its transfection efficacy in presence of phospholipid approached the transfection achieved by 
the positive control bPEI 25 kDa without phospholipid. Even more, the cell toxicity of 
bPEI10-PA12 was significantly lower than that of bPEI25. Therefore, bPEI10-PA12 has been 
selected as a suitable transfection agent for further studies. 
4.6.4. The effect of US-mediated destruction of MBs 
Cell cultures were further treated with pDNA-loaded polyplex-associated MBs in 
combination with US. The obtained data revealed that cavitation effects caused by US-
mediated destruction of MBs did not significantly improve the transfection efficacy of pDNA-
loaded polycationic liposomes (Figure 74). Transfection rates of 
3.67 x 105 ± 2.25 x 105 RLU / 6 x 104 cells and a cell viability of 92.25% ± 5.47% were 
achieved by incubation of 200 ng pDNA, 430 ng bPEI10-PA12, and 1.82 µg phospholipid for 
24 hours. Under the same experimental conditions, but treating cells with MBs, instead of 
polycationic liposomes, transfection rates of 4.11 x 105 ± 2.43 x 105 RLU / 6 x 104 cells at a 
cell viability of 78.79% ± 6.14% were reached with no statistically significant difference of 
the transfection rates (p = 0.9801). 
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Figure 74: Comparison between the in-vitro transfection activity of pDNA-loaded polycationic liposomes and 
polyplex-associated MBs in combination with US, both comprising bPEI10-PA12 (n = 10, RLU – relative 
luminescence units). Cell viability is expressed in percents regarding untreated cells. 
 
The obtained results confirmed the suggestion that cellular uptake by means of cell membrane 
poration is size-limited to macromolecules in the range of proteins or plasmids [33, 56, 58, 
245]. However, shell fragments, resulting from the in-vitro destruction of polyplex-associated 
MBs, are sized 151.15 nm ± 13.06 nm and are apparently too large to pass through the 
sonopores. Therefore, after the fragmentation of MBs the pDNA-bearing shell fragments can 
be only taken up by the cells via the endosomal pathway.  
Nonetheless, under in-vivo conditions MBs are supposed to fulfill a different function than 
enhancing the cellular uptake of pDNA. When exposed to diagnostic US on the target site, 
MB oscillation enhance the permeability of capillary endothelium for colloidal particles. This 
allows the DNA-bearing shell fragments (secondary carriers) to leave the capillary bed, to 
reach the target cells, and to be taken up by phagocytosis. Further in-vivo clinical studies are 
still necessary to prove this concept. 
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5. Summary and outlook 
 
Recently, microbubble ultrasound contrast agents (MBs) have become a promising tool for 
targeted drug and gene delivery. This is because MB drug carriers provide several distinctive 
advantages. On the one hand, they aid the visualization of the target site by diagnostic 
ultrasound (US) by acting as contrast agents. On the other hand, drug-loaded MBs can deliver 
their load specifically to the site of disease after they are fragmented by subsequently 
increasing the US intensity. At last, MBs in combination with US can increase the 
permeability of many physiological membranes such as the blood-brain barrier, capillary 
endothelium, or the cell membrane for macromolecules or even colloidal particles.  
Because of their potential as carriers for targeted gene therapy MBs, loaded with plasmid 
DNA [56, 233], antisense oligonucleotides [301], or siRNA [243, 302], have been newly 
intensively investigated on a laboratory and clinical scale. Although numerous promising 
therapeutic outcomes have been acquired [118, 241] the clinically relevant application of MB-
mediated gene therapies is still posed to several challenges. On the first place, the carrier 
capacity of MBs is limited based on their structure, comprising over 95% gas. Furthermore, 
current gene-loaded MBs do not provide protection of gene material from degradation by 
serum nucleases.  
In the present research project a new type of secondary-carrier associated MBs was developed 
and characterized. The MBs comprised a gas core of perfluoropropane, surrounded by a soft 
phospholipid monolayer shell. The active gene load of plasmid DNA, encoding for luciferase, 
was encapsulated into polyplexes comprising properly synthesized amphiphilic conjugates of 
branched polyethylenimine (bPEI) and palmitic acid (PA). The DNA-bearing polyplexes were 
anchored by hydrophobic interactions to the MB shell monolayer.  
Amphiphilic polycationic conjugates (bPEI-PA) were synthesized by pyridine-catalyzed 
nucleophilic substitution between branched PEI and PA after chemical activation of the fatty 
acid. After extensive purification the successful covalent conjugation was proven by 1H and 
13C NMR. Initially, twelve bPEI-PA conjugates were synthesized from bPEI with molecular 
weights of 1.8 kDa, 10 kDa, and 25 kDa with various substitution degrees with PA, ranging 
from 2 mol% to 50 mol% according to the bPEI monomer units. In following development 
conjugates were assessed in their applicability for MB formulation and in their transfection 
efficacy and cell toxicity. Five highly-saturated candidates were excluded during the early 
development owing to solubility problems. Totally seven candidates were launched into later 
development studies and in-vitro biological studies (refer to Table 21, p.161). 
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The development and production of polyplex-associated MBs have been carried out according 
to the properly established liposomal-controlled microbubble production (LCMP) approach. 
MBs were produced by mechanical agitation of DNA-loaded polycationic liposome 
precursors together with the MB core gas octafluoropropane. The polycationic liposomes 
comprised amphiphilic polycation (bPEI-PA), and the saturated C16 zwitterionic 
phospholipids DPPC and DPPE.  
In following studies the pH buffering capacity of bPEI-PA conjugates in the pH region 
between 4 and 6 was demonstrated. Their ability to complex DNA was either demonstrated 
with the conclusion that chemical grafting of PA lowers the binding potential of bPEI-PA 
especially at higher substitution rates. 
The relationship between polyplex size and N/P loading ratio was governed by the shift of 
Zeta potential, as the highest degree of agglomeration was observed at Zeta potential 
approaching zero. Additionally, several trends of polycationic liposome particle size were 
observed at various bPEI molecular weights and PA substitution rates. Briefly, particle size of 
unloaded polycationic liposomes was independent from these two parameters as the 
liposomes were significantly smaller than the bPEI-PA nanoparticles formed by self-
association in aqueous medium in absence of phospholipids.  
After loading with pDNA the particle size decreased with increasing molecular weight of the 
bPEI moieties. There was no consistent trend according to the substitution grade with PA.  
Another intensive influence on the polycationic liposome size after loading with pDNA was 
observed at decreasing pH in the range from 8 to 3.5 resulting in about 8-fold smaller 
particles. This effect could be explained with the increasing charge density of bPEI-PA which 
allows the complexation of a greater number of negative charges per plasmid molecule.  
An intriguing effect of electrolyte concentration on the MB yield and stability was observed 
too. Because of the high positive charge density due to the presence of bPEI-PA the MB shell 
was destabilized by lateral repulsions leading to extremely low MB yields. However, when 
the electrostatic repulsions were shielded by electrolytes the shell integrity was recovered by 
the prevalence of attractive lateral hydrophobic forces. However, beyond a certain 
concentration limit the downgrading of electrostatic repulsions led to colloidal instability of 
polycationic liposomes and aggregation. Therefore, a narrow interval of electrolyte 
concentration was selected, where both conditions of MB shell stability and liposome 
colloidal stability are fulfilled.  
In comparison to conventional cationic phospholipid MBs [117] the newly developed 
polyplex-associated MBs reached a 5-fold higher plasmid loading of about 0.01 pg/µm2, 
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comparable to albumin-shelled MBs [56] (refer to Table 18, p.136), but providing much 
higher echogenicity and acoustic destructibility [15]. Furthermore, as shown in experimental 
studies polyplex-associated MBs are able to protect the active gene load from enzymatic 
degradation in serum due to its condensation with bPEI (refer to “4.5.4, Protection of pDNA 
against enzymatic degradation”, p.191).  
In-vitro transfection studies revealed the biological activity of the seven amphiphilic bPEI-PA 
candidates in terms of their transfection ability and cell toxicity. On the first place, the 
transfection efficacy of bPEI-PA was determined by the molecular weight of the bPEI moiety. 
Conjugates of low-molecular weight bPEI of 1.8 kDa reached marginal transfection rates, 
while transfection with conjugates of bPEI 10 kDa approached the efficacy of the positive 
control bPEI 25 kDa. The degree of substitution played a negative role both for the 
transfection efficacy and for the toxicity of bPEI-PA.  
The most intensive negative influence was exerted by the addition of phospholipids – 
20 mol% DPPE and 80 mol% DPPC, in order to form polycationic liposomes. Although the 
phospholipids had a positive effect of decreasing particle size compared to bPEI-PA self-
associates, their influence on the transfection efficiency was strongly inhibiting. However, the 
transfection activity loss was not as pronounced with every bPEI-PA candidates, but was 
greatest in the case of bPEI25-PA. The addition of phospholipid affected in some cases the 
cell viability, but did not allow drawing a consistent tendency.  
As a final outcome of the in-vitro cell culture studies one candidate – bPEI10-PA12, was 
selected for launching into in-vivo studies based on its superior transfection efficacy, 
approaching this of bPEI 25 kDa. Polycationic liposomes comprising bPEI10-PA12 also 
demonstrated very low cell toxicity expressed as 92.2% ± 5.5% remaining cell viability 
compared to untreated cells.  
In perspective, the targeting and transfection efficacies of polyplex-associated MBs 
comprising the selected candidate bPEI10-PA12 need to be demonstrated under in-vivo 
conditions as a final proof of concept. Thereby, the optimal dosage regimen and US 
parameters should be discriminated. A further aspect which deserves attention is the 
transfection interference in particle clearing organs such as the liver, the lungs, the spleen, and 
the kidneys. As a first step in this direction the acute toxicity of the newly developed MBs 
was already characterized in rat models, giving a promising outlook for further clinical 
studies. 
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VI. Chapter: General summary of the thesis 
In the past decades microbubbles (MBs) have gained wide clinical applications as well 
tolerated contrast agents for the ultrasound (US) diagnostics. Recently, their potential as 
specific drug and gene-carriers for targeted therapy has been discovered and many therapeutic 
applications have been established on clinical scale. These encompass thrombolysis [303], 
delivery of plasmid DNA [56, 212], siRNA [266, 323], protein delivery [58, 59], as well as 
the delivery of small drug molecules [134]. 
Because they are US contrast agents and drug carriers at the same time, MBs provide the 
unique ability to outline the site of disease and to achieve highly specific drug targeting in a 
single needle prick. MBs can be intravenously administered to the patient by either bolus 
injection or infusion and reach even distant tissues and organs. On the target site they can be 
visualized by well tolerated diagnostic US and aid the localization of e.g. solid tumors. 
Accordingly, the drug can be released from the MBs by increasing the US intensity and 
“bursting” them. Beyond the targeting effect, the combination of MBs and US can turn 
biological barriers such as the blood-brain barrier, capillary endothelium, and the cell 
membrane permeable for polar drugs, macromolecules, and even colloidal particles [23, 24, 
36].  
The above dissertation work focused on the pharmaceutical formulation of phospholipid-
shelled drug and gene-loaded MBs by mechanical high speed agitation. Thereby, a pre-filled 
sterile vial containing a liquid phase and a gas phase was agitated on its length-axis with 
definite duration and frequency using a mechanical device. In the context of the above work, 
the precursor vial comprised an aqueous phospholipid dispersion and octafluoropropane gas, 
in which form it can be stored for long terms. Immediately prior to the drug administration the 
vial was activated by agitation and the produced concentrated MB dispersion was diluted with 
physiological medium.  
A novel approach for formulation of drug-loaded MBs – the liposomal-controlled 
microbubble production (LCMP) was established here and implemented to develop MBs, 
loaded with doxorubicin and with plasmid-bearing nanoparticles. According to the LCMP 
approach, the pharmaceutical properties of drug-loaded MBs such as particle size, particle 
yield, and encapsulation efficacy, could be controlled by tuning the properties of the precursor 
liposomal formulations, e.g. ionic strength, pH, particle size, etc. This new strategy brought 
the advantage of having all formulation components – MB core gas, shell phospholipids, and 
drug, in a single ready-to-use vial, providing MBs with definite quality upon activation. 
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Several dependences and trends have been observed in the formulation development of 
phospholipid MBs which allowed hypothesizing about the physico-chemical aspects in their 
background. At the beginning of the thesis the exothermic character of high-speed agitation 
has been revealed. Based on the gradual temperature increase during the agitation on the one 
hand and on the melting transition temperature of the MB shell phospholipids on the other, 
the connection has been established between the time of agitation and the MB yield. Thereby, 
MBs were formed and downsized by high-shear forces, caused by the agitation, as long as the 
shell phospholipids persist in condensed gel phase state. As soon as the temperature in the 
tube reached the phospholipid melting temperature, a rapid process of MB degradation took 
place. Apparently, the gel-to-liquid crystalline phase transition attenuated the lateral 
hydrophobic cohesion between phospholipid molecules, impaired the monolayer integrity, 
and shifted the equilibrium from formation of MBs back to the formation of liposomes.  
A further intriguing correlation between the thermotropic phase behavior of phospholipids 
and their ability to form MBs upon agitation has been observed in several studies of this work. 
Apparently, the MB yield is reverse proportional to the peak sharpness and broadness, 
expressed as the ratio between peak width at half peak height (W0.5) and peak height (H). Pure 
phospholipids such as DPPC and DPPG, having sharp peaks and low W0.5/H ratios, failed to 
form MBs despite of their high ability to produce stable liposomes. On the contrary, their 
mixtures with up to 15-times higher W0.5/H ratios provided high MB yields. The same 
phenomenon was observed also in the cases of DPPC / DPPE mixtures (see Figure 50, p.169) 
and in complexes of DPPC / DPPG anionic bilayers with doxorubicin. 
A possible explanation for that relationship can be the large cooperative unit in DPPC 
bilayers, involving from 125 molecules [276] to 400-600 molecules [304]. Blending DPPC at 
equimolar ratios with DPPE increases the bilayer fluidity by diminishing the cooperative unit 
to only 15 phospholipid molecules [276]. The cooperation unit represents the number of lipid 
molecules in a membrane domain which simultaneously undergo a temperature phase 
transition. In highly cooperative phospholipid systems these domain units are extremely large 
and the transition shows a sharp peak in the thermogram. The size of cooperative unit can be 
reduced, leading to membrane fluidizing [274], e.g. through the absorption of small molecules 
such as doxorubicin. In such cases the transition usually starts at lower temperature and shows 
broadening and lowering of the thermogram peak. 
More detailed studies are needed to substantiate the relation between liposome membrane 
fluidity and MB production. Nonetheless, in the past research work phase transition behavior 
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and membrane fluidity were in several cases successfully exerted in order to predict the MB 
particle yield.  
In summary, two major factors appear to be decisive for the stability of the MB shell 
monolayer. On the one hand, the high lateral monolayer fluidity renders the shell flexible and 
plastic, as suggested by other authors too [86]. On the other hand, the equilibrium between 
lateral hydrophobic cohesions and electrostatic repulsions either promote or impair the 
monolayer stability. A characteristic example therefore is the occurring instability of cationic 
monolayers at high charge densities [113].  
At the begin of this research thesis, several early pre-formulation studies on unloaded 
phospholipid MBs were carried out in order to give the basics for further development of drug 
and gene-loaded MBs. Accordingly, available instrumental methods were compared in order 
to chose appropriate approaches for MB sizing, concentration measurements, measurements 
of the Zeta potential, and structure analysis. The laser diffraction in combination with a 
properly established optical model for MBs has been selected as the most reliable method for 
particle sizing. MB concentration was determined by light blockage with some approximation 
due to size range limitations. Determination of MB Zeta potential was abandoned due to setup 
complications and the Zeta potential of liposomes was measured instead. MB structure was 
reliably characterized by fluorescence confocal laser scanning microscopy. 
Two major formulation projects were described in the present thesis work. The aim of the first 
project was to establish doxorubicin-loaded carriers for targeted tumor therapy. Two 
constructs were developed and compared – thin-shelled phospholipid MBs and acoustically 
active lipospheres (AALs), comprising an additional oil layer. Within the phospholipid 
monolayer-shelled MBs, the cationic doxorubicin (DOX) was complexed by electrostatic 
interactions to an anionic phospholipid – dipalmitoyl phosphatidylglycerol (DPPG). 
Furthermore, the complex was stabilized by additional hydrophobic attractions. On this 
manner DOX was incorporated in a few nanometer thick soft phospholipid-monolayer MB 
shell. 
In the case of DOX-loaded AALs the drug was included in an oil layer of glycerol 
triacetate (triacetin) which was located between the innermost gas core and the outermost 
phospholipid monolayer. In order to make the drug loading more efficient, DOX was turned 
more lipophilic by transforming its hydrochloride salt into free base.  
Both candidates – DOX-loaded MBs and DOX-loaded AALs, were compared under in-vitro 
and in-vivo conditions and the more appropriate of them – the phospholipid MBs, was 
launched into clinical studies. DOX-loaded MBs were preferred rather than the triacetin 
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AALs mainly for their much better echogenicity and acoustic destructibility, demonstrated in-
vitro as well in-vivo.  
DOX-loaded MBs possessed a superior loading ability for DOX, reaching almost 90% of the 
input drug amount. Furthermore, the excipient burden of MBs, calculated on the basis of the 
mass concentrations of DOX and total phospholipid, was found to be 6.49 which value 
approximates that of the commercially available DOX-loaded liposome product (Doxil®, 
Ortho Biotech, Bridgewater, USA). The in-vivo US contrasting efficacy of DOX-loaded MBs 
was close to that of the commercial US contrast agent SonoVue® (Bracco International, B.V., 
The Netherlands) while their acoustic destructibility even surpassed the positive control 
by 175%. 
In-vitro studies on the therapeutic efficacy of DOX-loaded MBs in tissue cultures revealed a 
3.2-fold increase of therapeutic activity compared to free DOX and DOX liposomes (n = 10). 
In-vivo studies in subcutaneous xenograft tumor models in rat demonstrated an about 12-fold 
accumulation of DOX in US-treated tumors, compared to tumors which became no US (n = 6, 
p < 0.005). Further in-vivo studies in rat tumor models are foreseen in order to assess the 
therapeutic potential of DOX-loaded MBs by monitoring the pace of tumor growth. As a step 
forward, DOX-loaded MBs will be tested in their therapeutic efficacy i.e. the ability to inhibit 
tumor growth. Furthermore, they will be applied in large animal models in order to determine 
the optimal setting conditions for diagnostic US and to achieve the most effective therapeutic 
treatment. 
In summary, DOX-loaded MBs brought at least three important advantages in comparison to 
current administration forms for this anti-tumor agent. Firstly, because of their backscattering 
properties DOX-loaded MBs can act as contrast agents and aid tumor visualization. 
Furthermore, DOX-loaded MBs provide specific drug targeting which can be externally 
controlled by the clinician. Moreover, the released energy of MB “bursting” enhances the 
permeability of capillary endothelium and cell membrane for DOX and enhances its 
therapeutic effect. The combination of DOX, MBs and US demonstrated a synergistic 
augmentation of the therapeutic efficacy in-vitro. At last, MBs are generally considered 
blood-pool agents because of their size. Therefore, similarly to liposomes they obviously can 
reduce the distribution volume of DOX to that of blood plasma. 
 
Besides targeted tumor therapy, another key application of MB agents is the gene therapy. 
One conventional approach for formulation of gene-loaded MBs is by electrostatic bounding 
of the negatively charged nucleotides to the surface of the cationic MB phospholipid shell. 
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However, this approach is limited in the amount of loaded gene material since the MB surface 
becomes saturated at about 0.002 pg/µm2 plasmid DNA [113, 117]. Furthermore, the active 
gene load, attached to the MB surface, is liable to degradation by serum nucleases.  
The second research project in the above thesis addressed the above depicted problems about 
enhancing the active load amount and protection the gene load from enzymatic degradation. 
Therefore, micron-sized MBs were loaded with nanometer-sized particles – secondary 
carriers, encapsulating the gene material (see Figure 66, p.191). After such secondary-carrier 
associated MBs have been “burst” by US on the target site their destruction causes 
perforations in the capillary wall and turns it permeable for the nanoparticulate secondary 
carriers which are released from the MBs at the same moment. Thereupon the gene-loaded 
nanoparticles may leave the capillary bed and penetrate the interstitium where they are 
actively taken up by the cells via endocytosis.  
In the present work, novel MB carriers were established comprising a gas core and a 
phospholipid monolayer shell, decorated with polyplex nanoparticles, The nanoparticles were 
anchored apparently by hydrophobic interactions to the phospholipid monolayer (Figure 
2 D, p.19).  
Polyplex nanoparticles comprised properly synthesized amphiphilic conjugates of branched 
polyethylenimine (bPEI) and palmitic acid (PA) linked by covalent amine bridges. Conjugates 
were synthesized using bPEI of different molecular weight (1.8 kDa, 10 kDa, and 25 kDa) 
and at various substitution degrees with PA by activating PA with N,N-
dicyclohexylcarbodiimide. The substitution was further catalyzed by pyridine. The chemical 
structure and stoichiometric substitution degree with PA were confirmed by 1H and 13C NMR. 
As demonstrated in following characterization studies the amphiphilic bPEI-PA conjugates 
were able to complex pDNA. The conjugate binding capacity for pDNA mainly decreased 
with increasing substitution degrees with PA. Generally, maximum N/P binding ratios for 
bPEI-PA conjugates lied between 4 and 6. Phospholipid liposomes, comprising only DPPC 
and DPPE but no polycation did not complex pDNA. Similarly, gel retention assay studies 
revealed that complete complexation of pDNA is possible at N/P ratios of 5-7. However, in 
later studies loading was possible at N/P ratios of up to 10 because of colloidal instability, 
occurring at higher loading ratios. 
Amphiphilic bPEI-PA conjugates were able to buffer the pH range between 4 and 6, as 
revealed in pH titration studies. This finding was accepted as a proof of concept that the 
chemically modified conjugates retain their proton buffering capacity and can fulfill the 
mechanism of osmotic endosome degradation. 
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Furthermore, polyplex-associated MBs were able to protect their gene load from degradation 
by serum nucleases in DNAse challenge assay studies in the N/P range from 5 to 15.  
Exhaustive pre-formulation research has been dedicated to attaining control over the particle 
size of pDNA-loaded polyplex-liposomes and over the MB yield. Higher protonation degrees 
of bPEI-PA at lower pH values strongly improved the colloidal stability of polycationic 
liposomes upon loading with pDNA and lowered the liposome size. Apparently, at lower pH 
the higher density of cationic charges in bPEI-PA can compensate more negative charges in 
the pDNA molecule. Therefore, less bPEI-PA molecules are necessary to condense a single 
plasmid which reduces the particle size of the final polyplex particle. 
Accordingly, the synthesized amphiphilic bPEI-PA candidates were subjected to in-vitro 
studies on their transfection efficacy and cell toxicity in human melanoma cell cultures. The 
conjugates were compared and the candidate with the highest transfection ability and lowest 
toxicity was selected for further in-vivo clinical studies.As a positive control polyplexes of 
pDNA with bPEI 25 kDa were applied.  
The new polyplex-associated MBs allowed increasing the effective load amount of pDNA 
about 5-fold compared to conventional cationic phospholipid MBs. Although the transfection 
efficiency of pDNA-loaded polycationic liposomes was inhibited by the chemical grafting of 
PA and by the presence of shell phospholipids, the finally selected conjugate bPEI10-PA12 
retained 84.8% of the activity of the positive control bPEI 25 kDa. 
Further in-vivo studies are still necessary to demonstrate the proof of concept for US targeted 
delivery of pDNA by the newly established polyplex-associated MBs.  
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